0001607062-22-000026.txt : 20220120 0001607062-22-000026.hdr.sgml : 20220120 20220120093822 ACCESSION NUMBER: 0001607062-22-000026 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220120 DATE AS OF CHANGE: 20220120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regen BioPharma Inc CENTRAL INDEX KEY: 0001589150 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455192997 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-191725 FILM NUMBER: 22540921 BUSINESS ADDRESS: STREET 1: 4700 SPRING ST #304 CITY: LA MESA STATE: CA ZIP: 91942 BUSINESS PHONE: 619-722-5505 MAIL ADDRESS: STREET 1: 4700 SPRING ST #304 CITY: LA MESA STATE: CA ZIP: 91942 10-Q 1 rgbp123121form10q.htm 10-Q

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File No. 333-191725

REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

Nevada	45-5192997
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

619 722-5505

(Issuer’s telephone number)

None

(Former name, address and fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer	☐ Accelerated filer
☐ Non-accelerated filer	☒ Smaller reporting company
	☐ Emerging Growth Company

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of June 30, 2021 Regen Biopharma, Inc. had 4,564,002,832 common shares outstanding.

As of December 31, 2021 Regen Biopharma, Inc. had 439,293,006 shares of Series A Preferred Stock outstanding.

As of December 31, 2021 Regen Biopharma, Inc. had 50,000 shares of Series AA Preferred Stock outstanding.

As of December 31, 2021 Regen Biopharma, Inc. had 44,000,000 shares of Series M Preferred Stock outstanding.

As of December 31, 2021 Regen Biopharma, Inc. had 10,000 shares of Series NC Preferred Stock outstanding

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes ☐ No ☒

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements


REGEN BIOPHARMA , INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

	As of			As of
	December 31, 2021 (Unaudited)			September 30, 2021
ASSETS
CURRENT ASSETS
Cash	$	353,492		$	727,162
Accounts Receivable, Related Party		240,617			213,192
Note Receivable, Related Party		5,396			5,396
Accrued Interest Receivable		365			230
Prepaid Expenses		41,288			48,144
Total Current Assets		641,157			994,124

OTHER ASSETS
Investment Securities		74,115			198,006
Investment Securities, Related Party		19,969			19,969
Total Other Assets		94,084			217,975

TOTAL ASSETS	$	735,241		$	1,212,099
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable		32,288			91,498
Notes Payable		1,451,630			1,429,179
Accrued payroll taxes		4,241			4,241
Accrued Interest		661,934			954,861
Accrued Rent		0			0
Accrued Payroll		1,266,679			1,266,679
Other Accrued Expenses		41,423			41,423
Bank Overdraft		1,000			1,000
Due to Investor		20,000			20,000
Unearned Income		1,812,166			1,843,806
Derivative Liability		3,927,538			6,892,477
Convertible Notes Payable Less unamortized discount		1,262,310			2,131,311
Convertible Notes Payable, Related Parties Less unamortized discount		10,000			21,500
Total Current Liabilities		10,491,210			14,697,976
Long Term Liabilities:
Convertible Notes Payable, Related Parties Less unamortized discount					0
Total Long Term Liabilities
Total Liabilities		10,491,210			14,697,976

STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 4,800,000,000 authorized and 4,564,002,832 issued and outstanding as of December 31,2021 and 4,800,000,000 authorized and 4,350,554,514 shares issued and outstanding as of September 30 ,2021.		456,399			435,054
Preferred Stock, 0.0001 par value, 800,000,000 authorized as of December 31,2021 and September 30,2021 respectively		-			-
Series A Preferred 300,000,000 authorized, 439,293,406 and 431,998,817 outstanding as of December 31,2021 and September 30, 2021 respectively		43,929			43,200
Series AA Preferred $0.0001 par value 600,000 authorized and 50,000 and 50,000 outstanding as of December 31,2021 and September 30,2021 respectively		5			5
Series M Preferred $0.0001 par value 300,000,000 authorized and 44,000,000 outstanding as of September 30,2021 and December 31, 2021 respectively		4,400			4,400
Series NC Preferred $0.0001 par value 20,000 and 0 authorized and 10,000 and 0 outstanding as of September 30, 2021 and December 31,2021 respectively		1			1
Additional Paid in capital		9,706,891			8,644,037
Contributed Capital		736,326			736,326
Retained Earnings (Deficit)		(20,703,920	)		(23,348,900	)
Total Stockholders' Equity (Deficit)		(9,755,969	)		(13,485,877	)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$	735,241		$	1,212,099

The Accompanying Notes are an Integral Part of These Financial Statements


REGEN BIOPHARMA , INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
( Unaudited)

		Quarter Ended December 31,2021			Quarter Ended December 31,2020
REVENUES
Revenues	$	31,640		$	—
Revenues, Related Party		27,425			27,425
TOTAL REVENUES		59,065			27,425

COST AND EXPENSES
Research and Development		35,418			1,127
Research and Development, Related Party		80,275			0
General and Administrative		6,658			44,778
Consulting and Professional Fees		38,136			0
Rent		5,000			0
Total Costs and Expenses		165,487			45,905
OPERATING INCOME (LOSS)	$	(106,423	)	$	(18,480	)

OTHER INCOME & (EXPENSES)
Interest Income		135			0
Interest Expense		(35,010	)		(73,212	)

Interest Expense attributable to Amortization of Discount		(22,451	)		(36,717	)
Unrealized Gain ( Loss) on sale of Investment Securities		(123,891	)		0
Gain (Loss) on derecognition of Accounts Payable		62,700			0
Derivative Income (Expense)		2,964,939			1,794,776
Gain (Loss) on Extinguishment Convertible Debt		(95,019	)		0
TOTAL OTHER INCOME (EXPENSE)		2,751,403			1,684,847

NET INCOME (LOSS)	$	2,644,980		$	1,666,367
NET INCOME (LOSS) attributable to common shareholders	$	2,391,062		$	1,385,417
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$	0.001		$	0.000
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING		4,506,953,931			1,769,079,104

The Accompanying Notes are an Integral Part of These Financial Statements


	REGEN BIOPHARMA , INC.
	Condensed Consolidated Statement of Shareholder's Deficit
	(Unaudited)
	Quarters ended December 31, 2020 and December 31, 2021

			Series A Preferred				Series AA Preferred				Series NC Preferred				Common				Series M Preferred
			Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Additional Paid-in Capital			Retained Earnings			Contributed Capital		Total
Balance September 30,2020		Balance September 30,2020		381,768,689	$	38,177		50,000	$	5		—		—		1,605,000,246	$	160,498		44,000,000	$	4,400	$	8,313,876		$	(16,583,666	)	$	731,711	$	(7,334,998	)
Shares issued for Debt	10/28/2020	Shares issued for Debt														57,726,183		5,773						(2,021	)							3,752
Shares Issued For Interest	10/28/2020	Shares Issued For Interest														22,339,663		2,234						(782	)							1,452
Shares issued for Debt	11/6/2020	Shares issued for Debt														60,007,919		6,001						(2,101	)							3,900
Shares Issued For Interest	11/6/2020	Shares Issued For Interest														23,926,234		2,393						(838	)							1,555
Shares issued for Debt	12/11/2020	Shares issued for Debt														60,834,498		6,083						1,217								7,300
Shares Issued For Interest	12/11/2020	Shares Issued For Interest														26,185,501		2,619						523								3,142
Shares issued for Debt	12/16/2020	Shares issued for Debt														3,300,000		330						99								429
Shares Issued For Interest	12/16/2020	Shares Issued For Interest														1,819,077		182						54								236
Shares issued for Fees	12/16/2020	Shares issued for Fees														1,228,077		123						36								159
Shares issued for Debt	12/16/2020	Shares issued for Debt														62,003,571		6,200						(2,170	)							4,030
Shares Issued For Interest	12/16/2020	Shares Issued For Interest														26,155,352		2,616						(916	)							1,700
Shares issued for Debt	12/17/2020	Shares issued for Debt														68,333,539		6,833						1,367								8,200
Shares Issued For Interest	12/17/2020	Shares Issued For Interest														14,883,378		1,488						212								1,700
Shares issued for Debt	12/17/2020	Shares issued for Debt		20,000,437		2,000																		11,000								13,000
Shares Issued For Interest	12/17/2020	Shares Issued For Interest		12,378,732		1,238																		6,808								8,046
Shares issued for Debt	12/23/2020	Shares issued for Debt														88,888,889		8,889						7,111								16,000
Shares Issued For Interest	12/23/2020	Shares Issued For Interest														19,555,555		1,956						1,294								3,250
Shares issued for Debt	12/31/2020	Shares issued for Debt														82,004,603		8,200						(2,870	)							5,330
Shares Issued For Interest	12/31/2020	Shares Issued For Interest														35,832,781		3,583						(1,254	)							2,329
		Additions to Contributed Capital Quarter ended 12/31/2020				—			—					—				—				—								1,865		1,865
		Net Loss Quarter Ended December 31,2020																									1,666,367					1,666,367
Balance December 31, 2020		Balance December 31, 2020		414,147,858	$	41,415		50,000	$	5		—		—		2,260,025,066	$	226,001		44,000,000	$	4,400	$	8,330,646		$	(14,917,299	)	$	733,576	$	(5,581,256	)
Balance September 30, 2021		Balance September 30, 2021		431,998,817	$	43,200		50,000	$	5		10,000	$	1		4,350,554,514	$	435,054		44,000,000	$	4,400	$	8,644,037		$	(23,348,900	)	$	736,326	$	(13,485,877	)
Shares issued for Debt	10/1/2021	Shares issued for Debt														10,000,000		1,000						99,000								100,000
Shares issued for Interest	10/1/2021	Shares issued for Interest														2,666,200		267						26,395								26,662
Shares issued for Debt	10/1/2021	Shares issued for Debt														10,000,000		1,000						99,000								100,000
Shares issued for Interest	10/1/2021	Shares issued for Interest														3,883,700		388						38,449								38,837
Shares issued for Debt	10/1/2021	Shares issued for Debt														6,022,971		602						49,398								50,000
Shares issued for Interest	10/1/2021	Shares issued for Interest														2,361,366		236						19,367								19,603
Shares issued for Debt	10/1/2021	Shares issued for Debt														15,503,953		1,550						48,450								50,000
Shares issued for Interest	10/1/2021	Shares issued for Interest														5,759,719		576						17,999								18,575
Shares issued for Interest	10/1/2021	Shares issued for Interest														23,255,888		2,326						72,674								75,000
Shares issued for Debt	10/1/2021	Shares issued for Debt														9,945,768		995						31,080								32,075
Shares issued for Interest	10/1/2021	Shares issued for Interest														7,751,973		775						24,225								25,000
Shares issued for Interest	10/1/2021	Shares issued for Interest														3,211,178		321						10,035								10,356
Shares issued for Debt	10/1/2021	Shares issued for Debt														1,000,016		100						24,900								25,000
Shares issued for Interest	10/1/2021	Shares issued for Interest														355,326		36						8,847								8,883
Shares issued for Debt	10/1/2021	Shares issued for Debt		4,000,047		400																		49,600								50,000
Shares issued for Interest	10/1/2021	Shares issued for Interest		1,869,542		187																		23,182								23,369
Shares issued for Debt	10/29/2021	Shares issued for Debt														10,256,427		1,026						98,974								100,000
Shares issued for Interest	10/29/2021	Shares issued for Interest														4,082,878		408						39,400								39,808
Shares issued for Debt	10/29/2021	Shares issued for Debt														8,421,053		842						39,158								40,000
Shares issued for Interest	10/29/2021	Shares issued for Interest														2,987,789		299						13,893								14,192
Shares issued for Debt	11/4/2021	Shares issued for Debt														6,250,082		625						49,375								50,000
Shares issued for Interest	11/4/2021	Shares issued for Interest														2,376,531		238						18,774								19,012
Shares issued for Debt	11/24/2021	Shares issued for Debt														72,476,800		7,248						3,716								10,964
Shares issued for Debt	11/24/2021	Shares issued for Debt														1,000,014		100						24,900								25,000
Shares issued for Interest	11/24/2021	Shares issued for Interest														461,086		46						11,481								11,527
Shares issued for Debt	11/24/2021	Shares issued for Debt														2,400,000		240						59,760								60,000
Shares issued for Interest	11/24/2021	Shares issued for Interest														1,017,600		102						25,338								25,440
Shares issued for Debt	12/10/2021			1,000,000		100																		24,900								25,000
Shares issued for Interest	12/10/2021			425,000		43																		10,583								10,625
		Net Loss for the Quarter Ended December 31,2021				—				—				—				—				—					2,644,980			—		2,644,980
Balance December 31,2021		Balance December 31,2021		439,293,406	$	43,929		50,000	$	5		10,000	$	1		4,564,002,832	$	456,399		44,000,000	$	4,400	$	9,706,891		$	(20,703,920	)		—	$	(9,755,969	)

	The Accompanying Notes are an integral part of these Financial Statements

REGEN BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Quarter Ended			Quarter Ended
	December 31, 2021			December 31,2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$	2,644,980			1666367
Adjustments to reconcile net Income to net cash
Preferred Stock issued to Consultants		—			—
Common Stock issued for Expenses					159
Preferred Stock issued as compensation		—			—
Increase (Decrease) in Interest expense attributable to amortization of Discount		22,451			36,717
Increase (Decrease) in Accounts Payable		(59,210	)		3,369
(Increase) Decrease in Accounts Receivable		(27,425	)		(27,425	)
Increase (Decrease) in accrued Expenses		6,036			113712
(Increase) Decrease in Prepaid Expenses		6,856			12
Increase(Decrease) in Contributed Capital					1865
Increase (Decrease) in Derivative Expense		(2,964,939	)		(1,794,776	)
Increase (Decrease) in Unearned Income		(31,640	)
Increase (Decrease) in Bank Overdraft
(Increase( Decrease in Notes Receivable
(Increase( Decrease in Accrued Interest Receivable		(135	)
Securities accepted as compensation
Increase (Decrease) in Loss on Sale of Investment Securities
(Gain) Loss on Forgiveness of Debt
Unrealized Loss(Gain) on Investment Securities		123,891
Net Cash Provided by (Used in) Operating Activities	$	(279,135	)	$	—

Cash Flows from Investment Activities
Increase(Decrease) in Sale of Investment Securities
Net Cash Provided By Investment Activities

CASH FLOWS FROM FINANCING ACTIVITIES
Increase ( Decrease) in Notes Payable		—			—
Increase( Decrease) in Convertible Notes Payable		(94,535	)		0
Net Cash Provided by (Used in) Financing Activities	$	(94,535	)		0

Net Increase (Decrease) in Cash		(373,670	)		0
Cash at Beginning of Period	$	727,162		$	—
Cash at End of Period	$	353,492		$	—

Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt	$	710,964		$	48,941
Preferred Shares Issued for Debt	$	75,000		$	13,000
Cash Paid for Interest	$	28,973		$	—
Common shares Issued for Interest	$	264,970		$	15,721
Preferred Shares issued for Interest	$	33,994		$	8,046

The Accompanying Notes are an Integral Part of These Financial Statements

REGEN BIOPHARMA, INC.

Notes to Condensed Consolidated Financial Statements

As of December 31, 2021

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada

The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.

The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease.

The Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company.

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated.

The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model.

The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of December 31, 2021 utilized the following inputs:

Schedule of Derivative Liability
Risk Free Interest Rate	1.49	%
Expected Term	.(0.66) – (1.85) Yrs
Expected Volatility	824.95	%
Expected Dividends

H. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

I. BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended December 31,2020 and December 31, 2021..

K. NOTES RECEIVABLE

Notes receivable are stated at cost, less impairment, if any.

As of December 31,2021 the Company has the following Notes Receivable

Schedule of notes receivable
Zander Therapeutics, Inc.		$	5,396

$5,396 owed to the Company by Zander Therapeutics, Inc. bears simple interest at 10% and is due upon the demand of the Company.

L. REVENUE RECOGNITION

Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products.

The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

M. INTEREST RECEIVABLE

Interest receivable is stated at cost, less impairment, if any.

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.

As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification.

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.

On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.

On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position.

On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position.

In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $20,703,920 during the period from April 24, 2012 (inception) through December 31, 2021. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise.

NOTE 4. NOTES PAYABLE

(a) RELATED PARTY

Schedule of notes payable related party
	As of December 31, 2021
David Koos	$	227
Total:	$	227

$227 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.

(b) NON RELATED PARTY

Schedule of non related party
Coventry Enterprises LLC,	$	1,500,000
Total:	$	1,500,000

On September 17,2021 the “Company” issued a promissory note in the principal amount of $1,500,000 ( “Note”) of which $75,000 was retained by the Holder through an Original Issue Discount (“OID”) for due diligence and origination related to this transaction and Thirty-five Thousand Dollars $35,000 was remitted by the Holder, at the instance and on behalf of the Company, directly to Holder’s counsel for documentation preparation fees resulting in net consideration paid to the Company of $1,390,000.

The Note carries “Guaranteed Interest” on the principal amount at the rate of 5% per annum for the ten-month term of this Note for an aggregate Guaranteed Interest $62,500 all of which Guaranteed Interest shall be deemed earned as of September 17, 2021.

The Principal Amount and the Guaranteed Interest shall be due and payable in five equal monthly payments of $312,500 commencing on March 17, 2022 and continuing on the 17th day of each month thereafter until paid in full not later than July 18, 2022 (the “Maturity Date”).

Solely following an Event of Default (as such term is defined in the Note) the Note shall become convertible, in whole or in part, into shares of Common Stock at the option of the Holder. The conversion price of the Note is 90% of the lowest per-share Trading Price per share. Trading Price is defined as the lowest daily VWAP for the 20 Trading Days preceding a Conversion Date. VWAP is defined as the dollar volume-weighted average price for the common shares as reported by Bloomberg.

The OID is being amortized by the Company over the term of the Note. As of December 31 ,2021 the unamortized discount on this Note is $48,597.

NOTE 5. CONVERTIBLE NOTES PAYABLE

On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions:

(a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).

(b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).

(c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).

(d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities.

The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property

The issuance of the Note amounted in a beneficial conversion feature of $42,600 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $ 0. As of December 31, 2021 $100,000 of the principal amount of the Note remains outstanding.

On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

The issuance of the Note amounted in a beneficial conversion feature of $9,900 which is amortized under the Interest Method over the life of the Note. As of September 30,2021 the unamortized discount on the convertible note outstanding is $0. December 31,2021 $50,000 of the principal amount of the Note remains outstanding.

On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30,2021 the unamortized discount on the convertible note outstanding is $0. As of December 31,2021 $50,000 of the principal amount of the Note remains outstanding.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30,2021 the unamortized discount on the convertible note outstanding is $ 0 As of December 31,2021 $50,000 of the principal amount of the Note remains outstanding.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30,2021 the unamortized discount on the convertible note outstanding is $0. As of December 31 ,2021 $50,000 of the principal amount of the Note remains outstanding.

March 13, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is February 24, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share.

In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share.

The warrants shall be exercisable:

In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”)

In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note.

As of December 31,2021 $50,000 of the principal amount of the Note remains outstanding.

The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $204,082 was recognized by the Company as of December 31, 2021. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0.

On March 31, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 31, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share.

The warrants shall be exercisable:

In the event part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of December 31 ,2021 $50,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $204,082 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0.

On April 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is April 19, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share.

The warrants shall be exercisable:

As of December 31,2021 $50,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $204,082 was recognized by the Company as of September 30,2021. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0.

On May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $200,000 for consideration consisting of $200,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is May 5, 2020. The Note is convertible into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:

(i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction.

ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”).

(iii) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $200,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $816,327 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $200,000 which is amortized under the Interest Method over the life of the Note. As of December 31 ,2021 the unamortized discount on the convertible note outstanding is $0.

On June 26, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $150,000 for consideration consisting of $150,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is June 16, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:

(i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction.

(ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”).

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $150,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $612,245 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $150,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0.

On September 25, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is September 25, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share as of the date which is the earlier of:

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31, 2021 $50,000 of the principal amount of the Note remains outstanding.

On October 3, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 3, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021, $50,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $204,082 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0.

On October 16, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 9, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $100,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $408,163 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $100,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0.

On November 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is November 1, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $25,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $102,041 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party.

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $25,000 of the principal amount of the Note remains outstanding.

On December 20, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 20, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $100,000 of the principal amount of the Note remains outstanding.

On February 28, 2018 (“Issue date”) the Company issued a two Convertible Notes (“Notes”) in the aggregate face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Notes is February 28, 2021. The Notes may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:

(i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of these Notes, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Notes in part or in full, including outstanding principal and accrued interest.

In the event that that the Company exercises its right to prepay the notes, or if the Lender chooses not to convert the remaining amount of the notes into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Notes into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.

The warrants shall be exercisable:

In the event that the Company exercises its right to Prepay the Notes on or prior to the close of business on the three (3) month anniversary of the date that the Notes shall have been prepaid by the Company (“Prepayment Date”).

In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Notes, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Notes.

As of December 31,2021 $100,000 of the principal amount of the Notes remains outstanding.

The Company analyzed the conversion feature of the Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $408,163 was recognized by the Company as of December 31,2021. The issuance of the Notes amounted in a discount of $100,000 which is amortized under the Interest Method over the life of the Notes. As of December 31,2021 the unamortized discount on the convertible notes outstanding is $0.

On July 11, 2018 the Company issued a Convertible Note (“Note”) in the face amount of $11,500 to an entity controlled by the Company’s then Chief Financial Officer for consideration consisting of $11,500 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is May 4, 2021. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.01 per common share as of the date which is the earlier of:

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $11,500 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $46,938 was recognized by the Company as of December 31,2021. The issuance of the Notes amounted in a discount of $11,500 which is amortized under the Interest Method over the life of the Notes. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0.

On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date.

Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen.

As of December 31, 2021, 10,000 of the principal amount of the Note remains outstanding.

The issuance of the Note amounted in a beneficial conversion feature of $350,000 which is amortized under the Interest Method over the life of the Note. As of December 31 2021 the unamortized discount on the convertible note outstanding is $0.

Zander and Regen are under common control. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications.

On July 19, 2019 the Company issued a convertible promissory note in the face amount of $100,000 (“Note”) for consideration consisting of:

$95,000 cash

the payment of $5,000 of legal fees

The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is July 19, 2020. The Note may be converted into the common stock of Regen at a price per share ( “Conversion Price”) equivalent to 60% of the lowest Trading price of the common stock of the Company as reported on the National Quotations Bureau OTC Markets exchange upon which the Company's shares are traded or any exchange upon which the Common Stock of the Company may be traded in the future , for the twenty prior trading days including the day upon which a Notice of Conversion is received by the Company or its transfer agent. . In no event shall the Holder be allowed to effect a conversion if such conversion, along with all other shares of Company common stock beneficially owned by the Holder and its affiliates would exceed 9.9% of the outstanding shares of the Common Stock of the Company.

The proceeds from the issuance of the Note are to be allocated as follows:

$30,592 will be utilized to retire the outstanding balance of a $75,000 note issued by the Company on August 15, 2018 to One44 capital, LLC and $22,877 will be allocated to the Company’s accountants and auditors to bring the Company current with regards to the Company’s quarterly reporting requirements under the Securities and Exchange Act of 1934.

The Note may be prepaid with the following penalties:

Time Period		Payment Premium
<=60 days after note issuance		125% of the sum of principal plus accrued interest
>60 days <= 120 days after note issuance		135% of the sum of principal plus accrued interest
>120 days <=180 days after note issuance		140% of the sum· of principal plus accrued· interest

This Note may not be prepaid after the 180th day.

As of December 31,2021 $1,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $3,048 was recognized by the Company as of December 31,2021.

The issuance of the Note amounted in a discount of $100,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0.

NOTE 6. RELATED PARTY TRANSACTIONS

On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is under common control with the Company.

Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement.

The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander.

Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter.

Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement).

Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000).

The Agreement may be terminated by The Company:

If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product.

The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP.

The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated.

The Agreement may be terminated by either party in the event of a material breach by the other party.

On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto.

On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby:

1) Zander shall return for cancellation 194,285,714 shares of the Series A Preferred stock of Regen (“Conversion Shares”) acquired by Zander through conversion of $340,000 of principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement.

2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement.

3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement.

No actions were taken by any of the parties to enforce the terms of the Agreement.

On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be:

a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return

b) As of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between Zander and Regen on June 23, 2015 (“License Agreement”) whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto.

Zander and Regen are under common control.

As of September 30, 2021, $10,000 of the principal amount of the Note remains outstanding.

During the quarter ended June 30, 2021 Zander Therapeutics, Inc. issued a promissory note in the amount of $5,396 to the Company as consideration for expenses of Zander Therapeutics Inc., paid by the Company. The Note is payable on demand of the Holder and bears simple interest at 10% per annum.

On October 8,2021 the Company entered into an agreement with Dr. Brian Koos, MD PhD whereby Dr. Brian Koos would provide services to the Company consisting of :

a) Reviewing existing publications on research being conducted on Checkpoint NR2F6.

b) Identifying the most promising applications for the Company’s technology

c) Drafting a “white paper” on results for 1(b)

d) Making introductions to known experts in appropriate fields identified in 1(b).

Dr. Brian Koos is to be paid compensated $117,000 as total consideration for performing the abovementioned tasks. During the quarter ended December 31, 2021 Dr. Brian Koos was paid the amount of $80,275. Dr. Brian Koos is the brother of David Koos the Chairman and Chief Executive Officer of the Company.

As of December 31, 2021 the Company is indebted to David R. Koos the Company’s sole officer and director in the amount of $227. $227 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum.

During the quarter ended December 31, 2021 the Company paid $5,000 of rental expenses to the landlord of BST Partners as consideration to BST Partners for use of office space. BST Partners is controlled by David R. Koos the Chairman and Chief Executive Officer of the Company.

On January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning January 14, 2022.

BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

NOTE 7. ACCOUNTS RECEIVABLE, RELATED PARTY

Accounts Receivable due from Related Party as of December 31, 2021 consists solely of amounts earned by the Company not yet paid resulting from the Company’s license agreement with KCL Therapeutics (See Note 6).

NOTE 8. STOCKHOLDERS’ EQUITY

The stockholders’ equity section of the Company contains the following classes of capital stock as of December 31 2021:

Common stock, $ 0.0001 par value; 4,800,000,000 shares authorized: 4,564,002,832 shares issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation.

Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 50,000 shares issued and outstanding as of December 31,2021, 300,000,000 is designated Series A Preferred Stock of which 439,293,406 shares are outstanding as of December 31,2021, 300,000,000 is designated Series M Preferred Stock of which 44,000,000 shares are outstanding as of December 31,2021, and 20,000 is designated Series NC stock of which 10,000 shares are outstanding as of December 31, 2021. .

The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired.

Series AA Preferred Stock

On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”).

The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

Series A Preferred Stock

On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”).

The Board of Directors of the Company have authorized 300,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock.

Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them.

If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series M Preferred Stock" (hereinafter referred to as "Series M Preferred Stock").

The Board of Directors of Regen have authorized 300,000,000 shares of the Series M Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series M Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series M Preferred Stock owned by such holder times one. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series M Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore

On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

On March 26, 2021 Regen Biopharma, Inc. ( “Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Nonconvertible Series NC Preferred Stock (hereinafter referred to as "Series NC Preferred Stock").

The Board of Directors of Regen have authorized 20,000 shares of the Series NC Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series NC Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series NC Preferred Stock owned by such holder times 500,000. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series NC Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

The holders of Series NC Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore

On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series NC Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

NOTE 9. INVESTMENT SECURITIES, RELATED PARY

On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc.

On November 29, 2018 the Company accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $13,124.

On December 31,2021 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs:

Schedule of dividend income
Fair Value of Intellectual Property	$	1,500
Prepaid Expenses		74,298
Due from Employee		1,071
Note Receivable		64,400
Accrued Interest Receivable		20,274
Investment Securities		593,357
Convertible Note Receivable		10,000
Accounts Payable		1,269,041
Notes Payable		500,000
Accrued Expenses Related Parties		89,529
Accrued Expenses		203,037
Enterprise Value		2,826,507
Less: Total Debt		(2,061,607	)
Portion of Enterprise Value Attributable to Shareholders		764,900
Fair Value Per Share	$	0.0167

The abovementioned constitute the Company’s sole related party investment securities as of December 31, 2021

As of December 31, 2021:

	Schedule of comprehensive income
470,588 Common Shares of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Gains	Net Unrealized Gain or (Loss) realized during the quarter ended December 31,2021
$	5,741	$	7,858	$	2,118	$	0

725,000 Series M Preferred of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Loss		Net Unrealized Gain or (Loss) realized during the quarter ended September 30,2021
$	13,124	$	12,109	$	(1,104	)	$	0

NOTE 10. INVESTMENT SECURITIES

During the quarter ended June 30, 2021 the Company was paid 50,000 common shares of Oncology Pharma, Inc. pursuant to an agreement entered into by and between KCL Therapeutics, Inc. ( a wholly owned subsidiary of the Company) and Oncology Pharma, Inc. whereby Oncology Pharma, Inc. was granted a license for the development and commercialization of certain intellectual property (“License IP”) for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021.

During the quarter ended June 30, 2021 13,000 of the aforementioned common shares were sold to an unrelated party for $300,000 cash.

During the quarter ended September 30, 2021 18,000 of the aforementioned common shares were sold to an unrelated party for $195,000 cash.

As of December 31, 2021 18,300 common shares of Oncology Pharma, Inc. constitute the sole investment securities other than shares of Zander Therapeutics, Inc. held by the Company.

On December 31,2021 the Company revalued 18,300 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market.

As of December 31, 2021:

	Schedule of investment securities
18,300 Common Shares of Oncology Pharma, Inc.

	Basis		Fair Value		Total Unrealized Losses	Net Unrealized Gain or (Loss) realized during the quarter ended December 31,2021
$	677,100	$	74,115	$	602,985	$	(123,891)

NOTE 12. STOCK TRANSACTIONS

On October 1, 2021 the Company issued 101,718,058 common shares in satisfaction of $425,000 of convertible indebtedness and $154,991 of accrued interest on convertible indebtedness.

On October 1, 2021 the Company issued 5,869,589 shares of Series A Preferred stock in satisfaction of $50,000 of convertible indebtedness and $23,369 of accrued interest on convertible indebtedness.

On October 29, 2021 the Company issued 25748147 common shares in satisfaction of $140,000 of convertible indebtedness and $54,000 of accrued interest on convertible indebtedness.

On November 4 , 2021 the Company issued 8626613 common shares in satisfaction of $50,000 of convertible indebtedness and $69,012 of accrued interest on convertible indebtedness.

On November 24, 2021 the Company issued 77355500 common shares in satisfaction of $95,964 of convertible indebtedness and $36,967 of accrued interest on convertible indebtedness.

On December 10 2021 the Company issued 1,425,000 shares of Series A Preferred stock in satisfaction of $25,000 of convertible indebtedness and $10,625 of accrued interest on convertible indebtedness.

NOTE 13. SUBSEQUENT EVENTS

BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CERTAIN FORWARD-LOOKING INFORMATION

Information provided in this Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the Company’s expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company’s operations, economic performance, financial conditions, margins and growth in sales of the Company’s products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission. All references to” We”, “Us”, “Company” or the “Company” refer to Regen BioPharma, Inc.

As of September 30, 2021 we had Cash of $727,162 and as of December 31,2021 we had cash of $353,492.The decrease in cash of approximately 51.39% is primarily attributable to the payment of $218,529 in satisfaction $94,537 of convertible indebtedness and $28,973 of accrued interest on convertible indebtedness offset by funds expended in operation of the Company’s business.

As of September 30, 2021 we had Accounts Receivable, Related Party of $213,192 and as of December 31, 2021 we had Accounts Receivable, Related Party of $ 240,617. The increase of approximately 12.9% is attributable to the accrual during the quarter ended December 31,2021 of $27,425 of minimum royalties and anniversary fees pursuant to a license granted to Zander Therapeutics, Inc. by Regen Biopharma, Inc.

As of September 30, 2021 we had Prepaid Expenses of $48,144 and as of December 31, 2021 we had prepaid expenses of $41,288. The decrease in Prepaid Expenses of approximately 14.24% is attributable to the recognition of expenses incurred over the quarter resulting from an agreement to provide Research and Development services which was prepaid during the quarter ended September 30, 2021. The term of the agreement is from July 1, 2021 to July 1, 2023. The total consideration due of $55,000 was paid to the contractor as of July 1, 2021 and is being expensed over the term of the agreement.

As of December 31 , 2021 we had Investment Securities ( Not Related Party) of $74,115 and as of September 30,2021 we had Investment Securities (Not Related Party) of $198,006. As of December 31, 2021 18,300 common shares of Oncology Pharma, Inc. constitute the sole investment securities other than shares of Zander Therapeutics, Inc. held by the Company. On December 31, 2021 the Company revalued 18,300 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market resulting in the recognition of a decrease in fair value of 62.5% as compared to September 30, 2021.

As of December 31, 2021 we had Accounts Payable of $32,288 and as of September 30, 2021 we had Accounts Payable of $91,498. The decrease in Accounts Payable of approximately 64.91% is primarily attributable to the derecognition of $62,700 of payables for which recovery is barred by the statute of limitations imposed under California Code of Civil Procedure §337.

As of December 31, 2021 we had Accrued Interest Payable of $661,934 and as of September 30, 2021 we had Accrued Interest Payable of $954,861.

The decrease in Accrued Interest Payable of approximately 30.68% is attributable to the conversion during the quarter ended December 31, 2021 of $298,964 of interest accrued but unpaid on Convertible Notes issued by the Company and the satisfaction of $28,973 of interest accrued but unpaid in cash offset by additional interest accrued but unpaid during the quarter ended December 31, 2021 on Notes Payable and Convertible Notes Payable.

As of December 31, 2021 we had a Derivative Liability of $3.927,538 and as of September 30, 2021 we had a Derivative Liability of $6,892,477. The decrease in Derivative Liability of approximately 43% is attributable to the recognition by the Company of embedded derivatives on Convertible Notes Payable with an aggregate face value of $962,500 outstanding as of December 31, 2021.

As of December 31, 2021 we had Convertible Notes Payable of $1,272,310 as opposed to Convertible Notes Payable of $2,152,811 as of September 30, 2021. The decrease of 40.7% is attributable to :

(a)

the conversion of $785,964 of principal convertible indebtedness into the equity securities of the Company

(b)

the satisfaction of $94,537 of principal convertible indebtedness in cash.

. Material Changes in Results of Operations

Revenues from continuing operations were $59,065 for the quarter ended December 31,2021 and $27,425 for the same period ended 2020. The increase of approximately 115% is attributable to $31,640 of revenue recognized during the quarter ended December 31, 2021 pursuant to a license granted to Oncology Pharma,Inc. Operating Loss was $106,423 for the quarter ended December 31,2021 whereas Operating Loss was $18,480 for the same quarter ended 2020; an increase primarily attributable to revenue recognized during the quarter ended June 30,2021 pursuant to a license granted to Oncology Pharma Inc. as well as materially lower operating expenses recognized during the quarter ended December 31,2020 as compared to December 31,2021.

Net Income was $ 2,644,980 for the quarter ended December 30, 2021 versus Net Income of $1,666,367 recognized during the same period ended 2020. This was primarily attributable to greater Derivative income recognized during the quarter ended December 31, 2021 as compared to the same quarter ended 2020.

As of December 31, 2021 we had $353,492 in cash on hand and current liabilities of $10.491,210 such liabilities consisting of Accounts Payable, Notes Payable, Convertible Notes Payable , Derivative Liability Recognized, bank overdraft Unearned Income and Accrued Expenses. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.

As of December 31, 2021 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, as defined by Rule 229.10(f) (1) of Regulation S-K, we are not required to provide the information required by this Item. We have chosen to disclose, however, that we have not engaged in any transactions, issued or bought any financial instruments or entered into any contracts that are required to be disclosed in response to this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of David Koos, who is the Company’s Principal Executive Officer and Principal Financial Officer of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of achieving the Company’s disclosure control objectives. The Company’s Principal Executive Officer and Principal Financial Officer have concluded that the Company’s disclosure controls and procedures are, in fact, effective at this reasonable assurance level as of the period covered.

Changes in Internal Controls over Financial Reporting

In connection with the evaluation of the Company’s internal controls during the period commencing on October 1, 2021 and ending on December 31, 2021, David Koos, who serves as the Company’s Principal Executive Officer , Principal Financial Officer has determined that there were no changes to the Company’s internal controls over financial reporting that have been materially affected, or is reasonably likely to materially effect, the Company’s internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On October 1, 2021 the Company issued 101,718,058 common shares in satisfaction of $425,000 of convertible indebtedness and $154,991 of accrued interest on convertible indebtedness.

On October 1, 2021 the Company issued 5,869,589 shares of Series A Preferred stock in satisfaction of $50,000 of convertible indebtedness and $23,369 of accrued interest on convertible indebtedness.

On October 29, 2021 the Company issued 25748147 common shares in satisfaction of $140,000 of convertible indebtedness and $54,000 of accrued interest on convertible indebtedness.

On November 4, 2021 the Company issued 8626613 common shares in satisfaction of $50,000 of convertible indebtedness and $69,012 of accrued interest on convertible indebtedness.

On November 24, 2021 the Company issued 77355500 common shares in satisfaction of $95,964 of convertible indebtedness and $36,967 of accrued interest on convertible indebtedness.

On December 10 2021 the Company issued 1,425,000 shares of Series A Preferred stock in satisfaction of $25,000 of convertible indebtedness and $10,625 of accrued interest on convertible indebtedness.

All the abovementioned securities were issued pursuant to Section 4(a) (2) of the securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The securities were sold directly through our management. No commission or other consideration was paid in connection with the sale of the securities. There was no advertisement or general solicitation made in connection with this Offer and Sale of securities.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

Item 5. OTHER INFORMATION

None.

Item 6. Exhibit Index

31.1	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANESE-OXLEY ACT OF 2002
31.2	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANESE-OXLEY ACT OF 2002
32.1	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
32.2	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
10. 1	SUBLEASE*

* Incorporated by reference to Exhibit 10.1 of that Current Report on Form 8-K filed 1/14/2022

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Regen Biopharma, Inc.

	By:	/s/ David R. Koos
	Name:	David R. Koos
	Title:	Chairman, Chief Executive Officer
	Date:	January 20, 2022

		Regen Biopharma, Inc.

	By:	/s/ David R. Koos
	Name:	David R. Koos
	Title:	Acting Chief Financial Officer, Director
	Date:	January 20, 2022

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David R. Koos, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2021 of Regen Biopharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant’s, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles:

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: January 20, 2022	By:	/s/ David R. Koos
		David R. Koos
		Chief Executive Officer

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David R. Koos certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2021 of Regen Biopharma, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: January 20, 2022	By:	/s/ David R. Koos
		David R. Koos
		Chief Financial Officer

EX-32.1 4 ex32_1.htm EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Regen Biopharma, Inc. on Form 10-Q for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David R. Koos, Chief Financial Officer certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: January 20, 2022	By:	/s/ David R. Koos
		David R. Koos
		Chief Executive Officer

EX-32.2 5 ex32_2.htm EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: January 20, 2022	By:	/s/ David R. Koos
		David R. Koos
		Chief Financial Officer

EX-101.SCH 6 rgbp-20211231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statement of Shareholder's Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - ACCOUNTS RECEIVABLE, RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - INVESTMENT SECURITIES, RELATED PARY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - INVESTMENT SECURITIES link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - STOCK TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - INVESTMENT SECURITIES, RELATED PARY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - INVESTMENT SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - NOTES PAYABLE (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - INVESTMENT SECURITIES, RELATED PARY (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - INVESTMENT SECURITIES, RELATED PARY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - INVESTMENT SECURITIES, RELATED PARY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - INVESTMENT SECURITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - INVESTMENT SECURITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - STOCK TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 rgbp-20211231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 rgbp-20211231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 rgbp-20211231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series A A Preferred Stock [Member] Series M [Member] Series N C [Member] Equity Components [Axis] Preferred Stock Series A [Member] Series N C Preferred Stock [Member] Common Stock [Member] Series M Preferred Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Contributed Capital [Member] Statistical Measurement [Axis] Maximum [Member] Minimum [Member] Related Party Transaction [Axis] Zander Therapeutics Debt Instrument [Axis] David Koos Series [Axis] Coventry Enterprises L L C [Member] Convertible Note; March 8, 2016 Convertible Note; April 6, 2016 Convertible Note; October 31, 2016 Convertible Note #2; October 31, 2016 Convertible Note #3; October 31, 2016 Convertible Note; March 13, 2017 Convertible Note: March 31, 2017 Convertible Note; April 19, 2017 Convertible Note; May 5, 2017 Convertible Note; June 26, 2017 Convertible Note; September 25, 2017 Convertible Note; October 3, 2017 Convertible Note; October 16, 2017 Convertible Note; November 01, 2017 Convertible Note; #2 November 1, 2017 Convertible Note; December 20, 2017 Convertible Note; February 28, 2018 Convertible Note; July 11, 2018 Convertible Note; September 30, 2018 Convertible Note; July 19, 2019 Related Party [Axis] Unrelated Party [Member] Oncology Pharma [Member] Convertible Debt [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS Cash Accounts Receivable, Related Party Note Receivable, Related Party Accrued Interest Receivable Prepaid Expenses Total Current Assets OTHER ASSETS Investment Securities Investment Securities, Related Party Total Other Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable Notes Payable Accrued payroll taxes Accrued Interest Accrued Rent Accrued Payroll Other Accrued Expenses Bank Overdraft Due to Investor Unearned Income Derivative Liability Convertible Notes Payable Less unamortized discount Convertible Notes Payable, Related Parties Less unamortized discount Total Current Liabilities Long Term Liabilities: Convertible Notes Payable, Related Parties Less unamortized discount Total Long Term Liabilities Total Liabilities STOCKHOLDERS' EQUITY (DEFICIT) Common Stock ($.0001 par value) 500,000,000 shares authorized; 4,800,000,000 authorized and 4,564,002,832 issued and outstanding as of December 31,2021 and 4,800,000,000 authorized and 4,350,554,514 shares issued and outstanding as of September 30 ,2021. Preferred Stock, Value, Issued Additional Paid in capital Contributed Capital Retained Earnings (Deficit) Total Stockholders' Equity (Deficit) TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares outstanding Income Statement [Abstract] REVENUES Revenues Revenues, Related Party TOTAL REVENUES COST AND EXPENSES Research and Development Research and Development, Related Party General and Administrative Consulting and Professional Fees Rent Total Costs and Expenses OPERATING INCOME (LOSS) OTHER INCOME & (EXPENSES) Interest Income Interest Expense Interest Expense attributable to Amortization of Discount Unrealized Gain ( Loss) on sale of Investment Securities Gain (Loss) on derecognition of Accounts Payable Derivative Income (Expense) Gain (Loss) on Extinguishment Convertible Debt TOTAL OTHER INCOME (EXPENSE) NET INCOME (LOSS) NET INCOME (LOSS) attributable to common shareholders BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Beginning balance, value Beginning balance, Shares Shares issued for Debt Shares issued for Debt, Shares Shares issued for Interest Shares Issued For Interest, Shares Shares issued for Debt Shares issued for Debt, Shares Shares issued for Interest Shares Issued For Interest, Shares EX-101.PRE 10 rgbp-20211231_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Dec. 31, 2021	Jun. 30, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--09-30
Entity File Number	333-191725
Entity Registrant Name	REGEN BIOPHARMA, INC
Entity Central Index Key	0001589150
Entity Tax Identification Number	45-5192997
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	4700 Spring Street
Entity Address, Address Line Two	St 304
Entity Address, City or Town	La Mesa
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91942
City Area Code	619
Local Phone Number	722-5505
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,564,002,832

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Dec. 31, 2021	Sep. 30, 2021
CURRENT ASSETS
Cash	$ 353,492	$ 727,162
Accounts Receivable, Related Party	240,617	213,192
Note Receivable, Related Party	5,396	5,396
Accrued Interest Receivable	365	230
Prepaid Expenses	41,288	48,144
Total Current Assets	641,157	994,124
OTHER ASSETS
Investment Securities	74,115	198,006
Investment Securities, Related Party	19,969	19,969
Total Other Assets	94,084	217,975
TOTAL ASSETS	735,241	1,212,099
Current Liabilities:
Accounts payable	32,288	91,498
Notes Payable	1,451,630	1,429,179
Accrued payroll taxes	4,241	4,241
Accrued Interest	661,934	954,861
Accrued Rent	0	0
Accrued Payroll	1,266,679	1,266,679
Other Accrued Expenses	41,423	41,423
Bank Overdraft	1,000	1,000
Due to Investor	20,000	20,000
Unearned Income	1,812,166	1,843,806
Derivative Liability	3,927,538	6,892,477
Convertible Notes Payable Less unamortized discount	1,262,310	2,131,311
Convertible Notes Payable, Related Parties Less unamortized discount	10,000	21,500
Total Current Liabilities	10,491,210	14,697,976
Long Term Liabilities:
Convertible Notes Payable, Related Parties Less unamortized discount		0
Total Liabilities	10,491,210	14,697,976
STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 4,800,000,000 authorized and 4,564,002,832 issued and outstanding as of December 31,2021 and 4,800,000,000 authorized and 4,350,554,514 shares issued and outstanding as of September 30 ,2021.	456,399	435,054
Preferred Stock, Value, Issued
Additional Paid in capital	9,706,891	8,644,037
Contributed Capital	736,326	736,326
Retained Earnings (Deficit)	(20,703,920)	(23,348,900)
Total Stockholders' Equity (Deficit)	(9,755,969)	(13,485,877)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	735,241	1,212,099
Series A Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, Value, Issued	43,929	43,200
Series A A Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, Value, Issued	5	5
Series M [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, Value, Issued	4,400	4,400
Series N C [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, Value, Issued	$ 1	$ 1

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2021	Sep. 30, 2021
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	4,800,000,000	4,800,000,000
Common stock, shares issued	4,564,002,832	4,350,554,514
Common stock, shares outstanding	4,564,002,832	4,350,554,514
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	800,000,000	800,000,000
Series A Preferred Stock [Member]
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares outstanding	439,293,406	431,998,817
Series A A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares outstanding	50,000	50,000
Series M [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares outstanding	44,000,000	44,000,000
Series N C [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000	0
Preferred stock, shares outstanding	10,000	0

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
REVENUES
Revenues	$ 31,640
Revenues, Related Party	27,425	27,425
TOTAL REVENUES	59,065	27,425
COST AND EXPENSES
Research and Development	35,418	1,127
Research and Development, Related Party	80,275	0
General and Administrative	6,658	44,778
Consulting and Professional Fees	38,136	0
Rent	5,000	0
Total Costs and Expenses	165,487	45,905
OPERATING INCOME (LOSS)	(106,423)	(18,480)
OTHER INCOME & (EXPENSES)
Interest Income	135	0
Interest Expense	(35,010)	(73,212)
Interest Expense attributable to Amortization of Discount	(22,451)	(36,717)
Unrealized Gain ( Loss) on sale of Investment Securities	(123,891)	0
Gain (Loss) on derecognition of Accounts Payable	62,700	0
Derivative Income (Expense)	2,964,939	1,794,776
Gain (Loss) on Extinguishment Convertible Debt	(95,019)	0
TOTAL OTHER INCOME (EXPENSE)	2,751,403	1,684,847
NET INCOME (LOSS)	2,644,980	1,666,367
NET INCOME (LOSS) attributable to common shareholders	$ 2,391,062	$ 1,385,417
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ 0.001	$ 0.000
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	4,506,953,931	1,769,079,104

XML 15 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Shareholder's Deficit (Unaudited) - USD ($)	Preferred Stock Series A [Member]	Series A A Preferred Stock [Member]	Series N C Preferred Stock [Member]	Common Stock [Member]	Series M Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Contributed Capital [Member]	Total
Beginning balance, value at Sep. 30, 2020	$ 38,177	$ 5		$ 160,498	$ 4,400	$ 8,313,876	$ (16,583,666)	$ 731,711	$ (7,334,998)
Beginning balance, Shares at Sep. 30, 2020	381,768,689	50,000		1,605,000,246	44,000,000
Shares issued for Debt				$ 5,773		(2,021)			3,752
Shares issued for Debt, Shares				57,726,183
Shares issued for Interest				$ 2,234		(782)			1,452
Shares Issued For Interest, Shares				22,339,663
Shares issued for Debt				$ 6,001		(2,101)			3,900
Shares issued for Debt, Shares				60,007,919
Shares issued for Interest				$ 2,393		(838)			1,555
Shares Issued For Interest, Shares				23,926,234
Shares issued for Debt				$ 6,083		1,217			7,300
Shares issued for Debt, Shares				60,834,498
Shares issued for Interest				$ 2,619		523			3,142
Shares Issued For Interest, Shares				26,185,501
Shares issued for Debt				$ 330		99			429
Shares issued for Debt, Shares				3,300,000
Shares issued for Interest				$ 182		54			236
Shares issued for Interest, Shares				1,819,077
Shares issued for Fees				$ 123		36			159
Shares issued for Fees, shares				1,228,077
Shares issued for Debt				$ 6,200		(2,170)			4,030
Shares issued for Debt, Shares				62,003,571
Shares issued for Interest				$ 2,616		(916)			1,700
Shares issued for Interest, Shares				26,155,352
Shares issued for Debt				$ 6,833		1,367			8,200
Shares Issued for Debt, Shares				68,333,539
Shares issued for Interest				$ 1,488		212			1,700
Shares issued for Interest, Shares				14,883,378
Shares issued for Debt	$ 2,000					11,000			13,000
Shares Issued for Debt, Shares	20,000,437
Shares issued for Interest	$ 1,238					6,808			8,046
Shares issued for Interest, Shares	12,378,732
Shares issued for Debt				$ 8,889		7,111			16,000
Shares Issued for Debt, Shares				88,888,889
Shares issued for Interest				$ 1,956		1,294			3,250
Shares issued for Interest, Shares				19,555,555
Shares issued for Debt				$ 8,200		(2,870)			5,330
Shares Issued for Debt, Shares				82,004,603
Shares issued for Interest				$ 3,583		(1,254)			2,329
Shares issued for Interest, Shares				35,832,781
Additions to Contributed Capital Quarter ended 12/31/2020								1,865	1,865
Net Loss							1,666,367		1,666,367
Ending balance, value at Dec. 31, 2020	$ 41,415	$ 5		$ 226,001	$ 4,400	8,330,646	(14,917,299)	733,576	(5,581,256)
Ending balance, Shares at Dec. 31, 2020	414,147,858	50,000		2,260,025,066	44,000,000
Beginning balance, value at Sep. 30, 2021	$ 43,200	$ 5	$ 1	$ 435,054	$ 4,400	8,644,037	(23,348,900)	736,326	(13,485,877)
Beginning balance, Shares at Sep. 30, 2021	431,998,817	50,000	10,000	4,350,554,514	44,000,000
Shares issued for Debt				$ 1,000		99,000			100,000
Shares issued for Debt, Shares				10,000,000
Shares issued for Interest				$ 267		26,395			26,662
Shares Issued For Interest, Shares				2,666,200
Shares issued for Debt				$ 1,000		99,000			100,000
Shares issued for Debt, Shares				10,000,000
Shares issued for Interest				$ 388		38,449			38,837
Shares Issued For Interest, Shares				3,883,700
Shares issued for Debt				$ 602		49,398			50,000
Shares issued for Debt, Shares				6,022,971
Shares issued for Interest				$ 236		19,367			19,603
Shares Issued For Interest, Shares				2,361,366
Shares issued for Debt				$ 1,550		48,450			50,000
Shares issued for Debt, Shares				15,503,953
Shares issued for Interest				$ 576		17,999			18,575
Shares issued for Interest, Shares				5,759,719
Shares issued for Debt				$ 995		31,080			32,075
Shares issued for Debt, Shares				9,945,768
Shares issued for Interest				$ 2,326		72,674			75,000
Shares issued for Interest, Shares				23,255,888
Shares issued for Debt				$ 100		24,900			25,000
Shares Issued for Debt, Shares				1,000,016
Shares issued for Interest				$ 775		24,225			25,000
Shares issued for Interest, Shares				7,751,973
Shares issued for Debt	$ 400					49,600			50,000
Shares Issued for Debt, Shares	4,000,047
Shares issued for Interest				$ 321		10,035			10,356
Shares issued for Interest, Shares				3,211,178
Shares issued for Debt				$ 1,026		98,974			100,000
Shares Issued for Debt, Shares				10,256,427
Shares issued for Interest				$ 408		39,400			39,808
Shares issued for Interest, Shares				4,082,878
Shares issued for Interest				$ 36		8,847			8,883
Shares issued for Interest, Shares				355,326
Shares issued for Debt				$ 842		39,158			40,000
Shares Issued for Debt, Shares				8,421,053
Shares issued for Interest				$ 299		13,893			14,192
Shares issued for Interest, Shares				2,987,789
Shares issued for Debt				$ 625		49,375			50,000
Shares Issued for Debt, Shares				6,250,082
Shares issued for Interest				$ 238		18,774			19,012
Shares issued for Interest, Shares				2,376,531
Shares issued for Debt				$ 7,248		3,716			10,964
Shares Issued for Debt, Shares				72,476,800
Shares issued for Debt				$ 100		24,900			25,000
Shares Issued for Debt, Shares				1,000,014
Shares issued for Interest				$ 46		11,481			11,527
Shares issued for Interest, Shares				461,086
Shares issued for Debt				$ 240		59,760			60,000
Shares Issued for Debt, Shares				2,400,000
Shares issued for Interest				$ 102		25,338			25,440
Shares issued for Interest, Shares				1,017,600
Shares issued for Debt	$ 100					24,900			25,000
Shares issued for debt, Shares	1,000,000
Shares issued for Interest	$ 43					10,583			10,625
Shares issued for Interest, Shares	425,000
Shares issued for Interest	$ 187					23,182			23,369
Shares issued for Interest, Shares	1,869,542
Net Loss							2,644,980		2,644,980
Ending balance, value at Dec. 31, 2021	$ 43,929	$ 5	$ 1	$ 456,399	$ 4,400	$ 9,706,891	$ (20,703,920)		$ (9,755,969)
Ending balance, Shares at Dec. 31, 2021	439,293,406	50,000	10,000	4,564,002,832	44,000,000

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ 2,644,980	$ 1,666,367
Adjustments to reconcile net Income to net cash
Preferred Stock issued to Consultants
Common Stock issued for Expenses		159
Preferred Stock issued as compensation
Increase (Decrease) in Interest expense attributable to amortization of Discount	22,451	36,717
Increase (Decrease) in Accounts Payable	(59,210)	3,369
(Increase) Decrease in Accounts Receivable	(27,425)	(27,425)
Increase (Decrease) in accrued Expenses	6,036	113,712
(Increase) Decrease in Prepaid Expenses	6,856	12
Increase(Decrease) in Contributed Capital		1,865
Increase (Decrease) in Derivative Expense	(2,964,939)	(1,794,776)
Increase (Decrease) in Unearned Income	(31,640)
(Increase( Decrease in Accrued Interest Receivable	(135)
Unrealized Loss(Gain) on Investment Securities	123,891
Net Cash Provided by (Used in) Operating Activities	(279,135)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase ( Decrease) in Notes Payable
Increase( Decrease) in Convertible Notes Payable	(94,535)	0
Net Cash Provided by (Used in) Financing Activities	(94,535)	0
Net Increase (Decrease) in Cash	(373,670)	0
Cash at Beginning of Period	727,162
Cash at End of Period	353,492
Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt	710,964	48,941
Preferred Shares Issued for Debt	75,000	13,000
Cash Paid for Interest	28,973
Common shares Issued for Interest	264,970	15,721
Preferred Shares issued for Interest	$ 33,994	$ 8,046

XML 17 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada

A. BASIS OF ACCOUNTING

B. PRINCIPLES OF CONSOLIDATION

Schedule of Derivative Liability
Risk Free Interest Rate	1.49	%
Expected Term	.(0.66) – (1.85) Yrs
Expected Volatility	824.95	%
Expected Dividends

H. INCOME TAXES

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

I. BASIC EARNINGS (LOSS) PER SHARE

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended December 31,2020 and December 31, 2021..

K. NOTES RECEIVABLE

Notes receivable are stated at cost, less impairment, if any.

As of December 31,2021 the Company has the following Notes Receivable

Schedule of notes receivable
Zander Therapeutics, Inc.		$	5,396

$5,396 owed to the Company by Zander Therapeutics, Inc. bears simple interest at 10% and is due upon the demand of the Company.

L. REVENUE RECOGNITION

M. INTEREST RECEIVABLE

Interest receivable is stated at cost, less impairment, if any.

XML 18 R8.htm IDEA: XBRL DOCUMENT

RECENT ACCOUNTING PRONOUNCEMENTS

3 Months Ended

Dec. 31, 2021

Accounting Changes and Error Corrections [Abstract]

RECENT ACCOUNTING PRONOUNCEMENTS

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (c)

+ Details

XML 19 R9.htm IDEA: XBRL DOCUMENT

GOING CONCERN

3 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

NOTE 3. GOING CONCERN

Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise.

XML 20 R10.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

3 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

NOTES PAYABLE

NOTE 4. NOTES PAYABLE

(a) RELATED PARTY

Schedule of notes payable related party
	As of December 31, 2021
David Koos	$	227
Total:	$	227

$227 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.

(b) NON RELATED PARTY

Schedule of non related party
Coventry Enterprises LLC,	$	1,500,000
Total:	$	1,500,000

The OID is being amortized by the Company over the term of the Note. As of December 31 ,2021 the unamortized discount on this Note is $48,597.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE

3 Months Ended

Dec. 31, 2021

Convertible Notes Payable

CONVERTIBLE NOTES PAYABLE

NOTE 5. CONVERTIBLE NOTES PAYABLE

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30,2021 the unamortized discount on the convertible note outstanding is $ 0 As of December 31,2021 $50,000 of the principal amount of the Note remains outstanding.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.

The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30,2021 the unamortized discount on the convertible note outstanding is $0. As of December 31 ,2021 $50,000 of the principal amount of the Note remains outstanding.

The warrants shall be exercisable:

As of December 31,2021 $50,000 of the principal amount of the Note remains outstanding.

The warrants shall be exercisable:

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $204,082 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0.

The warrants shall be exercisable:

As of December 31,2021 $50,000 of the principal amount of the Note remains outstanding.

(iii) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $200,000 of the principal amount of the Note remains outstanding.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $150,000 of the principal amount of the Note remains outstanding.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31, 2021 $50,000 of the principal amount of the Note remains outstanding.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021, $50,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $204,082 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $100,000 of the principal amount of the Note remains outstanding.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $25,000 of the principal amount of the Note remains outstanding.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party.

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $25,000 of the principal amount of the Note remains outstanding.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $100,000 of the principal amount of the Note remains outstanding.

(i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of these Notes, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $100,000 of the principal amount of the Notes remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $408,163 was recognized by the Company as of December 31,2021. The issuance of the Notes amounted in a discount of $100,000 which is amortized under the Interest Method over the life of the Notes. As of December 31,2021 the unamortized discount on the convertible notes outstanding is $0.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31,2021 $11,500 of the principal amount of the Note remains outstanding.

As of December 31, 2021, 10,000 of the principal amount of the Note remains outstanding.

Zander and Regen are under common control. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications.

On July 19, 2019 the Company issued a convertible promissory note in the face amount of $100,000 (“Note”) for consideration consisting of:

$95,000 cash

the payment of $5,000 of legal fees

The proceeds from the issuance of the Note are to be allocated as follows:

The Note may be prepaid with the following penalties:

Time Period		Payment Premium
<=60 days after note issuance		125% of the sum of principal plus accrued interest
>60 days <= 120 days after note issuance		135% of the sum of principal plus accrued interest
>120 days <=180 days after note issuance		140% of the sum· of principal plus accrued· interest

This Note may not be prepaid after the 180th day.

As of December 31,2021 $1,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $3,048 was recognized by the Company as of December 31,2021.

XML 22 R12.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

3 Months Ended

Dec. 31, 2021

RELATED PARTY TRANSACTIONS

NOTE 6. RELATED PARTY TRANSACTIONS

The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander.

The Agreement may be terminated by The Company:

The Agreement may be terminated by either party in the event of a material breach by the other party.

On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby:

2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement.

3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement.

No actions were taken by any of the parties to enforce the terms of the Agreement.

On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be:

a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return

Zander and Regen are under common control.

As of September 30, 2021, $10,000 of the principal amount of the Note remains outstanding.

On October 8,2021 the Company entered into an agreement with Dr. Brian Koos, MD PhD whereby Dr. Brian Koos would provide services to the Company consisting of :

a) Reviewing existing publications on research being conducted on Checkpoint NR2F6.

b) Identifying the most promising applications for the Company’s technology

c) Drafting a “white paper” on results for 1(b)

d) Making introductions to known experts in appropriate fields identified in 1(b).

BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

XML 23 R13.htm IDEA: XBRL DOCUMENT

ACCOUNTS RECEIVABLE, RELATED PARTY

3 Months Ended

Dec. 31, 2021

Credit Loss [Abstract]

ACCOUNTS RECEIVABLE, RELATED PARTY

NOTE 7. ACCOUNTS RECEIVABLE, RELATED PARTY

XML 24 R14.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ EQUITY

3 Months Ended

Dec. 31, 2021

Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 8. STOCKHOLDERS’ EQUITY

The stockholders’ equity section of the Company contains the following classes of capital stock as of December 31 2021:

Common stock, $ 0.0001 par value; 4,800,000,000 shares authorized: 4,564,002,832 shares issued and outstanding.

Series AA Preferred Stock

Series A Preferred Stock

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARY

3 Months Ended

Dec. 31, 2021

Investment Securities Related Pary

INVESTMENT SECURITIES, RELATED PARY

NOTE 9. INVESTMENT SECURITIES, RELATED PARY

On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc.

Schedule of dividend income
Fair Value of Intellectual Property	$	1,500
Prepaid Expenses		74,298
Due from Employee		1,071
Note Receivable		64,400
Accrued Interest Receivable		20,274
Investment Securities		593,357
Convertible Note Receivable		10,000
Accounts Payable		1,269,041
Notes Payable		500,000
Accrued Expenses Related Parties		89,529
Accrued Expenses		203,037
Enterprise Value		2,826,507
Less: Total Debt		(2,061,607	)
Portion of Enterprise Value Attributable to Shareholders		764,900
Fair Value Per Share	$	0.0167

The abovementioned constitute the Company’s sole related party investment securities as of December 31, 2021

As of December 31, 2021:

	Schedule of comprehensive income
470,588 Common Shares of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Gains	Net Unrealized Gain or (Loss) realized during the quarter ended December 31,2021
$	5,741	$	7,858	$	2,118	$	0

725,000 Series M Preferred of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Loss		Net Unrealized Gain or (Loss) realized during the quarter ended September 30,2021
$	13,124	$	12,109	$	(1,104	)	$	0

XML 26 R16.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES

3 Months Ended

Dec. 31, 2021

Disclosure Investment Securities Abstract

INVESTMENT SECURITIES

NOTE 10. INVESTMENT SECURITIES

During the quarter ended June 30, 2021 13,000 of the aforementioned common shares were sold to an unrelated party for $300,000 cash.

During the quarter ended September 30, 2021 18,000 of the aforementioned common shares were sold to an unrelated party for $195,000 cash.

As of December 31, 2021 18,300 common shares of Oncology Pharma, Inc. constitute the sole investment securities other than shares of Zander Therapeutics, Inc. held by the Company.

On December 31,2021 the Company revalued 18,300 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market.

As of December 31, 2021:

	Schedule of investment securities
18,300 Common Shares of Oncology Pharma, Inc.

	Basis		Fair Value		Total Unrealized Losses	Net Unrealized Gain or (Loss) realized during the quarter ended December 31,2021
$	677,100	$	74,115	$	602,985	$	(123,891)

XML 27 R17.htm IDEA: XBRL DOCUMENT

STOCK TRANSACTIONS

3 Months Ended

Dec. 31, 2021

Stock Transactions

STOCK TRANSACTIONS

NOTE 12. STOCK TRANSACTIONS

On October 1, 2021 the Company issued 101,718,058 common shares in satisfaction of $425,000 of convertible indebtedness and $154,991 of accrued interest on convertible indebtedness.

On October 1, 2021 the Company issued 5,869,589 shares of Series A Preferred stock in satisfaction of $50,000 of convertible indebtedness and $23,369 of accrued interest on convertible indebtedness.

On October 29, 2021 the Company issued 25748147 common shares in satisfaction of $140,000 of convertible indebtedness and $54,000 of accrued interest on convertible indebtedness.

On November 4 , 2021 the Company issued 8626613 common shares in satisfaction of $50,000 of convertible indebtedness and $69,012 of accrued interest on convertible indebtedness.

On November 24, 2021 the Company issued 77355500 common shares in satisfaction of $95,964 of convertible indebtedness and $36,967 of accrued interest on convertible indebtedness.

On December 10 2021 the Company issued 1,425,000 shares of Series A Preferred stock in satisfaction of $25,000 of convertible indebtedness and $10,625 of accrued interest on convertible indebtedness.

XML 28 R18.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Dec. 31, 2021

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 13. SUBSEQUENT EVENTS

BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

XML 29 R19.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

BASIS OF ACCOUNTING

A. BASIS OF ACCOUNTING

PRINCIPLES OF CONSOLIDATION

B. PRINCIPLES OF CONSOLIDATION

Schedule of Derivative Liability
Risk Free Interest Rate	1.49	%
Expected Term	.(0.66) – (1.85) Yrs
Expected Volatility	824.95	%
Expected Dividends

INCOME TAXES

H. INCOME TAXES

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

BASIC EARNINGS (LOSS) PER SHARE

I. BASIC EARNINGS (LOSS) PER SHARE

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

ADVERTISING

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended December 31,2020 and December 31, 2021..

NOTES RECEIVABLE

K. NOTES RECEIVABLE

Notes receivable are stated at cost, less impairment, if any.

As of December 31,2021 the Company has the following Notes Receivable

Schedule of notes receivable
Zander Therapeutics, Inc.		$	5,396

$5,396 owed to the Company by Zander Therapeutics, Inc. bears simple interest at 10% and is due upon the demand of the Company.

REVENUE RECOGNITION

L. REVENUE RECOGNITION

INTEREST RECEIVABLE

M. INTEREST RECEIVABLE

Interest receivable is stated at cost, less impairment, if any.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

XML 30 R20.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Schedule of Derivative Liability

Schedule of Derivative Liability
Risk Free Interest Rate	1.49	%
Expected Term	.(0.66) – (1.85) Yrs
Expected Volatility	824.95	%
Expected Dividends

Schedule of notes receivable

Schedule of notes receivable
Zander Therapeutics, Inc.		$	5,396

XML 31 R21.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Tables)

3 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

Schedule of notes payable related party

Schedule of notes payable related party
	As of December 31, 2021
David Koos	$	227
Total:	$	227

Schedule of non related party

Schedule of non related party
Coventry Enterprises LLC,	$	1,500,000
Total:	$	1,500,000

XML 32 R22.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARY (Tables)

3 Months Ended

Dec. 31, 2021

Investment Securities Related Pary

Schedule of dividend income

Schedule of dividend income
Fair Value of Intellectual Property	$	1,500
Prepaid Expenses		74,298
Due from Employee		1,071
Note Receivable		64,400
Accrued Interest Receivable		20,274
Investment Securities		593,357
Convertible Note Receivable		10,000
Accounts Payable		1,269,041
Notes Payable		500,000
Accrued Expenses Related Parties		89,529
Accrued Expenses		203,037
Enterprise Value		2,826,507
Less: Total Debt		(2,061,607	)
Portion of Enterprise Value Attributable to Shareholders		764,900
Fair Value Per Share	$	0.0167

Schedule of comprehensive income

	Schedule of comprehensive income
470,588 Common Shares of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Gains	Net Unrealized Gain or (Loss) realized during the quarter ended December 31,2021
$	5,741	$	7,858	$	2,118	$	0

725,000 Series M Preferred of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Loss		Net Unrealized Gain or (Loss) realized during the quarter ended September 30,2021
$	13,124	$	12,109	$	(1,104	)	$	0

XML 33 R23.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES (Tables)

3 Months Ended

Dec. 31, 2021

Disclosure Investment Securities Abstract

Schedule of investment securities

	Schedule of investment securities
18,300 Common Shares of Oncology Pharma, Inc.

	Basis		Fair Value		Total Unrealized Losses	Net Unrealized Gain or (Loss) realized during the quarter ended December 31,2021
$	677,100	$	74,115	$	602,985	$	(123,891)

XML 34 R24.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	3 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Risk Free Interest Rate	1.49%
Expected Volatility	824.95%
Maximum [Member]
Property, Plant and Equipment [Line Items]
Expected Term	7 months 28 days
Minimum [Member]
Property, Plant and Equipment [Line Items]
Expected Term	1 year 10 months 6 days

XML 35 R25.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)	Dec. 31, 2021 USD ($)
Zander Therapeutics
Defined Benefit Plan Disclosure [Line Items]
Long-term Investments and Receivables, Net	$ 5,396

XML 36 R26.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2021	Dec. 30, 2020
Accounting Policies [Abstract]
Valuation allowance	100.00%
Advertising expenses	$ 0	$ 0

XML 37 R27.htm IDEA: XBRL DOCUMENT

GOING CONCERN (Details Narrative)	116 Months Ended
GOING CONCERN (Details Narrative)	Dec. 31, 2021 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss since inception	$ 20,703,920

XML 38 R28.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details)	Dec. 31, 2021 USD ($)
Short-term Debt [Line Items]
Notes Payable	$ 227
David Koos
Short-term Debt [Line Items]
Notes Payable	$ 227

XML 39 R29.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details 1)	Dec. 31, 2021 USD ($)
Short-term Debt [Line Items]
Notes Payable	$ 1,500,000
Coventry Enterprises L L C [Member]
Short-term Debt [Line Items]
Notes Payable	$ 1,500,000

XML 40 R30.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Sep. 17, 2021	Dec. 31, 2021	Dec. 31, 2020
Debt instrument interest rate	5.00%
Principal amount	$ 1,500,000
Original ssue discount	75,000
Transaction cost	35,000
Paymemt for fee	1,390,000
Interest amount	62,500	$ 28,973
Periodic payments	$ 312,500
Unamortized discount		48,597
David Koos
Note payable		$ 227
Debt instrument interest rate		15.00%

XML 41 R31.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Details Narrative)	3 Months Ended
CONVERTIBLE NOTES PAYABLE (Details Narrative)	Dec. 31, 2021 USD ($)
Short-term Debt [Line Items]
Unamortized discount	$ 48,597
Convertible Note; March 8, 2016
Short-term Debt [Line Items]
Convertible note issued and outstanding	100,000
Cash issued for convertible note	$ 100,000
Convertible note, interest rate	8.00%
Beneficial conversion feature	$ 42,600
Unamortized discount	0
Outstanding balance	100,000
Convertible Note; April 6, 2016
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	8.00%
Beneficial conversion feature	$ 9,900
Unamortized discount	0
Outstanding balance	50,000
Convertible Note; October 31, 2016
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Outstanding balance	50,000
Convertible Note #2; October 31, 2016
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Outstanding balance	50,000
Convertible Note #3; October 31, 2016
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Outstanding balance	50,000
Convertible Note; March 13, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	50,000
Converted value that exceeds the principal amount	50,000
Derivative Liability	204,082
Convertible Note: March 31, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	50,000
Converted value that exceeds the principal amount	50,000
Derivative Liability	204,082
Convertible Note; April 19, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	50,000
Converted value that exceeds the principal amount	50,000
Derivative Liability	204,082
Convertible Note; May 5, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	200,000
Cash issued for convertible note	$ 200,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	200,000
Converted value that exceeds the principal amount	200,000
Derivative Liability	816,327
Convertible Note; June 26, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	150,000
Cash issued for convertible note	$ 150,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	150,000
Converted value that exceeds the principal amount	150,000
Derivative Liability	612,245
Convertible Note; September 25, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	50,000
Converted value that exceeds the principal amount	50,000
Derivative Liability	204,082
Convertible Note; October 3, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	50,000
Converted value that exceeds the principal amount	50,000
Derivative Liability	204,082
Convertible Note; October 16, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	100,000
Cash issued for convertible note	$ 100,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	100,000
Converted value that exceeds the principal amount	100,000
Derivative Liability	408,163
Convertible Note; November 01, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	25,000
Cash issued for convertible note	$ 25,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	25,000
Converted value that exceeds the principal amount	25,000
Derivative Liability	102,041
Convertible Note; #2 November 1, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	25,000
Cash issued for convertible note	$ 25,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	25,000
Converted value that exceeds the principal amount	25,000
Derivative Liability	102,041
Convertible Note; December 20, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	100,000
Cash issued for convertible note	$ 100,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	100,000
Converted value that exceeds the principal amount	100,000
Derivative Liability	408,163
Convertible Note; February 28, 2018
Short-term Debt [Line Items]
Convertible note issued and outstanding	100,000
Cash issued for convertible note	$ 100,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	100,000
Converted value that exceeds the principal amount	100,000
Derivative Liability	408,163
Convertible Note; July 11, 2018
Short-term Debt [Line Items]
Convertible note issued and outstanding	11,500
Cash issued for convertible note	$ 11,500
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	11,500
Converted value that exceeds the principal amount	11,500
Derivative Liability	46,938
Convertible Note; September 30, 2018
Short-term Debt [Line Items]
Convertible note issued and outstanding	350,000
Cash issued for convertible note	$ 350,000
Convertible note, interest rate	10.00%
Beneficial conversion feature	$ 350,000
Unamortized discount	0
Outstanding balance	10,000
Converted value that exceeds the principal amount	10,000
Convertible Note; July 19, 2019
Short-term Debt [Line Items]
Convertible note issued and outstanding	100,000
Cash issued for convertible note	95,000
Unamortized discount	0
Outstanding balance	1,000
Derivative Liability	$ 3,048

XML 42 R32.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative)	Dec. 31, 2021 USD ($)
Short-term Debt [Line Items]
Notes Payable, related party	$ 227
Convertible Note; September 30, 2018
Short-term Debt [Line Items]
Convertible Notes Payable, Current	350,000
Notes Payable, Current	10,000
David Koos
Short-term Debt [Line Items]
Notes Payable, related party	227
Notes payable	$ 227

XML 43 R33.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ EQUITY (Details Narrative) - $ / shares	Dec. 31, 2021	Sep. 30, 2021
Class of Stock [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common stock, authorized	4,800,000,000	4,800,000,000
Common stock issued	4,564,002,832	4,350,554,514
Common stock outstanding	4,564,002,832	4,350,554,514
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	800,000,000	800,000,000
Series A A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares issued and outstanding	50,000
Preferred stock, shares outstanding	50,000	50,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares outstanding	439,293,406	431,998,817
Series M [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares outstanding	44,000,000	44,000,000
Series N C [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000	0
Preferred stock, shares outstanding	10,000	0

XML 44 R34.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARY (Details) - USD ($)	Dec. 31, 2021	Sep. 30, 2021
Prepaid Expenses	$ 41,288	$ 48,144
Accrued Interest Receivable	365	230
Accounts Payable	32,288	$ 91,498
Common Stock [Member] \| Zander Therapeutics
Fair Value of Intellectual Property	1,500
Prepaid Expenses	74,298
Due from Employee	1,071
Note Receivable	64,400
Accrued Interest Receivable	20,274
Investment Securities	593,357
Convertible Note Receivable	10,000
Accounts Payable	1,269,041
Notes Payable	500,000
Accrued Expenses, Related Party	89,529
Accrued Expenses	203,037
Enterprise Value	2,826,507
Less: Total Debt	2,061,607
Portion of Enterprise Value attributable to Shareholders	$ 764,900
Fair Value per share	$ 0.0167
Series M [Member] \| Zander Therapeutics
Fair Value of Intellectual Property	$ 1,500
Prepaid Expenses	74,298
Due from Employee	1,071
Note Receivable	64,400
Accrued Interest Receivable	20,274
Investment Securities	593,357
Convertible Note Receivable	10,000
Accounts Payable	1,269,041
Notes Payable	500,000
Accrued Expenses, Related Party	89,529
Accrued Expenses	203,037
Enterprise Value	2,826,507
Less: Total Debt	2,061,607
Portion of Enterprise Value attributable to Shareholders	$ 764,900
Fair Value per share	$ 0.0167

XML 45 R35.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARY (Details 1) - USD ($)	3 Months Ended
	Dec. 31, 2021	Sep. 30, 2021
Investment Securities, Fair Value	$ 74,115	$ 198,006
Common Stock [Member] \| Zander Therapeutics
Investment Securities, Basis	5,741
Investment Securities, Fair Value	7,858
Investment Securities, Total Unrealized Gain	2,118
Investment Securities, net Unrealized Gain or (Loss) realized	0
Series M [Member] \| Zander Therapeutics
Investment Securities, Basis	13,124
Investment Securities, Fair Value	12,109
Investment Securities, Total Unrealized Gain	(1,104)
Investment Securities, net Unrealized Gain or (Loss) realized	$ 0

XML 46 R36.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARY (Details Narrative) - Zander Therapeutics - USD ($)		1 Months Ended	3 Months Ended
	Jun. 11, 2019	Nov. 29, 2019	Dec. 31, 2021
Number of shares issued for property dividend	470,588		470,588
Series M [Member]
Number of shares issued in satisfaction of prepaid rent and accrued interest		725,000	725,000
Shares issued in satisfaction of prepaid rent and accrued interest, value		$ 13,124

XML 47 R37.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES (Details) - USD ($)	3 Months Ended
INVESTMENT SECURITIES (Details) - USD ($)	Dec. 31, 2021	Sep. 30, 2021
Available-for-sale Securities	$ 74,115	$ 198,006
Common Stock [Member] \| Oncology Pharma [Member]
Investment Securities, Basis	677,100
Available-for-sale Securities	74,115
Investment Securities, Total Unrealized Gain	602,985
Series M [Member] \| Oncology Pharma [Member]
Equity Securities, FV-NI, Unrealized Gain (Loss)	$ (123,891)

XML 48 R38.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES (Details Narrative) - Unrelated Party [Member] - USD ($)	3 Months Ended
	Sep. 30, 2021	Jun. 30, 2021
Defined Benefit Plan Disclosure [Line Items]
Number of shares sold	18,000	13,000
Proceeds from Issuance or Sale of Equity	$ 195,000	$ 300,000

XML 49 R39.htm IDEA: XBRL DOCUMENT

STOCK TRANSACTIONS (Details Narrative) - Convertible Debt [Member] - USD ($)				1 Months Ended
	Dec. 10, 2021	Nov. 04, 2021	Oct. 02, 2021	Nov. 24, 2021	Oct. 29, 2021
Common Stock [Member]
Short-term Debt [Line Items]
Shares issued in satisfaction of convertible identedness		8,626,613	101,718,058	77,355,500	25,748,147
Value of shares issued in satisdaction of convertible debt		$ 50,000	$ 425,000	$ 95,964	$ 140,000
Accrued Interest		$ 69,012	$ 154,991	$ 36,967	$ 54,000
Series A Preferred Stock [Member]
Short-term Debt [Line Items]
Shares issued in satisfaction of convertible identedness	1,425,000		5,869,589
Value of shares issued in satisdaction of convertible debt	$ 25,000		$ 50,000
Accrued Interest	$ 10,625		$ 23,369

XML 50 rgbp123121form10q_htm.xml IDEA: XBRL DOCUMENT 0001589150 2021-10-01 2021-12-31 0001589150 2021-06-30 0001589150 2021-12-31 0001589150 2021-09-30 0001589150 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001589150 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2021-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesMMember 2021-12-31 0001589150 RGBP:SeriesMMember 2021-09-30 0001589150 RGBP:SeriesNCMember 2021-12-31 0001589150 RGBP:SeriesNCMember 2021-09-30 0001589150 2020-10-01 2020-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2020-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2020-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2020-09-30 0001589150 us-gaap:CommonStockMember 2020-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2020-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001589150 us-gaap:RetainedEarningsMember 2020-09-30 0001589150 RGBP:ContributedCapitalMember 2020-09-30 0001589150 2020-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2020-10-01 2020-12-31 0001589150 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2020-10-01 2020-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001589150 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001589150 RGBP:ContributedCapitalMember 2020-10-01 2020-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2020-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2020-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2020-12-31 0001589150 us-gaap:CommonStockMember 2020-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2020-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001589150 us-gaap:RetainedEarningsMember 2020-12-31 0001589150 RGBP:ContributedCapitalMember 2020-12-31 0001589150 2020-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2021-09-30 0001589150 us-gaap:CommonStockMember 2021-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2021-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001589150 us-gaap:RetainedEarningsMember 2021-09-30 0001589150 RGBP:ContributedCapitalMember 2021-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-10-01 2021-12-31 0001589150 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-10-01 2021-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001589150 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001589150 RGBP:ContributedCapitalMember 2021-10-01 2021-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-12-31 0001589150 us-gaap:CommonStockMember 2021-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001589150 us-gaap:RetainedEarningsMember 2021-12-31 0001589150 RGBP:ContributedCapitalMember 2021-12-31 0001589150 srt:MaximumMember 2021-10-01 2021-12-31 0001589150 srt:MinimumMember 2021-10-01 2021-12-31 0001589150 2020-10-01 2020-12-30 0001589150 RGBP:ZanderTherapeuticsMember 2021-12-31 0001589150 2012-04-24 2021-12-31 0001589150 RGBP:DavidKoosMember 2021-12-31 0001589150 RGBP:DavidKoosMember 2021-12-31 0001589150 RGBP:DavidKoosMember 2021-10-01 2021-12-31 0001589150 RGBP:CoventryEnterprisesLLCMember 2021-12-31 0001589150 2021-09-17 0001589150 2021-09-01 2021-09-17 0001589150 RGBP:March82016Member 2021-12-31 0001589150 RGBP:March82016Member 2021-10-01 2021-12-31 0001589150 RGBP:April62016Member 2021-12-31 0001589150 RGBP:April62016Member 2021-10-01 2021-12-31 0001589150 RGBP:October312016Member 2021-12-31 0001589150 RGBP:October312016Member 2021-10-01 2021-12-31 0001589150 RGBP:October3120162Member 2021-12-31 0001589150 RGBP:October3120162Member 2021-10-01 2021-12-31 0001589150 RGBP:October3120163Member 2021-12-31 0001589150 RGBP:October3120163Member 2021-10-01 2021-12-31 0001589150 RGBP:March132017Member 2021-12-31 0001589150 RGBP:March132017Member 2021-10-01 2021-12-31 0001589150 RGBP:March312017Member 2021-12-31 0001589150 RGBP:March312017Member 2021-10-01 2021-12-31 0001589150 RGBP:April192017Member 2021-12-31 0001589150 RGBP:April192017Member 2021-10-01 2021-12-31 0001589150 RGBP:May52017Member 2021-12-31 0001589150 RGBP:May52017Member 2021-10-01 2021-12-31 0001589150 RGBP:June262017Member 2021-12-31 0001589150 RGBP:June262017Member 2021-10-01 2021-12-31 0001589150 RGBP:Sept252017Member 2021-12-31 0001589150 RGBP:Sept252017Member 2021-10-01 2021-12-31 0001589150 RGBP:Oct0317Member 2021-12-31 0001589150 RGBP:Oct0317Member 2021-10-01 2021-12-31 0001589150 RGBP:Oct1617Member 2021-12-31 0001589150 RGBP:Oct1617Member 2021-10-01 2021-12-31 0001589150 RGBP:Nov0117Member 2021-12-31 0001589150 RGBP:Nov0117Member 2021-10-01 2021-12-31 0001589150 RGBP:Nov0120172Member 2021-12-31 0001589150 RGBP:Nov0120172Member 2021-10-01 2021-12-31 0001589150 RGBP:Dec2017Member 2021-12-31 0001589150 RGBP:Dec2017Member 2021-10-01 2021-12-31 0001589150 RGBP:Feb2818Member 2021-12-31 0001589150 RGBP:Feb2818Member 2021-10-01 2021-12-31 0001589150 RGBP:July112018Member 2021-12-31 0001589150 RGBP:July112018Member 2021-10-01 2021-12-31 0001589150 RGBP:September302018Member 2021-12-31 0001589150 RGBP:September302018Member 2021-10-01 2021-12-31 0001589150 RGBP:July192019Member 2021-12-31 0001589150 RGBP:ZanderTherapeuticsMember 2019-05-30 2019-06-11 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2019-11-01 2019-11-29 0001589150 RGBP:ZanderTherapeuticsMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2021-10-01 2021-12-31 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2021-12-31 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2021-12-31 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2021-10-01 2021-12-31 0001589150 RGBP:UnrelatedPartyMember 2021-04-01 2021-06-30 0001589150 RGBP:UnrelatedPartyMember 2021-07-01 2021-09-30 0001589150 us-gaap:CommonStockMember RGBP:OncologyPharmaMember 2021-12-31 0001589150 RGBP:SeriesMMember RGBP:OncologyPharmaMember 2021-10-01 2021-12-31 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2021-09-25 2021-10-02 0001589150 us-gaap:ConvertibleDebtMember us-gaap:SeriesAPreferredStockMember 2021-09-25 2021-10-02 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2021-10-01 2021-10-29 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2021-11-01 2021-11-04 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2021-11-01 2021-11-24 0001589150 us-gaap:ConvertibleDebtMember us-gaap:SeriesAPreferredStockMember 2021-12-01 2021-12-10 iso4217:USD shares iso4217:USD shares pure 0001589150 false --09-30 2022 Q1

10-Q true 2021-12-31 false 333-191725 REGEN BIOPHARMA, INC NV 45-5192997 4700 Spring Street St 304 La Mesa CA 91942 619 722-5505 No No Non-accelerated Filer true false 4564002832 false

353492

727162

240617

213192

5396

365

230

41288

48144

641157

994124

74115

198006

19969 19969

94084

217975

735241

1212099

32288

91498

1451630

1429179

4241

661934

954861

0 0

1266679

41423 41423

1000

20000 20000 1812166 1843806

3927538

6892477

1262310

2131311

10000 21500

10491210

14697976

10491210

14697976

0.0001

4800000000

4564002832

4800000000

4350554514

456399

435054

0.0001

800000000

300000000

439293406

431998817

43929

43200

0.0001

600000

50000

0.0001

300000000

44000000

4400

0.0001

20000

10000

9706891

8644037

736326

-20703920

-23348900

-9755969

-13485877

735241

1212099

31640

27425 27425 59065 27425

35418

1127

80275 0

6658

44778

38136

5000

165487

45905

-106423

-18480

135

35010

73212

-22451 -36717

-123891

62700 0

2964939

1794776

-95019

2751403

1684847

2644980

1666367

2391062

1385417

0.001

0.000

4506953931

1769079104

381768689

38177

50000

1605000246

160498

44000000

4400

8313876

-16583666

731711

-7334998

57726183 5773 -2021 3752 22339663 2234 -782 1452 60007919 6001 -2101 3900 23926234 2393 -838 1555 60834498 6083 1217 7300 26185501 2619 523 3142 3300000 330 99 429 1819077 182 54 236 1228077 123 36 159 62003571 6200 -2170 4030 26155352 2616 -916 1700 68333539 6833 1367 8200 14883378 1488 212 1700 20000437 2000 11000 13000 12378732 1238 6808 8046 88888889 8889 7111 16000 19555555 1956 1294 3250 82004603 8200 -2870 5330 35832781 3583 -1254 2329 1865 1865

1666367

414147858

41415

50000

2260025066

226001

44000000

4400

8330646

-14917299

733576

-5581256

431998817

43200

50000

10000

4350554514

435054

44000000

4400

8644037

-23348900

736326

-13485877

10000000 1000 99000 100000 2666200 267 26395 26662 10000000 1000 99000 100000 3883700 388 38449 38837 6022971 602 49398 50000 2361366 236 19367 19603 15503953 1550 48450 50000 5759719 576 17999 18575 23255888 2326 72674 75000 9945768 995 31080 32075 7751973 775 24225 25000 3211178 321 10035 10356 1000016 100 24900 25000 355326 36 8847 8883 4000047 400 49600 50000 1869542 187 23182 23369 10256427 1026 98974 100000 4082878 408 39400 39808 8421053 842 39158 40000 2987789 299 13893 14192 6250082 625 49375 50000 2376531 238 18774 19012 72476800 7248 3716 10964 1000014 100 24900 25000 461086 46 11481 11527 2400000 240 59760 60000 1017600 102 25338 25440 1000000 100 24900 25000 425000 43 10583 10625

2644980

439293406

43929

50000

10000

4564002832

456399

44000000

4400

9706891

-20703920

-9755969

2644980

1666367

-159

22451

36717

-59210

3369

27425

6036

113712

-6856

-12

1865

-2964939

-1794776

-31640

135

-123891

-279135

-94535 0

-94535

-373670

727162

353492

710964 48941 75000 13000

28973

264970 15721 33994 8046

<p id="xdx_805_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zzYKqNUho8og" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was organized April 24, 2012 under the laws of the State of Nevada The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of December 31, 2021 utilized the following inputs: <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zuArwRGRcOa8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: justify">Schedule of Derivative Liability</td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 71%; text-align: justify">Risk Free Interest Rate</td> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 17%; text-align: right">1.49</td> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 1%">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: justify">Expected Term</td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: right">.(<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zCJsNepExmS1" title="Expected Term">0.66) – (<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zbN0qdJbDItd" title="Expected Term">1.85) Yrs</td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: justify">Expected Volatility</td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: right">824.95</td> <td style="font: 10pt/107% Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt/107% Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">Expected Dividends</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> H. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. I. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. J. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended December 31,2020 and December 31, 2021.. K. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any. As of December 31,2021 the Company has the following Notes Receivable <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zknlcp1Gsz1i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Schedule of notes receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">Zander Therapeutics, Inc.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--LongTermInvestmentsAndReceivablesNet_c20211231__us-gaap--RelatedPartyTransactionAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Long-term Investments and Receivables, Net">5,396</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> </table> $5,396 owed to the Company by Zander Therapeutics, Inc. bears simple interest at 10% and is due upon the demand of the Company. L. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company. M. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of December 31, 2021 utilized the following inputs: <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zuArwRGRcOa8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: justify">Schedule of Derivative Liability</td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 71%; text-align: justify">Risk Free Interest Rate</td> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 17%; text-align: right">1.49</td> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 1%">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: justify">Expected Term</td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: right">.(<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zCJsNepExmS1" title="Expected Term">0.66) – (<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zbN0qdJbDItd" title="Expected Term">1.85) Yrs</td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: justify">Expected Volatility</td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: right">824.95</td> <td style="font: 10pt/107% Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt/107% Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">Expected Dividends</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zuArwRGRcOa8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: justify">Schedule of Derivative Liability</td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 71%; text-align: justify">Risk Free Interest Rate</td> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 17%; text-align: right">1.49</td> <td style="font: 10pt/107% Times New Roman, Times, Serif; width: 1%">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: justify">Expected Term</td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: right">.(<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zCJsNepExmS1" title="Expected Term">0.66) – (<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zbN0qdJbDItd" title="Expected Term">1.85) Yrs</td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: justify">Expected Volatility</td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif"> </td> <td style="font: 10pt/107% Times New Roman, Times, Serif; text-align: right">824.95</td> <td style="font: 10pt/107% Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt/107% Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">Expected Dividends</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

0.0149

P0Y7M28D

P1Y10M6D

8.2495

H. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

I. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

J. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended December 31,2020 and December 31, 2021..

K. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any. As of December 31,2021 the Company has the following Notes Receivable <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zknlcp1Gsz1i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Schedule of notes receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">Zander Therapeutics, Inc.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--LongTermInvestmentsAndReceivablesNet_c20211231__us-gaap--RelatedPartyTransactionAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Long-term Investments and Receivables, Net">5,396</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> </table> $5,396 owed to the Company by Zander Therapeutics, Inc. bears simple interest at 10% and is due upon the demand of the Company.

<table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zknlcp1Gsz1i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Schedule of notes receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">Zander Therapeutics, Inc.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--LongTermInvestmentsAndReceivablesNet_c20211231__us-gaap--RelatedPartyTransactionAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Long-term Investments and Receivables, Net">5,396</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> </table>

5396

L. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

M. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

<p id="xdx_80D_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zK3LiEayKrY9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard. As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure. On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following: The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $20,703,920 during the period from April 24, 2012 (inception) through December 31, 2021. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise.

20703920

NOTE 4. NOTES PAYABLE (a) RELATED PARTY <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfDebtTableTextBlock_zYk0LVnyJfGk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of notes payable related party</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">As of December 31, 2021</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">David Koos</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_c20211231__us-gaap--DebtInstrumentAxis__custom--DavidKoosMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Notes Payable">227</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Total:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_c20211231_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable">227</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> $227 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum. (b) NON RELATED PARTY <table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--NonRelatedPartyTextBlock_zdGQWryNRWVi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of non related party</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">Coventry Enterprises LLC,</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--NotesPayableRelatedPartiesNoncurrent_c20211231__us-gaap--DebtInstrumentAxis__custom--CoventryEnterprisesLLCMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Notes Payable">1,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Total:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--NotesPayableRelatedPartiesNoncurrent_c20211231_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable">1,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> On September 17,2021 the “Company” issued a promissory note in the principal amount of $1,500,000 ( “Note”) of which $75,000 was retained by the Holder through an Original Issue Discount (“OID”) for due diligence and origination related to this transaction and Thirty-five Thousand Dollars $35,000 was remitted by the Holder, at the instance and on behalf of the Company, directly to Holder’s counsel for documentation preparation fees resulting in net consideration paid to the Company of $1,390,000. The Note carries “Guaranteed Interest” on the principal amount at the rate of 5% per annum for the ten-month term of this Note for an aggregate Guaranteed Interest $62,500 all of which Guaranteed Interest shall be deemed earned as of September 17, 2021. The Principal Amount and the Guaranteed Interest shall be due and payable in five equal monthly payments of $312,500 commencing on March 17, 2022 and continuing on the 17th day of each month thereafter until paid in full not later than July 18, 2022 (the “Maturity Date”). Solely following an Event of Default (as such term is defined in the Note) the Note shall become convertible, in whole or in part, into shares of Common Stock at the option of the Holder. The conversion price of the Note is 90% of the lowest per-share Trading Price per share. Trading Price is defined as the lowest daily VWAP for the 20 Trading Days preceding a Conversion Date. VWAP is defined as the dollar volume-weighted average price for the common shares as reported by Bloomberg. The OID is being amortized by the Company over the term of the Note. As of December 31 ,2021 the unamortized discount on this Note is $48,597.

<table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfDebtTableTextBlock_zYk0LVnyJfGk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of notes payable related party</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">As of December 31, 2021</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">David Koos</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_c20211231__us-gaap--DebtInstrumentAxis__custom--DavidKoosMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Notes Payable">227</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Total:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_c20211231_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable">227</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

227

0.15

<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--NonRelatedPartyTextBlock_zdGQWryNRWVi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of non related party</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">Coventry Enterprises LLC,</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--NotesPayableRelatedPartiesNoncurrent_c20211231__us-gaap--DebtInstrumentAxis__custom--CoventryEnterprisesLLCMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Notes Payable">1,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Total:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--NotesPayableRelatedPartiesNoncurrent_c20211231_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable">1,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

1500000

75000 35000

1390000

0.05

62500

312500

48597

NOTE 5. CONVERTIBLE NOTES PAYABLE On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property The issuance of the Note amounted in a beneficial conversion feature of $42,600 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $ 0. As of December 31, 2021 $100,000 of the principal amount of the Note remains outstanding. On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property The issuance of the Note amounted in a beneficial conversion feature of $9,900 which is amortized under the Interest Method over the life of the Note. As of September 30,2021 the unamortized discount on the convertible note outstanding is $0. December 31,2021 $50,000 of the principal amount of the Note remains outstanding. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30,2021 the unamortized discount on the convertible note outstanding is $0. As of December 31,2021 $50,000 of the principal amount of the Note remains outstanding. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30,2021 the unamortized discount on the convertible note outstanding is $ 0 As of December 31,2021 $50,000 of the principal amount of the Note remains outstanding. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30,2021 the unamortized discount on the convertible note outstanding is $0. As of December 31 ,2021 $50,000 of the principal amount of the Note remains outstanding. March 13, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is February 24, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of December 31,2021 $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_pp0p0_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--March132017Member_zpCHkkU5eC0i" title="Converted value that exceeds the principal amount">50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $204,082 was recognized by the Company as of December 31, 2021. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0. On March 31, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 31, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of December 31 ,2021 $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--March312017Member_pp0p0" title="Converted value that exceeds the principal amount">50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $204,082 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0. On April 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is April 19, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of December 31,2021 $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--April192017Member_pp0p0" title="Converted value that exceeds the principal amount">50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $204,082 was recognized by the Company as of September 30,2021. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0. On May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $200,000 for consideration consisting of $200,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is May 5, 2020. The Note is convertible into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iii) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of December 31,2021 $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--May52017Member_pp0p0" title="Converted value that exceeds the principal amount">200,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $816,327 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $200,000 which is amortized under the Interest Method over the life of the Note. As of December 31 ,2021 the unamortized discount on the convertible note outstanding is $0. On June 26, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $150,000 for consideration consisting of $150,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is June 16, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of December 31,2021 $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--June262017Member_pp0p0" title="Converted value that exceeds the principal amount">150,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $612,245 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $150,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0. On September 25, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is September 25, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of December 31, 2021 $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--Sept252017Member_pp0p0" title="Converted value that exceeds the principal amount">50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $204,082 was recognized by the Company as of December 31, 2021. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0. On October 3, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 3, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of December 31,2021, $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_pp0p0_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--Oct0317Member_zxMUNSiJ0v1f" title="Converted value that exceeds the principal amount">50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $204,082 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0. On October 16, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 9, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of December 31,2021 $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--Oct1617Member_pp0p0" title="Converted value that exceeds the principal amount">100,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $408,163 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $100,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0. On November 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is November 1, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of December 31,2021 $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--Nov0117Member_pp0p0" title="Converted value that exceeds the principal amount">25,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $102,041 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0. On November 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is November 1, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party. (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property. (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of December 31,2021 $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--Nov0120172Member_pp0p0" title="Converted value that exceeds the principal amount">25,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $102,041 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0. On December 20, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 20, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of December 31,2021 $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--Dec2017Member_pp0p0" title="Converted value that exceeds the principal amount">100,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $408,163 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $100,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0. On February 28, 2018 (“Issue date”) the Company issued a two Convertible Notes (“Notes”) in the aggregate face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Notes is February 28, 2021. The Notes may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of these Notes, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Notes in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the notes, or if the Lender chooses not to convert the remaining amount of the notes into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Notes into Common shares of the Company. The warrants shall have a strike price of $0.025 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Notes on or prior to the close of business on the three (3) month anniversary of the date that the Notes shall have been prepaid by the Company (“Prepayment Date”). In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Notes, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Notes. As of December 31,2021 $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--Feb2818Member_pp0p0" title="Converted value that exceeds the principal amount">100,000 of the principal amount of the Notes remains outstanding. The Company analyzed the conversion feature of the Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $408,163 was recognized by the Company as of December 31,2021. The issuance of the Notes amounted in a discount of $100,000 which is amortized under the Interest Method over the life of the Notes. As of December 31,2021 the unamortized discount on the convertible notes outstanding is $0. On July 11, 2018 the Company issued a Convertible Note (“Note”) in the face amount of $11,500 to an entity controlled by the Company’s then Chief Financial Officer for consideration consisting of $11,500 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is May 4, 2021. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.01 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.01 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of December 31,2021 $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--July112018Member_pp0p0" title="Converted value that exceeds the principal amount">11,500 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $46,938 was recognized by the Company as of December 31,2021. The issuance of the Notes amounted in a discount of $11,500 which is amortized under the Interest Method over the life of the Notes. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0. On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date. Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen. As of December 31, 2021, <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_pp0p0_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--September302018Member_zNuOPqXwH4Gl" title="Converted value that exceeds the principal amount">10,000 of the principal amount of the Note remains outstanding. The issuance of the Note amounted in a beneficial conversion feature of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pp0p0_c20211001__20211231__us-gaap--DebtInstrumentAxis__custom--September302018Member_zMJZybtSFCvc" title="Beneficial conversion feature">350,000 which is amortized under the Interest Method over the life of the Note. As of December 31 2021 the unamortized discount on the convertible note outstanding is $0. Zander and Regen are under common control. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications. On July 19, 2019 the Company issued a convertible promissory note in the face amount of $100,000 (“Note”) for consideration consisting of: $95,000 cash the payment of $5,000 of legal fees The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is July 19, 2020. The Note may be converted into the common stock of Regen at a price per share ( “Conversion Price”) equivalent to 60% of the lowest Trading price of the common stock of the Company as reported on the National Quotations Bureau OTC Markets exchange upon which the Company's shares are traded or any exchange upon which the Common Stock of the Company may be traded in the future , for the twenty prior trading days including the day upon which a Notice of Conversion is received by the Company or its transfer agent. . In no event shall the Holder be allowed to effect a conversion if such conversion, along with all other shares of Company common stock beneficially owned by the Holder and its affiliates would exceed 9.9% of the outstanding shares of the Common Stock of the Company. The proceeds from the issuance of the Note are to be allocated as follows: $30,592 will be utilized to retire the outstanding balance of a $75,000 note issued by the Company on August 15, 2018 to One44 capital, LLC and $22,877 will be allocated to the Company’s accountants and auditors to bring the Company current with regards to the Company’s quarterly reporting requirements under the Securities and Exchange Act of 1934. The Note may be prepaid with the following penalties: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify">Time Period</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify">Payment Premium</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><=60 days after note issuance</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">125% of the sum of principal plus accrued interest</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">>60 days <= 120 days after note issuance</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">135% of the sum of principal plus accrued interest</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">>120 days <=180 days after note issuance</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">140% of the sum· of principal plus accrued· interest</td></tr> </table> This Note may not be prepaid after the 180th day. As of December 31,2021 $1,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $3,048 was recognized by the Company as of December 31,2021. The issuance of the Note amounted in a discount of $100,000 which is amortized under the Interest Method over the life of the Note. As of December 31,2021 the unamortized discount on the convertible note outstanding is $0.

100000

0.08

42600

100000

50000

0.08

9900

50000

0.10

50000

0.10

50000

0.10

50000

0.10

50000

204082

50000

0.10

50000

204082

50000

0.10

50000

204082

50000

200000

0.10

200000

816327

200000

150000

0.10

150000

612245

150000

50000

0.10

50000

204082

50000

0.10

50000

204082

50000

100000

0.10

100000

408163

100000

25000

0.10

25000

102041

25000

0.10

25000

102041

25000

100000

0.10

100000

408163

100000

0.10

100000

408163

100000

11500

0.10

11500

46938

11500

350000

0.10

10000

350000

100000

95000

1000

3048

NOTE 6. RELATED PARTY TRANSACTIONS On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is under common control with the Company. Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement. The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander. Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter. Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement). Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000). The Agreement may be terminated by The Company: If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product. The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP. The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated. The Agreement may be terminated by either party in the event of a material breach by the other party. On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto. On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby: 1) Zander shall return for cancellation 194,285,714 shares of the Series A Preferred stock of Regen (“Conversion Shares”) acquired by Zander through conversion of $340,000 of principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement. 2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement. 3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement. No actions were taken by any of the parties to enforce the terms of the Agreement. On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be: a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return b) As of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between Zander and Regen on June 23, 2015 (“License Agreement”) whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto. Zander and Regen are under common control. On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date. Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen. As of September 30, 2021, $10,000 of the principal amount of the Note remains outstanding. During the quarter ended June 30, 2021 Zander Therapeutics, Inc. issued a promissory note in the amount of $5,396 to the Company as consideration for expenses of Zander Therapeutics Inc., paid by the Company. The Note is payable on demand of the Holder and bears simple interest at 10% per annum. On October 8,2021 the Company entered into an agreement with Dr. Brian Koos, MD PhD whereby Dr. Brian Koos would provide services to the Company consisting of : a) Reviewing existing publications on research being conducted on Checkpoint NR2F6. b) Identifying the most promising applications for the Company’s technology c) Drafting a “white paper” on results for 1(b) d) Making introductions to known experts in appropriate fields identified in 1(b). Dr. Brian Koos is to be paid compensated $117,000 as total consideration for performing the abovementioned tasks. During the quarter ended December 31, 2021 Dr. Brian Koos was paid the amount of $80,275. Dr. Brian Koos is the brother of David Koos the Chairman and Chief Executive Officer of the Company. As of December 31, 2021 the Company is indebted to David R. Koos the Company’s sole officer and director in the amount of $227. $227 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum. During the quarter ended December 31, 2021 the Company paid $5,000 of rental expenses to the landlord of BST Partners as consideration to BST Partners for use of office space. BST Partners is controlled by David R. Koos the Chairman and Chief Executive Officer of the Company. On January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning January 14, 2022. BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

350000

10000

227

NOTE 7. ACCOUNTS RECEIVABLE, RELATED PARTY Accounts Receivable due from Related Party as of December 31, 2021 consists solely of amounts earned by the Company not yet paid resulting from the Company’s license agreement with KCL Therapeutics (See Note 6).

NOTE 8. STOCKHOLDERS’ EQUITY The stockholders’ equity section of the Company contains the following classes of capital stock as of December 31 2021: Common stock, $ 0.0001 par value; 4,800,000,000 shares authorized: 4,564,002,832 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation. Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_zt5FLgdZN7X2" title="Preferred stock, shares issued and outstanding">50,000 shares issued and outstanding as of December 31,2021, 300,000,000 is designated Series A Preferred Stock of which 439,293,406 shares are outstanding as of December 31,2021, 300,000,000 is designated Series M Preferred Stock of which 44,000,000 shares are outstanding as of December 31,2021, and 20,000 is designated Series NC stock of which 10,000 shares are outstanding as of December 31, 2021. . The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired. Series AA Preferred Stock On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”). The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Series A Preferred Stock On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”). The Board of Directors of the Company have authorized 300,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board. On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series M Preferred Stock" (hereinafter referred to as "Series M Preferred Stock"). The Board of Directors of Regen have authorized 300,000,000 shares of the Series M Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series M Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series M Preferred Stock owned by such holder times one. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series M Preferred Stock shall vote as a single class on all matters submitted to the stockholders. The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen. On March 26, 2021 Regen Biopharma, Inc. ( “Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Nonconvertible Series NC Preferred Stock (hereinafter referred to as "Series NC Preferred Stock"). The Board of Directors of Regen have authorized 20,000 shares of the Series NC Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series NC Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series NC Preferred Stock owned by such holder times 500,000. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series NC Preferred Stock shall vote as a single class on all matters submitted to the stockholders. The holders of Series NC Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series NC Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

0.0001

4800000000

4564002832

0.0001

800000000

600000

50000

300000000

439293406

300000000

44000000

20000

10000

600000

0.0001

300000000

0.0001

20000

0.0001

NOTE 9. INVESTMENT SECURITIES, RELATED PARY On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc. On November 29, 2018 the Company accepted <span id="xdx_900_ecustom--NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest_c20191101__20191129__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pdd" title="Number of shares issued in satisfaction of prepaid rent and accrued interest">725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $<span id="xdx_90F_ecustom--SharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterestValue_c20191101__20191129__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Shares issued in satisfaction of prepaid rent and accrued interest, value">13,124. On December 31,2021 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and <span id="xdx_909_ecustom--NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest_c20211001__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pdd" title="Number of shares issued in satisfaction of prepaid rent and accrued interest">725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs: <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_zGfNvUQDluMe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT SECURITIES, RELATED PARY (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Schedule of dividend income</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">Fair Value of Intellectual Property</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span id="xdx_90A_ecustom--FairValueOfIntellectualProperty_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Fair Value of Intellectual Property"><span id="xdx_900_ecustom--FairValueOfIntellectualProperty_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Fair Value of Intellectual Property">1,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Prepaid Expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--PrepaidExpenseCurrent_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Prepaid Expenses">74,298</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Due from Employee</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--DueFromEmployees_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Due from Employee">1,071</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ReceivablesNetCurrent_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Note Receivable">64,400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Interest Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--AccruedInvestmentIncomeReceivable_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accrued Interest Receivable"><span id="xdx_906_eus-gaap--AccruedInvestmentIncomeReceivable_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accrued Interest Receivable">20,274</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Investment Securities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">593,357</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible Note Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_ecustom--ConvertibleNoteReceivable_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Convertible Note Receivable"><span id="xdx_901_ecustom--ConvertibleNoteReceivable_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Convertible Note Receivable">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accounts Payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--AccountsPayableCurrent_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accounts Payable"><span id="xdx_907_eus-gaap--AccountsPayableCurrent_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accounts Payable">1,269,041</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Notes Payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">500,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Expenses Related Parties</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--AccruedExpensesRelated_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accrued Expenses, Related Party"><span id="xdx_903_ecustom--AccruedExpensesRelated_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accrued Expenses, Related Party">89,529</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--AccruedLiabilitiesCurrent_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accrued Expenses"><span id="xdx_901_eus-gaap--AccruedLiabilitiesCurrent_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accrued Expenses">203,037</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Enterprise Value</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,826,507</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Less: Total Debt</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,061,607</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Portion of Enterprise Value Attributable to Shareholders</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--PortionOfEnterpriseValueAttributableToShareholders_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Portion of Enterprise Value attributable to Shareholders"><span id="xdx_905_ecustom--PortionOfEnterpriseValueAttributableToShareholders_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Portion of Enterprise Value attributable to Shareholders">764,900</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair Value Per Share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_ecustom--FairValuePerShare_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pdd" title="Fair Value per share">0.0167</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> The abovementioned constitute the Company’s sole related party investment securities as of December 31, 2021 As of December 31, 2021: <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfComprehensiveIncomeLossTableTextBlock_zJRFLjV22SIk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT SECURITIES, RELATED PARY (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Schedule of comprehensive income</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="11" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">470,588 Common Shares of Zander Therapeutics, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 1%"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 11%">Basis</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Fair Value</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Total Unrealized Gains</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended December 31,2021</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_ecustom--InvestmentSecuritiesBasis_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Basis">5,741</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecurities_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Fair Value">7,858</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Total Unrealized Gain">2,118</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td id="xdx_988_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20211001__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, net Unrealized Gain or (Loss) realized">0</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="11" style="font: 10pt Times New Roman, Times, Serif; text-align: left">725,000 Series M Preferred of Zander Therapeutics, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 1%"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 11%">Basis</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Fair Value</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Total Unrealized Loss</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended September 30,2021</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_ecustom--InvestmentSecuritiesBasis_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Basis">13,124</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleSecurities_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Fair Value">12,109</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Total Unrealized Gain">(1,104</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td id="xdx_981_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20211001__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, net Unrealized Gain or (Loss) realized">0</td></tr> </table> 470588 725000 13124 470588 725000

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_zGfNvUQDluMe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT SECURITIES, RELATED PARY (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Schedule of dividend income</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">Fair Value of Intellectual Property</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span id="xdx_90A_ecustom--FairValueOfIntellectualProperty_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Fair Value of Intellectual Property"><span id="xdx_900_ecustom--FairValueOfIntellectualProperty_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Fair Value of Intellectual Property">1,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Prepaid Expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--PrepaidExpenseCurrent_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Prepaid Expenses">74,298</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Due from Employee</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--DueFromEmployees_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Due from Employee">1,071</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ReceivablesNetCurrent_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Note Receivable">64,400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Interest Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--AccruedInvestmentIncomeReceivable_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accrued Interest Receivable"><span id="xdx_906_eus-gaap--AccruedInvestmentIncomeReceivable_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accrued Interest Receivable">20,274</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Investment Securities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">593,357</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible Note Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_ecustom--ConvertibleNoteReceivable_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Convertible Note Receivable"><span id="xdx_901_ecustom--ConvertibleNoteReceivable_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Convertible Note Receivable">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accounts Payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--AccountsPayableCurrent_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accounts Payable"><span id="xdx_907_eus-gaap--AccountsPayableCurrent_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accounts Payable">1,269,041</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Notes Payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">500,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Expenses Related Parties</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--AccruedExpensesRelated_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accrued Expenses, Related Party"><span id="xdx_903_ecustom--AccruedExpensesRelated_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accrued Expenses, Related Party">89,529</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--AccruedLiabilitiesCurrent_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accrued Expenses"><span id="xdx_901_eus-gaap--AccruedLiabilitiesCurrent_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Accrued Expenses">203,037</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Enterprise Value</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,826,507</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Less: Total Debt</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,061,607</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Portion of Enterprise Value Attributable to Shareholders</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--PortionOfEnterpriseValueAttributableToShareholders_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Portion of Enterprise Value attributable to Shareholders"><span id="xdx_905_ecustom--PortionOfEnterpriseValueAttributableToShareholders_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" title="Portion of Enterprise Value attributable to Shareholders">764,900</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair Value Per Share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_ecustom--FairValuePerShare_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pdd" title="Fair Value per share">0.0167</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

1500 1500

74298

1071

64400

20274

593357

10000 10000

1269041

500000

89529 89529

203037

2826507 2826507

2061607

764900 764900 0.0167 0.0167

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfComprehensiveIncomeLossTableTextBlock_zJRFLjV22SIk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT SECURITIES, RELATED PARY (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Schedule of comprehensive income</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="11" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">470,588 Common Shares of Zander Therapeutics, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 1%"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 11%">Basis</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Fair Value</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Total Unrealized Gains</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended December 31,2021</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_ecustom--InvestmentSecuritiesBasis_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Basis">5,741</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecurities_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Fair Value">7,858</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Total Unrealized Gain">2,118</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td id="xdx_988_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20211001__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, net Unrealized Gain or (Loss) realized">0</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="11" style="font: 10pt Times New Roman, Times, Serif; text-align: left">725,000 Series M Preferred of Zander Therapeutics, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 1%"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 11%">Basis</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Fair Value</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Total Unrealized Loss</td><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended September 30,2021</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_ecustom--InvestmentSecuritiesBasis_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Basis">13,124</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleSecurities_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Fair Value">12,109</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Total Unrealized Gain">(1,104</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td id="xdx_981_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20211001__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, net Unrealized Gain or (Loss) realized">0</td></tr> </table>

5741

7858

2118

13124

12109

-1104

NOTE 10. INVESTMENT SECURITIES During the quarter ended June 30, 2021 the Company was paid 50,000 common shares of Oncology Pharma, Inc. pursuant to an agreement entered into by and between KCL Therapeutics, Inc. ( a wholly owned subsidiary of the Company) and Oncology Pharma, Inc. whereby Oncology Pharma, Inc. was granted a license for the development and commercialization of certain intellectual property (“License IP”) for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021. During the quarter ended June 30, 2021 <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedPartyMember_zm5cTLDwffu5" title="Number of shares sold">13,000 of the aforementioned common shares were sold to an unrelated party for $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedPartyMember_zVas1bm0PQj8" title="Proceeds from Issuance or Sale of Equity">300,000 cash. During the quarter ended September 30, 2021 18,000 of the aforementioned common shares were sold to an unrelated party for $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20210701__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnrelatedPartyMember_zIThwdFFGS2a" title="Proceeds from Issuance or Sale of Equity">195,000 cash. As of December 31, 2021 18,300 common shares of Oncology Pharma, Inc. constitute the sole investment securities other than shares of Zander Therapeutics, Inc. held by the Company. On December 31,2021 the Company revalued 18,300 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market. As of December 31, 2021: <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--MarketableSecuritiesTextBlock_zK3YBJBCrNZ3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT SECURITIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">Schedule of investment securities</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="11" style="font: 10pt Times New Roman, Times, Serif; text-align: left">18,300 Common Shares of Oncology Pharma, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 11%">Basis</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">Total Unrealized Losses</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended December 31,2021</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td id="xdx_986_ecustom--InvestmentSecuritiesBasis_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--OncologyPharmaMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Basis">677,100</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td id="xdx_981_eus-gaap--AvailableForSaleSecurities_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--OncologyPharmaMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Available-for-sale Securities">74,115</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td id="xdx_986_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--OncologyPharmaMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Total Unrealized Gain">602,985</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">$</td> <td id="xdx_986_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20211001__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--OncologyPharmaMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Equity Securities, FV-NI, Unrealized Gain (Loss)">(123,891) </td></tr> </table>

13000

300000

18000

195000

<table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--MarketableSecuritiesTextBlock_zK3YBJBCrNZ3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT SECURITIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">Schedule of investment securities</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="11" style="font: 10pt Times New Roman, Times, Serif; text-align: left">18,300 Common Shares of Oncology Pharma, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 11%">Basis</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">Total Unrealized Losses</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended December 31,2021</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td id="xdx_986_ecustom--InvestmentSecuritiesBasis_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--OncologyPharmaMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Basis">677,100</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td id="xdx_981_eus-gaap--AvailableForSaleSecurities_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--OncologyPharmaMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Available-for-sale Securities">74,115</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td> <td id="xdx_986_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--OncologyPharmaMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities, Total Unrealized Gain">602,985</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">$</td> <td id="xdx_986_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20211001__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--OncologyPharmaMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Equity Securities, FV-NI, Unrealized Gain (Loss)">(123,891) </td></tr> </table>

677100

74115

602985

-123891

NOTE 12. STOCK TRANSACTIONS On October 1, 2021 the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210925__20211002__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zJ6JfJEt5r86" title="Shares issued in satisfaction of convertible identedness">101,718,058 common shares in satisfaction of $<span id="xdx_906_ecustom--StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities_pp0p0_c20210925__20211002__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zkTKKRum0aUj" title="Value of shares issued in satisdaction of convertible debt">425,000 of convertible indebtedness and $<span id="xdx_90C_eus-gaap--InterestExpenseDebt_pp0p0_c20210925__20211002__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zTxFk8XofiLa" title="Accrued Interest">154,991 of accrued interest on convertible indebtedness. On October 1, 2021 the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210925__20211002__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVCBI3Km8eFh" title="Shares issued in satisfaction of convertible identedness">5,869,589 shares of Series A Preferred stock in satisfaction of $<span id="xdx_905_ecustom--StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities_pp0p0_c20210925__20211002__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zRDvSRxhE9Nl" title="Value of shares issued in satisdaction of convertible debt">50,000 of convertible indebtedness and $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_pp0p0_c20210925__20211002__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziB6Ysof6j0a" title="Accrued Interest">23,369 of accrued interest on convertible indebtedness. On October 29, 2021 the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20211001__20211029__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zlRB59qLPOll" title="Shares issued in satisfaction of convertible identedness">25748147 common shares in satisfaction of $<span id="xdx_90B_ecustom--StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities_pp0p0_c20211001__20211029__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zZVSDvE7so0l" title="Value of shares issued in satisdaction of convertible debt">140,000 of convertible indebtedness and $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_pp0p0_c20211001__20211029__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zO0cQp2d2KBk" title="Accrued Interest">54,000 of accrued interest on convertible indebtedness. On November 4 , 2021 the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20211101__20211104__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zvdD5q7RmFa6" title="Shares issued in satisfaction of convertible identedness">8626613 common shares in satisfaction of $<span id="xdx_906_ecustom--StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities_pp0p0_c20211101__20211104__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zJ6DYcOrMe6" title="Value of shares issued in satisdaction of convertible debt">50,000 of convertible indebtedness and $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_pp0p0_c20211101__20211104__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z6pUWveXkz4h" title="Accrued Interest">69,012 of accrued interest on convertible indebtedness. On November 24, 2021 the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20211101__20211124__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zR5ln40rn846" title="Shares issued in satisfaction of convertible identedness">77355500 common shares in satisfaction of $<span id="xdx_905_ecustom--StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities_pp0p0_c20211101__20211124__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zY1y8gfqwhSk" title="Value of shares issued in satisdaction of convertible debt">95,964 of convertible indebtedness and $<span id="xdx_903_eus-gaap--InterestExpenseDebt_pp0p0_c20211101__20211124__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUXxszcppSC5" title="Accrued Interest">36,967 of accrued interest on convertible indebtedness. On December 10 2021 the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20211201__20211210__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZyRZTPks6X" title="Shares issued in satisfaction of convertible identedness">1,425,000 shares of Series A Preferred stock in satisfaction of $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities_pp0p0_c20211201__20211210__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBzerZCPCx12" title="Value of shares issued in satisdaction of convertible debt">25,000 of convertible indebtedness and $<span id="xdx_901_eus-gaap--InterestExpenseDebt_pp0p0_c20211201__20211210__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zshlJlrH1fw" title="Accrued Interest">10,625 of accrued interest on convertible indebtedness.

101718058

425000

154991

5869589

50000

23369

25748147

140000

54000

8626613

50000

69012

77355500

95964

36967

1425000

25000

10625

NOTE 13. SUBSEQUENT EVENTS On January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning January 14, 2022. BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,A,-%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #(3#14$)S3PNX K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VU%)'1[43PI""XHWD(RNQML_I",M/OVIG&WB^@#>,S,+]]\ M ].K()2/^!Q]P$@&T]5L1Y>$"AMV( H"(*D#6IGJG'"YN?/12LK/N(<@U8?< M([2QAPM@@1%&F[X+J%=BJ?Z)+1U@I^2NI++.S3P]O3X4M:MC$LD MG<+\*QE!QX ;=I[\VMW=;Q_8T/*VK7A3M7S;7(ON5O#N?7']X7<1MEZ;G?G' MQF?!H8=?=S%\ 5!+ P04 " #(3#14F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M ,A,-%0RP"<^\ 0 #\4 8 >&PO=V]R:W-H965T&UL ME9A=<^(V%(:OM[]"X\[T*@1;YB.DP QADUW:A!!(M]-V>J'8 CRQ+:\D0_+O M>V0;F\V88WJ3^.N\/#JRWG.LX5[(5[7E7).W*(S5R-IJG5RWV\K;\HBI2Y'P M&.ZLA8R8AE.Y::M$TD6#P;\>G/ R-$G!\+T2M\C=- MX/'Q0?TN&SP,YH4I/A7AGX&OMR/KRB(^7[,TU$NQ_\J+ 76-GB="E?TE^_S9 M3LB* %@'T0X!SZA?<(L#-!IJ39!C5SD.4FBX;1!+&9QI66<#> .#V>BAV7I$74EDFNAFT-FN9.VROB M;_)X>B+>)0\BUEM%;F.?^S_&MX&E!*('H!N*"G[FWB5QG0M";>K4\$SQ\-_2 M&,+MNO ?<-PR/VZFYZ+Y^6?RHK2$5^Y?1+)32G8RRB6%%U49@((?H9Q%[)-'08>OV:AX@A'K^3HG9>-IY1)S67X3I8\ M$5+7(>%26J884;\DZI\Y/Y*!765NTX++0/AFM1%8[[6O M3X-2L;Y^^O2I88D,2K;!>6QW@?)8>$"\@\NUAH*K/6%(CEW9FOV_H/[B3)Y& M:A"#1%&,ZLAL'51HFDKY$0J;R@:Y5LL>M%P;0Z,5&D6U;F,=Z'<@"SF9I]$+ ME[5 N(CKNBUGX/1I%V.JO-=QSV%:\DU@[!<2-V=1?:)PH>7ME]LYN9D]+KY. ME@^3"S*;3S'"RLH=W(P+PBE,JH0)G4$1?"._\_=:1ES*MFVG>S5PNNA\5O;N MX/Y$L]H0$=\W@ M+LA*PUH@0I*I2"&ID%OAUT\YKC[_AD%6M<#!#;R G/@^M$?JXG! [N$Y\AC7 MD^&2G;YMDU4B@W@#HY70N6&D585P<&-'29_WHI84E32?$- ,.EB9 MHU4MH7@9R&9P E^5IU%P@9XSP$"J D)QW[\764.R%3%6U!I$^I2VNET;*VFT M*ACTO()1- )Y7YD[ =/US4F#XEQ@8%6]H&?5BUD,/7C^;6VZ$G8@K07#%7&P MJDS0L\J$:4R@*,#ZVPA96U\;=.8B;C'/XR #(GXNB!%6-8*>52-6$0M#5@MN(RXUYM[Z @M["8HP2%M?G#A=L^HRAE=G3L\Q^ MM>60*PP(EVD"$")H#=::>&]@L]GNR'D,=5@JK$/.:S;B2B4NYFR MV2_;08O4Z]@VO7+!2'?'7.VC+1HS+=G.E2*>:7+RW9KR:KD[-LGVA-K5X_G6 MV@,SLZI(R-<0:E_V 4#FNU7YB19)MN'S(K0647:XY( MJ+XQ^#R?$#8R_K*&%I'F4IX&QST1O"CR.W;% B_HS84UZ[!D4H]UGVM;B9KB]Z M3L&(Q6PEBBZH_//(1BR.BYXDC[^J3GO'9Q8-Z]?/O?]6!B^#N:/7UF54!NT=\JB_/R-WBJL$X/K/:YR)*JL6201.GA+_U6 M#42M 20=#5#5 +VT :X:X#+0 [,RK#$5]/*<9T^ %VC96W%1CDW96D83I44: M%X++3R/93ER.;J['D^O%9 SDU>)F-AT/E_+F:C@;7H\F8/%Y,EDNP+N[E.[7 MD6#K]^ #N%N,P;N?WY\/A"10=#-850^[.CP,=3QLS%9G ,,^0 Z"AN8C>_,% MV\GFCJGY0(9]C!T=8T=E?[@K]KOY?'*]!,/%0@9IZ1 ?.\1EAZ2K0YIO3:-R M:.65K8IU]7B)74Q"=#YXK$>OPWSD0T_!&J3(D12QDAJN5MD^%3F8LQ6+'NE] MS/KR.J8RF^"6V:.H8A!TS2__(TK>R MO.5L1Z,UF'R3\I^SW$3-UQY+( J"%CD#*H"$F.D%1WJ!C5YA51_S'5VQBY[T MHISQ1]:[_.4GZ#F?NGXO,T%C,-ISSE(!AGG.A#&J0./K$0C=]CS686$HP^^( M*SS&%5H%YF;Y>3(_+2_046+M6/,X31_E'$N*D!=LM>>1B,S)K/JI!^07<;?" M-L!@&,@*P!PWK+D*?#W1%ZSCJMLFH= +V[Q/P9JTE2% 9*5]F%4W8LNX94Y5 MG31F"W$"TB:IPQ#T0]_M8*E%TDE\3!\$Q.\4SK]I!A$S-D$'_D>9[?5ML7 )LLE4T@NTU4 M2EMQM54G2%=\(A<#;E,]!6L2K>T4[,9P1=.OX.:1\36G&V.>D:[VT'':J3Z% M:M)3CH#LCC#>,R R<'#=C!OYZ6(OM_HZP5.P)D/E",B^"[E+&>5IN9A766+4 M1:1O)F @#U>W&P<+0N8YF"#!83(M_%;9,Q M +T@1,3W.Z@JFT%VFQEE,ME<1-)D0,-RP(SE>;U4WJ9TX\\J2)$O!0F2KK^#= MSV=R*4%95W+P2.,]>P_DFND[AQ^0;ZFLXP#=BVW&B]1] J0?U #J$T#3=3W? MI.]Z1&)0/\ (1'F^/V! MA>YD!>1G*4T!]D&C-F*)?>RKL"P7YP4EC#;<^2' MV'7ZKBL? LDS2^LS%FPGJHD2[=W.09@X!'BX XOQ\K+\4DO%SRZWQ>" M-[(PU7W7QQY&[?KH-*[)4]DSMMOSG D:%47<1-9R62IH&FJ 8DR#LLERL+!>_Q'++^;_-XC7CN93"O_:RM#M!7_?4#Z'O MNOIQE D))7DWZ*KSL+)?;-]?'@Y[9M/AU70V74XG"_ +37:?P&NDO8I'WV8: MCX4,..NQ$%%^3^Q^OY#EM536(6C)$OC?EU),_V]9_D39,X$_QO2(\E5BWPZ^ M7E:)OO$CPN?1SYMXU][;LF^\'?V\=>J3NQJ_L;QM[P MQ4][W&V0)E&EZL2NZM68?WG1""L-)OX/&F$EF,0NF&\885T I3&V1?X4JDE7 M*22Q*V0USM=@])*1=I5:N9$%E27FX9E5Y: .3GFTQN MWZJ;XK6$XVLHE_\ 4$L#!!0 ( ,A,-%3*JP:;N0, L1 8 >&PO M=V]R:W-H965T&ULM9A=;Z,X%(;_BH7VHI5F"S:0CU$2*4VR MFI&FG6B8V;D8[84;G& 5,&L[S>S^^K6!\E$(D&BG%XT-YQR>*9VK$Z?HW^1YJ\2N8)"[)BX7?JRV!N3 S@ MDST^AO(+.WT@>4*NCK=CH4C_@U-F.YX:8'<4DD6YLR*(:)Q]XI]Y(2H.T#GC M@'('--3!SAWL--&,+$UKC25>S#@[ :ZM530]2&N3>JML:*R7T9-SXZ\_PUV=T!&[X#R$*PQ7W5 M[>Z11+E;;>ZFJD11#E24 Z7QG'/E8%&DFDN5???\#B28@Q<<'@FXH3'P61AB M+D!">);N;5NZ6?QQ&E^_0R\+Z\ZR+ 7W4DVKUZR&;Q?X]@7XV9H ?)0!X_1? MXK?Q9@'="H@SL?*_-\R#3&O<3L'M7,Y-A3BV,SM-$'?D6!::V.@-A#FKI<:-TYSIZB&4-?%* 3SK!/<*IXER",@-/9P!^/)#H MB?"_.O:J:?&,Z2\HSK21LGVF.$,L:^#0*D7'N@J]Y_7)H]9?BBF:VHXU>@/? M:@JGT\D$CL_05R03#EO?KLZ;JD]L%M\KNM'V%25 M45LW]MO5L4OI@=W:VP$&F=?A2(6"W1%S;=Y/FQN:TPP^PK+.7R@.[I2?O MOD>P&M)_J-0%=*$N=/9?'JS_NW:O71VW% +4+037]5\>M+HNJ&7Y6LS.K!NJ MG&XN5)1A/9='K:+ -N*FV5MBLW)2U3\3/&!^H+$ (=DK'^MNK)QY=O+.)I(E MZ>'UB4EU%$Z' <$^X=I W=\S)E\G^CQ<_/ZQ^ ]02P,$% @ R$PT5*A8 M#BC2!0 ?!0 !@ !X;"]W;W)K4!H[*1HO[1) MN/?F'/OZ',>W;RSYR3>4"O0>A3&_:VV$V-ZTVWRYH9'/K]F6QO#+FB61+^ V M>6WS;4+]5984A6VB:68[\H.XU;W-GDV3[BW;B3"(Z31!?!=%?O+[GH;L[:Z% M6X<'L^!U(]('[>[MUG^E'A6+[32!N_:QRBJ(:,P#%J.$KN]:/7S3)U::D$5\ M#^@;/[E&*947QGZF-\/574M+$=&0+D5:PH=_>]JG89A6 AR_BJ*MXSO3Q-/K M0_6'C#R0>?$Y[;/P1[ 2F[N6W4(KNO9WH9BQMR=:$.JD]98LY-E?]);'6EH+ M+7=$'!X\ MN^.YAR8/:#)U9[WY$$+1Q2+V=ZM T-4END(+;X N_KZ\;0N DA9L+XO7WN>O M)36OU=$SB\6&(S=>T=7'_#90./(@!Q[WI+'@@"ZOD8Z_(J(1K,#3/S]=:X"C M'X=5S^KI-?5F[G=WO'"]AE+&L921E3+J2M$]C7>4JP8YSS2SS'3![KLZ-@T@ ML#^EWE@_U8D;OO67]*X%0L!ILJ>M+FH WCD"[YP%_"N:T="'CD%3/Q&_53SR M0IT3'L0R2*?"X[.H#RC-(TJS$>5\,N^-D'J^C,":6FKES1.G\+Y1G-),CP;$U8E7G2X[2U(BQ5DJIUHCYD<8T\<,, MC:#[#CLK7C-PNKQ"S(YA6U6<$&!U<9:.(TTT+UQ@-+IT&-UO-(H;OGS#X Y[R M"-\]Z *-&.>7"*!S'_@ _F&\![JI_R"/+G=)((*:E2[;RA4FNNU(;,[V'U+Z M#_G$?S+T1_ KF*,E>XV#PRSTEMDD<+#.W^E,J0@0A2L12U)415@=_-*22+,E M#6@2[#.[+!8FK/N\OY1*162;(8YI.+I3Q2H'8LL!$S5K$)>N1)I=Z>. ?_D+ MF]JW_*_[GEKK+N";K&G ;?<45D2Z/ ;T1;D.B&Q25PZL:HG.V69&2C,CGYA9 MM@G^H+P'S56/O6Q4L,/"AE9U"44@-L$EC)I52TI/(\V>-G;GG[L9D4V*F(;A MV%(_RX'8-$W0EQJTX\]HCO@ MS:3*10[$N@W[]CHNI7&29N.\[WG#?O8]\K 8C?Y%@^%HD9X;N+W9&'87WH$A M;#>0]]2;N4H>^3OLT_Z]UK2J0!9AYAEM7IHK:3;7'^[P\2D%W/L.&Z)'%XT7 MS_> =?* 8(*>)^,,B<--^H+C@6/W/U!+ M P04 " #(3#14.^8:D&P- "X6@ & 'AL+W=O+X%C(+[)%IJ#-&G:AZ(/C$7'0B31 MI>CXG'_?I2QIR9U9FBQ6>8@E^]OASNQPOYG9(4^?R^K'YJ$HZNR/U7*]>7_R M4->/[R:3S=U#L3S[:#5I.CLMG^KE8EU\JK+-TVJ55W^>%\OR^?T)/=G_XO/B^T/=_&)R=OJ8 M?R^^%/77QT^5^S8Y2)DO5L5ZLRC7657=/ZG#6Z M?"O+'\V7V_G[$]),J5@6=W4C(W<_?A87Q7+9B'(3^>].ZLGAHLW ]N>]].NM M]DZ;;_FFN"B7_UK,ZX?W)^8DFQ?W^=.R_EP^WQ0[C60C[ZY<;K;_9\\O6$U. MLKNG35VN=H/=#%:+]T&J*%3TKL!.IR2C@PPNP$F'& C ^QN@ T&4!Y;.+)?.;+UH)E,N%_.\ M+N;9E]K]<-Y?9^5]]N4AKXJ'1'S(0ND]0B\'"?T]NQ@C]*I?Z$6Y6KFMX54QUX/F]G', MS*;](C_,W=*Z;2M?9I_RQ?S-8IU=Y(^+VGWO$7K3+_1S4;N-VLWN*J_6B_7W M39^LV]=,MZZKQ;>GQEL'S&S6+^T?I1O?'39Q]\_A)F*'FXAMY8B(G//B^V+= MJ.:VZF6^OBM^RW[FRZB&SGZ><4.U/IW\ M;/L^1,DNXK)WB@W/OML\YG?%^Q-'I)NB^EFW"9HA S;FP+34Z*\T/*\W'KO1V MG]P,6NH7V3)8:F64L<%R0Z0D)#3O9>]<1RPYO)I;\N:"3 3VOX;09MD[<^L8 M5AP,*WH-N[/B8K-YV"_P"=HS0/'$V":;]RBA%X"45Q+ABLB M#XK(_T.1O9M@"DFXUEHS10W'9Z(.,U$C9W*[K@OW*]2L"IB5,2X"LRIH5FU8 M8%4(HB)F57W010_1Y?9%E^N6+GV6U6 F3B=NE8I8UAQF8Q(YJP%6580$;C@U MB+/2$#6#*&YC=YT]*&(3.ZL%LW *$6VIQ6="B0]$24)WW0GK^"NWX3:P0W5, M:WA 93,$1:64$85:D34]@L_NA,JN8DRU;\;NA'R40OO#E.%N2R%_*F* =1FT M&Z,ZM"Y$:1YS7.J)F/8S\7C7I9"[&J6$B 4%U),7'O;X+*1ZC@XALC-M"%G,*Q2,NZEF,CJ6Q7J^%7$9#[I]2R%)2A(:% M&,951!G/9'0LE0UR6!"; MSQ ,E1&/99[&V" :"Q3Y+=M$CPU@J#F.0PY3A8$M $BVNPO +01D6M:[G,38F M(1ODNY#'&J6XY+$MRA,92TED#"$R84QH782E:)CJ(J >U_526<1USSF2EX'"U90C3$4!;(;!>#3PX9[2^)C,;(#SGG,D*VM" M,,$CG,8]I_&QG-;CO.<<*<^R,*.=\\Y M4H1DSG4UCVR\W%,;3U5;Y)#6C F+LU,."4M34()&4%3%G=?S&A^3FPW9>3GD M-//R+[+SHU:&40-'>(W9,(M 4)S)F'4]K_&Q^=F0K9=#;G.* M;?]%)N2YC:>J-7+(:P:&O!RK-AH0\B(PR6,A+_?,Q@==%*D&7J01= MI1)TG4K0K4"*NT;)T(]?077=QH<0HC^$^+VHL[^5&\Q;;P1V6JD4S'P& +O3 M:YU5]@<45^LY?MA_6=R]S3B-GP +&& (*FA@U@L$%A[W]T]QC.LAJ3R#IU37 MV-3AB;^ 48_+0(@*#Y)O$. ;*BS5+*S$WB)0[?+&L(M@AHF4TKCM-Q+3"A]T MB?Z@*UQQ?^C_^I+#Z*M9/%-:9& M_\F_#R)%?Q YM'V&HN:%,:7@(.RY0&#@CD*BTR[D"KV8)"&]7V,XY%Y!2C/* MX;@.[Q7DW)UQ+HP-9=XB4,T59^!>0412)U&:6)56^!A:],?0@YMD\ 6%L;3@ MU%ICPJ/%"P2*WB](= YA5^B%W>)*(2E88 3;?S?X@%^D"O@%4LB"M18!(WEK M8:T%@=$^?7S(+U+W& BDD$7ZC"M]R"]3AOP2*6:%8<94(J&\XC:,E%"84K%N M(Q_RRV-T&4BDGM7,)FIA'_'+5$5,,+$W!>!];FO]*&H3'U((Y&X ML]]]?> I4Q[22!BQ<5#GED@'@1$B/ U'8296_92M;KEC=!I(&(QL9Q.UL(]% M9*I#&HD_S%,[%,W6T@D5,:PIB-'3!*SVLRY2&- MA-S&P@/OJ40XR\)$$(5%ZT?2,YL<4\P:[+N0W9QFE*M(DJ(\N:E$IS17"FDY MD#+<>A6D+&%$")LAL![G59[9U-ABUFO.JY#& Z>6(^-8*ZVG-97PE.9*(>WZ M8;HZ50AE:0OZD#"8D3I28U&>V-01CFFN%-*9KJ7;'B*U2^6Y3:4ZI5&0UVP8 M;TT5UAE'#'!>!,9(U+J>UU3J-G %.X-&LG%!&-ARH;!XM;5GMCT,4YI M-"0WIQFU.L)MVG.;3I2RG6ODJ2_@NQKIEG/A5NB["*PG;-">U_0@7AO1W*&1 MAYJVS1V1[$9[3M,I\S6-Y&OA,TM3C;05-!V H74Q&(\5PK7G-7V,KCJ-Y&N, M4AKK3-*>VW2J?$TCY5T">$TCG>'& EY#8'WE!MUZSBEU7YW&JIM,*L%B[NM) M3:=,V30D-A'V'$TU]A@3V$-F**S=P=35R!.;/D9GG8;DYC1C)N:^QI.;24EN M!FE!"!W80-(R1H0I,8J*/7!H/+.98S";P?H/9#OF[$['$YM)58LTR)/*(BSF M&,A8W-+P%&^&P$1\:S">V$QB8KLRD-B<5I3$TF'CB>[4((S% M3?A(WPR#"6HC=73CBWDW):@8K1(:L9I *H_.",&K 8);0F$:> MUJUG-9NJ$&F1=(V)T+P6>?A)@^=($!0E5D4>F[6>U&SB M;O$KBZ1J3&AEHL]K>TJSJ2C-HL=KH64A5V%U!@P6SX2MIS2;FM)LY'"-QI;9 M4YI-26D6Z88*0S&+4!45)FP41V$R%KU;SVCV&(QFD3X?18F)!&/6$YI-16@6 MJ4 *X+D(4UFM@.="F(H3FO6$9E,3FD6*CZ(G9[2>T&Q*0K-8_3$,=2U66.3@ MS0DH3(B81JW74AR#T"Q6@Z1:Q2SL-H[#A)K/:6ID>TG]&^\>]=K.B^+B6Z_3 MMZ72V&1M_DJA;"\1:6V(3:?U<@J2\CFHO;1N*QXP,M85 IKV9SBN'40'6K7> M4D&.\3#47FIG%^Y=]M:K*DA"GCO?2^L^]A_V0.U1W5@2O!Y@AN.XBKX\IO7& M"G($MCO?2PT:V*V,OD.#M-Y90?H9KZ>+_?R5L2,>9D@FZ3*9I*MDDJZ32;K9 M2^KVO#5O?PE[:)-=VD+ZP[UASR)$%AX&;-N%YX(HL/C((X!(=S6&P]JKT6M+Y5:7&[A9=5G_P-02P,$% @ R$PT5)&$%S8]!@ M0QD !@ !X;"]W;W)KG:] MN\^N.'L1V;=\P;E$WY,XS<]["RF7I_U^'BYXPO(/8LE3^.5)9 F3<)L]]_-E MQMF\6)3$?6)9;C]A4=H;GA7/;K/AF5C).$KY;8;R59*P[,<%C\7+>0_W-@_N MHN>%5 _ZP[,E>^8S+A^6MQG<]6LM\RCA:1Z)%&7\Z;PWPJ%;XK58$V4JM.SJ[N8:W=Q>WHWN)]./:!3<3[Y,[B>7,\,V=KV-76QC=VPSA>2>I*%(.#J* M19ZWOHE2A5NH4*F\'A+7MOT!V+G>]I NAUW7I:Y7R^U@=&J,CM$5H_F_$+N0 M[C)'4D"^AR(-HYBCM $/S]5=R/*%P2MNO:-K],HMI#_/,CY',RG";RC*\Q7< MP":!2'-(:@98VCQE5*NJZ&F^9"$_[T&9S'FVYKTA:HNU7]>S8[=7V^T9[0Y$ MDD YW#$:JCNZ_ Z5/N=M)@>E1F?[I3M^^PL?U# &[W$_RQ&\:X6$J:K=YG^C MWC?X_]?U[!CNUX;[1L,AF($^<\A%*"?%U3&*4HAQR6$?B7CY'A"3,HL>5Y(] MQD7HLT1D,OI9N 6))S2.\E"L4MGF(E][7X38#MY+95T*TAAW)#*V&H*PWF/@ M*"S@YNB6_5 VM=*!I4$Z<7R"]XM0BQRE;D=$XBUJPT;D1QOHQV@#?0?Y'0]Y MM.X$CW7PQ+.)LP_^H-PN?-+ )^]Q/ O#3*66(<$O*LW;F%R+NOO(=2F,J8=) M!_*&!S%]C^.A1BQ9= YU9$/' VY+M6)NJ%5;.;5#>A==P-[E(D++@_8,I(L M;JL^E>X=1 .W*P8:&L7.6V/@KS^P:_U3?@*^,<\@AE4OO/%KJUN=EB#U7=NG M_KYK6R2QY]N>YW88TS T-E-T1T _I)QE*;BW[ M:X;LZ*(I=V^J U) G-K-G M':E'^R6BR+&ZBA\H%3JAGF#:]?(;2L5F3GU( 5 <_00@GZ'/._H(4]DQ$HI< MUKSLKM",AZLLDE%'-@U:\H0.?-P!K2$];&8]U8,&T+A!3HMU!-T\>OP!8T(. M%PKCS9)G$)/I,W@20K,;G\Y94#O];=]546F$\W9V)PW]$>M-3?W59#J:!J]N MZDG#5L3,5DUVH*Y'+>B:]KVKR]D#W^X@6=*0+#&3[-9,_7K, M.J-ZCF5I::B+8;HMMGL UK E-0^+9>533;X"N6F?VH!2?>8C ]^C>T#-^[T] MRIA4ST2MQ$.P>DU/?W M([U%; ^X-!?^LX.N'9S\L2^O)%B61QZ/PHI15)<+CB;\TP)P.]/ IJ( MZD9M4/]O,OP?4$L#!!0 ( ,A,-%1UJ12ORPT 'TB 8 >&PO=V]R M:W-H965T&ULO5I;;]LX%G[7KR"RLXL6<)Q+DTX[O0".X[3& MI$Y@IYW=6>P#+=$VMY+H(:FXGE^_WSFD9"EQBL$L,"^);9'G?KYSL=]NC/WJ M5DIY\:W(2_?N8.7]^J>C(Y>N5"%=WZQ5B2<+8POI\=8NC]S:*IGQI2(_.CT^ M?GE42%T>O'_+G]W:]V]-Y7-=JELK7%44TFXO5&XV[PY.#NH/IGJY\O3!T?NW M:[E4,^4_KV\MWATU5#)=J-)I4PJK%N\.!B<_79S1>3[P1:N-:[T6I,GY=&IH\E]T MYE?O#EX=B$PM9)7[J=E\5%&?'XBTNG :+YRRW($12WDIO7S_UIJ-L'0:U.@%J\JW(9PNR2DS;_%4XYY_ M?S/],)B,?QW?)W?C MR0=Q>W,]'HY'L[=''@(0F:,T,KL(S$Z?8/9"?#*E7SDQ*C.5=>\?0?!&^M-: M^HO3[Q*\5&E?O#CIB=/CTY/OT'O16.,%TWOQ!+U!FIJJ]+IJ;N 1MK@( G(E8M5:FLI$06A(E?F5B6K'N^Q=OL7I:I8N%;9\6BLLP*+&H1 M'\G8[_K! 6BLA5%@^.")C!P0 ).H# M>S*D7"-0F+)H\D!#G+E"./Y6::LXRLS<2[(99#3W,D\XVHCYU>6 Y# V"TY! M@']%K24ZX-TB^X^_O3H]^?&-VXE@;%N"B6FH"S@6 JA2+*U$H&=BOFV8+<*U MR C63T@5)W/.P\C7?X]O1W5^5X*W3?,J4W\*)/YLUA_]X;3W[6#9G__)@_P7?WG^UQ(F MJ2S)3?=(\ZZCV;=^3^#+.8+I,89Q'$2'A^"5OB?T(KBW?H"\=";/6O>R'I]( M0HSNR-7LH!54+YQ8R'MC:^8MP?IBT$\N!K/QC$I:JXP1'BQT"6V@-B$ S(\P M<4@@! =G$#!E+2F)*\=(!:KH\C0#A=RU R&FW M!H6R,'8?3T))U"[90[*'2$4&591BEL D)8R XQT!5DFOD'G 4[+%PS/!+Q[M M,:PEYSKG>L:'D!J4*ED7LQ *BT[93,VK+FO\\O"8*0 !5>9VZ MGAB7:1^!7/<&T&UM;(AB4GVS,F1OLRD9(>9.9QIS V@E4\KQOICI9:D7L'7I MN>#;PS2JBX:M=#(-V;-SMLHU>FB2O5LK9"GS[>]+CZ4+;I]K9'[*;F&\IZC&NQ"P)!CYB\HF(;H@YV<4 M22T%0)EJF,J2&-F/(+AE@DS-?8BP?:2HI9#6:GQJRIA3.6-*F#2ART)J*X#V M%6Z4J62T52[ [U2/!,$0[H,F2 DD"5 H4?-F#P7T, S ! M]W8V289T4\;Z0-(@1@U2IXG:NN01^!D$-!F+%-AR^2S(?/L5 2N9_1=CVJX& M!^F[V<["3%Q'J-B2,FUOEAS0&LB_TV/7IL>JU@J;I.MKLO8R3 62(+'-A@37Y;KR[J<$"JFL"BW*/H&3J79?DRNK4,\HT97S8DJCQ4G_ M[+7X>S("3*9P0G('S47_F3CNOWR)AZ_.=X^^F%SZH/ZKT[/^Z_/VO4M-]8_& MD8_]!!!X\VDD[@;_?# !-7A&F12#R,MOL-W.A7ECY$*AJ%-+J5QJ]3R8EI+[ MQ[/C7HT"XT#ECJCT^;.3-ZW*$8GT:-.@"-83\*,P5;%1>PC_K1RA;463@)E> M@("BT)TKOU$J?+R#<-1!8QF^.!G A>Z'HK6771)T5J4D"_(-RS60L:HNW@@? M![H.J*%E10T2D4RU0CK7N03B&[*;,IL<(@(2FD0MN";GRQ@,2- MS43+9FA'.G;9\-Z&M;R7.N?N0G$LI =S2E>&*L.<_T5:'H(YL\/P3 BS@:K 2QVO>B R*JL T;.S_*O!B1$",W MKAE_ BS6DQH7YPA%Y#F&/RKG#RHBM90Q7;DY=*$17=0!?'AR?'B^"^/6YN0* MN?$9UK-439 &XU*T@SS&>"\&0.P\43!RC/Z+V,8F5N4RAD 4@?KS-CYOT%*W MBRZE9%6S92MAHM.A VB9B6:QRNYM75"(JDS7=81NT58SH04H4TJG5,T[UTDWK6#70##2C MQ]H];BQ"[;*VDCS6/A$QO="!4K)26Z31IO.>*N"-Z@9;L@NTF'*+BAJS;D;% MJ93[[PXRI'BA"4^LJ98K40*XHHJ(:DYD;D6(YT9:Z/?1; @5>VW\$SO\@^XG MQ\=-G>3>$B&,^9%JA F:0@):;Y:\XNRF!^64S9@4Y]A@.&OG&>*SS"3#+[ : M6>L% DV,#"6 BCT29C?%9-JE<&)EFWU1 M&),H@E3-Z!FY^3D%,/I*,BL_C5O*X(5U-<=UI074D,5SW8_6F60=B\H@A]\M2CH5+$H3+97RA(JE#8J)WCI1AB!)F)0Y@W M2:2$ I[#O"5+$=HLFB/8NJ%WRJA)J_LLNA;C+7:LH913)"([:)]<5IS_D"78 M*U"'<.@Y*1C"M'7Y932]&\]H7S TSF,8>UAD,FZ4N=OAF >59:A-<3R/L1_G M[D'K?#._;Y",X@=Q+'[N)[28GXGI:#@:?QE<7(_"0(F:ERITOM2!$!LN3#SI MI!"K)W(J@!J6UY9"B#9)?)76D MR>/Y'2J=]UZ\?BE^X'\)H"E[4!O(/>'^GOD?-45:)YRF$AF&>.KMH?3)\=_# M#AAS']"WJ009JC*MX#O[QKZX[B?3T9?1Y/.(#'OS83+FG<5,PFQDGLYVL^XN MR+ ['C$L57'%4H/&Q5)]TR#[!C=P M!8,9CMNP@3%IB!%^AH++\&Y;WF;Y_#F%S^BZS+MS< M_4EGZ-@V;.UBPT';1-Z7D1Y^NZ;-7\[C"%LQIJI:RVW8F5(#<&_"),F[@Y5N MMJFU8;JUK!DR0E3%"9GG!EJP++G/,5N4G&V]Y=IUW;1OIZ)*WZE1Z9=+C'4! M%#G=* A84^X++-5"D(E+030HR<-1@-WD'C$DM]6KM-VW4\$R,7I:K,/&274V M'\TBQ\5>O0'3:+L$D3YGW)N3L_KBEQ6E>9"DGL@:Q27%3TJ8O(SM75")E_.N M9;-#2@HR8VW]7D>JQSHGC9%#Y[X-(*E=F^,3'1O231?Q6[JX2"8$Z@K7Q?TP M&#+]W6V,8&58I,55)^]G:C(-NZ!K;.=J@VTX?3RU?K4F7"L:IW-!; >-035< MQNXR-*M.7,>OTL8EZF9PU95JK4YC.C.2.#QWB[ A9,U#IYCZ6AVUX;_IE5K50!:D__! K#O M>^FCUD\""H5R13]\H+Q#HH9?!S2?-K^M&(2?%.R.AQ]F?$*UT[!)KA:X>MS_ M\?Q V/!CA_#&FS7_P&!NO#<%OUPI"2/1 3Q?&)23^(88-+\X>?\_4$L#!!0 M ( ,A,-%0^))9JH@\ #TM 8 >&PO=V]R:W-H965T&ULK5I=<]LV%GWGK\!X9W:2&?E#LIVD:9(9V7&ZZ6P3C^UL'SI]@$A(0DL2 M*@#*47_]GGL!@J0D.^YV7Q)+(H'[>>ZY%WAS;^SO;JF4%U^KLG9O#Y;>KUX? M'[M\J2KICLQ*U?AE;FPE/3[:Q;%;624+?JDJCR+#U]IX?^(]6]Z[WMR!-9L;\3A\^%F\/3D@@5:KQ&OW!JO+;$$[7Y)1;;_&KQGO^W5[P(*TX>6/%4_&1JOW3B MJBY4,7S_&-(E$2>MB!>31Q=\K_(C<3H>BJ=)Y5->[_2!]:9Y;IK: MZWHA+I>R7B@G9%V(*VN-%9?&VA P3OPRG3EO$3>_/K+K6=KUC'<]^S\:^O$5 M/WV^N\HF1^);*XN/=?9C4RO8;WPV$GZIQ ==RSK7LA0]8]QZF$':PHD+@_^$ M=JY1Q?XGOJP*Z97X9(YXUJL5Y<.A-X?L=%V'6D"@"N_2 MTGC==[[$*Z92(Y%+MQ1SP+X;<8:YI;1J:1$S.:4G!YY.Z[H&3G:JH-CE4 ^K \K-HM9]X[0P(-JESSMA;KK' M1QE%;(5!2)HE>(D/A'D[#B M"I;5,(E8& ,'(&Z/NA<4:[5B"TV(1 M-27@A2+->;5RKQ%P:B7&K\7'4#DVK0H<7L^0GA1@0B;UC\(;D^$;&8*)LXJ< M89#I"QD8082[=L'X]NEK\5YY0J9:=6Z0@79"D5S%!\]>BRD$SBEB]SY'-J0? M>OMGW][__'4;N;W N%\"KIX12$+KGK<P@=AMK)]WC/Y+\/?XII_G+\ZOFHMT5&87-+1>/P0E(D7\M- M2-^?23E2Z@Y6YSQ#D$SOB;5<6]1LX.\=)Y"X[JEX)^T"0'[)072AL!-''0)J M#N_Q>C<$$DY#F]L0G[0 BL=1-AU8RX>E*'="63N>[R M.9E_]%27P1ZT+6H2NI_ *5N3.*Z8$4,"#G#XP0:Q3+65G?R5"O "N> %!])< M:BO6LFR0-P-YB-J@RXO&2V!89&;=MQY5P*'Q1D*#EK!P@,49EV7VQ%:R]6S' MY;?GHNWZ@YK/[D5/&;D(\9 L[ ?^I1:ZKMGK[-KQ.3 B#Q44Z7'.P3 D**'Z ML;E"<6=B$W]+3"D2A0$9VBGQ&7%H=<\U7K7LBI0FVDL[4[V&FP"NP09Y@[:' MXE83!R+66"[A7^K8\#!]DS-B!8"EJR'1 MG,YT23@,I"?:HPFK.84'NX$62Y*8NB0%35)%8 MY3YV7>H_*'%8J)FB[@"UK*)Z6:.(;?EDWRX1RF+XD:0I"[!:9>IR@Y@'\Z'< MIXXH*#'4,JA$1DDF1&3-670NEXEI/$GPT7Y[1)(R4]%PJDC"J^%ZN^)P0<$G M&T"&R4H;=H+"CLCW=>@$'HWAB-S_[K;++MKMICWMKT 6GJ)[1/5.]9#;E=R0 MH@DUF=D1 ?&1P5H)"DJM*K49GD8 A8$^,3OV1(KLTB,?I,? E00($291*D.T MN_W^:$EC6HUI:K;'-]\,EA'Z/;_3E&XU(LG[@9N&<"P2/82MN0&D+V,;E_5; MN,XP5I5J336Q9UV*U&#>/8.-@1S0;:M L=S]FM*V=ER@LE2=QN?Y.!QXH3TM_2.UBHN#HEH?.7$V],*@^^B4!*RGNK-3P]J2CXHN%V'< M41@5 C@6J!"<*%A4!ROEVS(4[9R%'BSYWR7#"F#G\%#_Y;AU1KYU&#UIIH0MPRQ%C;5@];Z*3'MRGF+^&YV\M? MLT#V)S0R3-I M$_$).O<^4]L;BROG"@5'HE](X]:<48KQX;AO_%[AW[:QV&]C&H\28K*8S,)( M)5!7OV7ZOG(TDXDP5_3<6IM[EKEB T,-9+S<^]<(1YR+3"@')NQVHGB?!Q.FF6F2,B-O MCUI"#^+?/I%F?Z_C<4H<8.YHN EYQJ9>@;#&KC,1/$V>Z.0F,9F!'+*$QE)R MUINL5^##7F[_9KUQ:-QMII:RG+=;#19&E)4J4\/6OG_R0?/;WLPAT:AP)!2/ M(=+AV6AGCIP&(F$Z2R=>K&48S/0&_2Y,O!]%B?#[I#36NV5P"IO M#4W5">A*)OWH=:FM)=VB!/'@(TZ[^M/0K?A\#%,#-*WC[Q9RKBGRP]CDUM0V[ / W?.%K[1JN_. SMZE(5 WK/-J&L ERJPJIC#/&@A/J1Z M9^'X$H%UB, _7%DS1\,R.$/NMN<3Y%48?;ON\,1E;>?7/PDC/3J26F[5B1X# M9-B]5]!$4K:5#PWHVAP=G$)6J4W-MON&7B#M:50?.-'=G:GNX,Z0Z.PLD#U* M>6[V\]@^@';!\9A&JP&F,331*X4,34KV^##LFV/>_2#T\B^#4/;70$AT(/2Q MZVG#H.#)5TJ>Q3L"@A'1VJ8:,-L'<0DY_T#:GVLT[!BE+K& ),D M1U*O3?BH?AC2\+Y$O +L $:<8S,ROK9',J1]$<>QF9=?6[S9JMA-;94LZ01' M0 ='@%=W%R<8]IQ$.U6HF>_U>2$/:G6?+B_L=DQ]9D.&RK:)S;? Y&4P>C.\ MG?'(672O^,PV%&%UJ!B(FZHIN<\]##*"2O[6A&AHC3OLQQ]B)7-MG=^]ZJ+K MWJ'\WA.J/;#";5QWG49]I>.%-"CD4N+BB3]Y%3;NA64>,V,894^,YJTHR+K@ M[&Y8Y @<5#NKW>^D7K@T0W71JB7="%VK>,MH.$Y,5U "+K[@.8CKS/?PM9:L MO=8"LI^MD0L*/@ZW* !\BN\3L13W--!>&:]XG-U/=Y=0B^I&1 L8/9C"^:;8 M4&2DF&T'1L8N4.W_E-V(E_8W#35@"XH<8ZF%43 RQ?[[)ET3\ $*UGQ)C+ A MW/C"X[7T\50J%+ND1A)RM)>(=C/3+!X1=K/K(G&7Q.$3)W,-PJ\S0#JC3:4' M$E/SLW<:L.]VY7'O2FNE[((O[E+S!&.'VZWIVW0W>!JNQ':/AXO%/TF+/'*B M5'.\>G+T\OP @<67=<,';U9\079FO#<5_[E4$DZC!_#[W,#=\0-MD&Y,O_LO M4$L#!!0 ( ,A,-%1U*9N;PP( .4% 8 >&PO=V]R:W-H965T&ULG51-<]HP$+WS*W8\/3(8#&G:## 3R$=S"#!)VAXZ/0AK;6LB M2ZXDA]!?WY4,#FD;IM.++:WVO7V[TNYXH\VC+1 =/)=2V4E4.%>=Q;%-"RR9 M[>D*%9UDVI3,T=;DL:T,,AY I8R3?O]]7#*AHNDXV%9F.M:UDT+ARH"MRY*9 M[0REWDRB0;0WW(F\<-X03\<5R_$>W>=J96@7MRQK,%GLM;ZT6]N^"3J>T$H,76>@='O">+^>7=8AP[HO0'<;J#SQIX\@9\"+=:N<+"I>+(7^-CDM+J M2?9Z9LE1P@M,>S <="'I)X,C?,,VOV'@&[[!MS0Y4^(G\T^@"W.MK):"L^9% M* XK@Q:5:PPZ@RNAF$H%DW!/1J3GYRQ\.U];9^@!?3^B:-0J&@5%H_^M^''X M8OEPV1GVX!4-/!3886FJRXJIK5 Y9&T>]B6/@CTAK!$54 -7S" '9JD=/< 5 MS-$'J4:!A-ZAE)#2[0I5(_D!@UQ[3[*E:%3/!VV]^ B]*RL*6HQ,8Q%1QA$Y+95N@EM#R_9]>I*3(1%G2!99T6 MQ%P)1Q+^*$,0V?O;Y<<'K5>BR<. L52C6KFF"UMK.\/.F]9]<6\&X"TSN:"B M2,P(VN^=GD1@FJ'2;)RN0B.OM:.Q$)8%S6$TWH'.,ZW=?N,#M)-]^@M02P,$ M% @ R$PT5*7LN_,N! !PD !D !X;"]W;W)K&ULG59M;]LV$/ZN7W'PNJ$!7$N6[3I)'0-V[*Y!T\2(O1;%L ^4=+:$ M4*1*4G&]7]\C]1)G:S)@7RS>\>ZYYX[DG2=[J>YUBFC@>\Z%ONBDQA3GOJ_C M%'.F>[) 03M;J7)F2%0[7Q<*6>*<Y4ZY1$SCI>1?LL2D%YW3#B2X924W=W+_ >M\1A8OEER[7]A7MN&X M W&ICRMHHVLW(STQO;C?+-:QF7V?SZ^7$-P1I-_RX=I]7[N$S[@/X)(5) M-2Q%@LE3?Y^HM'S"AL\\?!%P@7$/!OTNA$'8?P%OT.8W<'B#9_$B XM,QUSJ M4B'\.8NT4707_GH!?-B"#QWX\/\6[[_=O6$/GL# :W;BW2VO9YOE@G1WFZ_> MFEYB4G($N04A#6HHV(%%I%#(F<&$9&4.WDQ[9$$5Q#Q"U5;16["'+/$^2JGA M%83AV-M(P_AY)=2__1&\CDZ\F]L;>"FX^$?(2_F PJB#MQ0&5:$R3>RNKR^[ M!-OOCH*@&P3!8[Q6!;?"6V-A*J;]<=<2!9,B_/;+:1@&[RYE7C!Q<%+_'61: MEQ240:%D3H)4!U<*R(3SHL@BS@K&@>6R%,:R/0XW'KG/H/KTNX.S2K])T;NQ M.#%3*B/N=?C?2Z88I40QKVQFJ$U#13X3D1FG5U0=&WT$;T,;WH58M<:SVE@D MSOHG<4"GC'.($)(2G6%SVI3KEEH8X+>2D'+[\/C![E*3-+I*>="OHJXE1W[P MMI)3V\W$CH!@:<\*W!5Q78NNFJ9N'*= D7.JL6UG=$>3IJJV,B?MJB46RYP* M)L4#*I,1L:ZUWZ?27A)EU_9N6*61UH>2LO>23I0HP]K(^+XIEBQ<:Z9=*WV0 M/$'5LQ6KX5WKITK'V-@X(L3T+/BU45&"MFP%JC$(*6$9U?7SE]D*:.JYG3!H41?L0 ]0T2MS(J/$6JK4@K%7>?X;/:&S M8,I[D+S,\S0N[2\XT_NHTFX!Q5:VJ?!9!82&5M8\.,.=2VH>S<[7R;J\6 M-ER$CD].9MG?E:%%JE\2T$NMH-UA'Y6S!S,-3QL'/+['4CPB)M1'J]=E[P>% M;$[C%0Q/NZ.S\<]ZJG\TG'+B[$:P!@=4S:E6VT[Y637<'LVKOPB?F-IE0@/' M+;D&O?&H ZH:NY5@9.%&720-#4ZW3.F?"BIK0/M;281KP09H__M,?P!02P,$ M% @ R$PT5/0:,M51#@ %X@ !D !X;"]W;W)K&UL[5Q;<]LV%G[GK\!XVQU[1I$EV7++ASO#G>:'%_IJ5M$/^Z<)OVJU<)WO@BB9&/.:'IYD#W<&A)#*55H1 M!(F/:W6A\IP 8T_ LR==DM:V/W>0/^!:0$=D:BKK MO'IA%C^J0,^8X*4F=_Q7+/S?B/&\I&LY.F)-0MA:3:@T1K) M^4^/Q;/+5X]?BN=GOYWAZ62_ GB:M)\&4.<>U.@64 ?BJ2FKF1./RTQEZ^OW M@5:+VZC![7QT)\!'*NV+@V%/C :CX1WP#EI:#QC>P6VTFO):V4I/F4HY M\5PN)9[N@'W8PCYDV( MC0;?/W&N5B*3E>(?AM_OB6JFQ(4IYK)<"DW#F9!BDQ,M 'IHE^J25T]EJH0L M3%U6PDS%-V(X&/0&@T'[>2Q>S53RDX+88>XSF>=B)J\5+[9D%6)J32$J&+.H M3/N9>B0$S3<66,VEY1UH'?R'JV29Z?)*X$/4Y5SJ3,RM+E,]EWD'H6JFG:=" MEY5)IG6>+P7/IH6E*>\)Z9QRCD1-^%E('NO E0)^X65ETM<]3(%C DN[OPKU M1KL*DSTC/'=A9JK'"(.C*VBIG.L*>#E:FX G8H=+:ZDK[26O" +)B,=/8 M\^;&@8L*?G9: 3D<'(VA6TMBU,2I M/VJUVK2SH%&EWY2T8M@JDQ3CP;)5U;R#L^MAJ[M0A9P MK# +0@U3]D"4;9BW8E(&SF(1_5ZI4NP.!WLMI$=RN0U.(#@09$J/!- &$BD$ MDRM0T(4!A:.M3=B=-);C$9-*(]@X!2,<@?;J('99J@I387'B"C*$)/;Z8G=R M)^?)<)=;> L"H%O+GX^ M7TG'P>G.C:V(54LX,ZMRS2#\SP3$*7O-X@D07K0C+_U(ZPLSY?15*0,PVC0$ MSUW=5WUQGAM33)2]V@.Z/:%]W&"$$C"L-)57V#86;I!!RL A)02?9>\VIDW7 MYS5<7$'NA"_UQD<@X)1L;+B@0+4!"HCF")X^8-%\_L;4E.9=< $ >2UUSER& M "EFAA * M65H1!7R+*$QGD"D7-8>:6:63?VX!!,8 +:A7R-M3?9A=42:0E( M"A2$1"C(=:Y+"M#(N%V0:!*D^$Q2C 7;?JY-Q=^A?U#ONB>>E,AEGWC$UJTY M!0F0*$5XF:=USFIQ$R? XA\HN6L0\M2#.'.MP=]$3LRUZFW9PZ<3$Q7R.6T; M%ES+''$;VEW452TI<)RS7$A;R<"M=[8L-4X4W:-CAMR-S97:SHRQ# MKG/#2T'.I!XLYFE(JX(;:HR:-)]-]QWUT^=>26H/$ M7TU>%ZT[ZE!)X,J:;);UV">%'DC2"*[K-3?<"8_?@#AC00\*>0I:E=63F@=939PN8+A6P,>3Z]]0)/A.67&" M:CH*16P=WO_>=63*'$B:9=LJ"T)%V53[W!X\(E/*D>N3#9<(U)B\.UX+>R[$ MK 7VH.B$%<36-5QZ]#B'B.1RLQI)0J41JA5+7ZGD@&B'(^9V3GT@4,W#BFB B.\BD;)UVOD*"%UV4?(A946I.EDF.J#Z":;HDZ +-,V5K)2^Y+: MQSL)#U,B-Z0-0Z7./FB*9 TAS3<"#D>](]3_JT[ 99F< 8=<''V2QL388S&. M;8G8EHAMB=B6^&(+X=B6^)RD$=L2L2T1VQ*Q+1';$K$M$=L2L2T1VQ*?=UOB MN]YWW)48MTV)R[0RY 7]89)/W)<8#K[\QD00/\4$BF-G" (*GMN"61N-BW?K M6"2W="S$>W0L_N]6!655'65*VLSOFT%_,!R-5S7"!WO^;07/9^;Y/YX=!GV/ MAA@-,1IB-,1HB%^M(?XU:LIG7)/A 6OH_<]!0[]NA_/$OW=0H;B3[9\5[67H0EHJ*\I?Q=OMX9W8*5OH[0H=C1*"NI;O%9M!S(AJ[MA9GN=U*BK2;V#"ZMF5L'&#O9$0=< H&.E)C-'W==( ME)N$+2Z\0X?NB8()L";IS29?8[D>OX)(>M2U_S5B>Q\>!M@^P*:S8"-/@HT$ MF;LUJ('^I^3)=+5,_#N&E2[T/@H/&XC--F)SF[XX<\3H1U#>(H1VNCBQ\F5= M#R9+F2__#)J\W2&W,J+V'=1?7TNZ04..@SA&I*_W;VHVDK.7%^)X.+XW'#>] ME4?M6M^&^U%E5UC=M&7IITY[M]4/HB*C_OP6]-R,K95"6"=J.>Z$R(G.B4%9 MW;A2;4,#M330?'K- GO/=:';%UJ^2YITNJ2&@&9[+]/6]EXAYB/_LQOFME($Z>=?27;926,X[1H/#WN!XM$J& MVLL^(56/B5!,A&(B%!.AMR="_]@T2'32H.1@*&(>%/.@F =]^7F0/UL\_"[F M03$/BGE0S(-B0^BN3"CV@V(>%/.@KS$/>@J7//XD2= H7/0:M?\%C-C5>W2= M(]E^)P%Q)>43F/Z0LY!7<&A%F"#I,&I[(&\Q(R<8CO/S#VS3X3@?OT0,J%Z$ M$[7T!K:LK,F;PWH(C6L1E2Y1S&L[YTRCZ]![Q(E-**O V5P_8+-:KF%)1UG] M*UZ"MQIP/3IO7M&+V#;_>V1;3PCI@'$JMR=4UWL+"$SZYWSQD7 M'!7:+(0O(G#A#,^45@8CNBA4IKV[F5,*E#4*W3E4R?R^PK2QFY7/3\8&XX4,=7[Y8.S-I2/'@-5R7UB3( MKW,=8-,==X7)1ZF7W1?][.M]J*([=N$\^M2?B"!7CV7*NS4.7/ X64?(8;.D MXO25W2 4ZPU K8Z)^_AX<^O&3[SRJ>\EG=1N_$4?7H X_0KQ+.&DSNL9'5]? M !\266W%[N@P)#+;+NME(7]9BO66['>^OKJK29;B@57++AB MP?69%US'PZ/>P>A^:[0H[_@+*'K(U_WGXB?BFY5S!312]S<70LFJ$!*? MMA!JXEXLA"A!CY70WU,)7>\EEUO_DP:YY;:AZ-XVW!,?\QXB&^"F+Q#ATO]]2O O1#[W"F+SU"J/X>%<8=Z^):N 12^!8 G^%)?#-BQ^Q!HXU M\+O5P,/XTC'6P+$&_C)JX*/AJ#=NZV_4^3/H\+2+$$CR7XEU>" MWU(9QA(\EN"Q!(\E>"S!8PD>2_!8@O\%;Z%[L02/)7@LP;^*$GQX]$EJ\&%[ M[S56X;$*?VL5?K)?G9[L:X<_*?Y9L\!?-C2$+'EZPBRY0!)/O@A*]G!GN-/Y M%,=G,,U#9>8$4DQ, M59F"O\Z4A,71!(Q/#>0>'FB#A;&O&;W3_P%02P,$% @ R$PT5-[_S3#< M#0 3"< !D !X;"]W;W)K&ULM5I;<]NX%7[G MK\"X:<>>461)MF,GFV1&L;V[[B:.:WG;:3M]@$C(Q)BW$*!E]]?W.P< J7O< MV=V'Q"()G/OE.R#?S\OZP:1*6?&49X7YL)=:6[T[/#1QJG)I^F6E"CR9E74N M+2[K^T-3U4HFO"G/#D>#P9O#7.IB[^-[OG=3?WQ?-C;3A;JIA6GR7-;/GU16 MSC_L#??"C5M]GUJZ'+95$YZHPNBQ$K68?]L;#=Y^. M:3TO^+M6<[/P6Y FT[)\H(NKY,/>@ 12F8HM49#X\ZC.5981(8CQS=/<:UG2 MQL7?@?J/K#MTF4JCSLOL'SJQZ8>]LSV1J)EL,GM;SG]67I\3HA>7F>'_Q=RM M/<+BN#&VS/UF2)#KPOV53]X."QO.!ELVC/R&$_EY?'=Y(6[&MW?_%'>WX^O)^/SNZNOUY/VA M!7U:=1A[6I\&ILC:O_[.!SW/(Y M9C['OXM1=].Z_GIW&;WIB^TTQ=V%!)I<%\KA:RR8O\O?SH;C08_C,,=OA[^<( 0M*GXEX07:W&7JEI6JK$Z M-CUQ5< C^\+O=$O"MFB.I6KZ3%M:]OXJPQR$9*V2Q!Q"M1 M4_K@82(R'2/IE4#%84T2]8C:4;',]#PN\US5L9:9_J_DU"YG(E:U10DB-9'A M2/E&9E%5HWB1JV/$95WB?B)6Y-OWTHO/GNO536L&$J HB]=IDT/H1P5#Z@*5 MBZ0*-A&-EU0*/,Y)E)F>6:4*\:QD;?J15UL;T? /$A\R>Y&A!ZY]>,*%)99:)2CZ361>U*0OUVJ)F]EANU#>PE-,,UTTUJ\&1-K$A M(2<6BQ0+*#IL6C:&C/OK1"0P%"07^Z^&@T%O,!@<1-) O^ 776BKG>%G"BY, M=9R*'*5*3!7HZX1U@B_>#D0BGPWQ6HY/8D2A6!3PTHJHWY,PVB@AEH)']BR& M)S9E+F^8BY*0S313H[XU+GX*A%UMR(M@0.95LYGBU@!AK0IW6Z/WR<"1G):/ M? FM(8R7T: 2/Y/6N4Q@8VE%EQ'#TQ^,2+2):T6;>C";B*5)!065FD-4;4RC MDA /J/3Q W%W)'Y3&-3EL\RL5D9 ;5@8CV=E4PLD0\R9?_SG@Z#H-1K_1&98 M"P4,; 6#<20C8-'==,&U(UJ1 )N)D4\:5-2Z3)K8FETT5K7 '2G^UJ 6OTS= MN?;:+JIJD6BM6L.!TXO,@OPRJ"NU"]1]SQX>8!?KXO6#YEJRL(H].).ZAC_K M!V6C1YDUBC2"@Y2EF%E:?P!4$BM$#E<5+R72+*>(\]D"N^Z[>I?HXG[!,^OK M"%PD%,B=2YR9HS4S<\5QB;?D=R>.:7.H\D85WJCD%..+:)%HU_I6(_Z@[W6) MX+X2 MYST]P09\ C.F_RD,B=DZ5QD( M[@]'!V+)&A(]LUXMGS-=HZMT_5X89 4GQ1J'%YFG+23@6ZM[63,NX<;IE.M M@- SVC$C]9U5.&$9CWAKJ"<5-P%_+)DFD@@(#I)@F2D!@H"%IHP@Q*_HH[B: M6"PU80.Y'\ T452"Q-?9#!*MIMV*_!R(G>1_A"5:?9@7*?52A:+?KA#E82?] MB]13FB :1"#PYTL_4*1#%1)[",HAGJ8U%QPO?]EMZA.HQOBA\BEN#4^Y7)R) M6W4/M3_ILDHE1D*'AP..=A*7+1Y&0_WE_/-& !V0MS'ZOE"JW4'&VH2[HZ5M MWC3=MF6,+SY?G5]>3R[%>#*Y^NGZR^7UG1A?7XASS K\^Z?;RTN^ZP%[;]$! MACRP"4V+@*8CUWCF! J= FSSG;89AX4WC@B:1"L]^&E4SGF*DH?XF],R@FPZ MT52S-]NP%P5S"S]U6!KG9BCT#EXR0U8F6)EA 8\9H)$T)$./U_H>%YIA2]CA M]>6BYRUE*A@%Q!TN6E=..,H=:R+ TD"P)E<.(SDAUF2@,%2-'Y82BNYIB-=ALGN^\&,AXOQ?#&6(C":GZZ)7A?.* ZG[\3 MPX-H"0Q#Z:8N&![%LH@1O [_#=\>]T9G)[W3X3&MK%5KP DJ :[&<)Y"]) D M+11W:@0QSLN"< 21FS")3N7X6Z.Q,^HJJTWKLKE/"6>%32#XZNB8NSG]KH 1 M8ETAL0!$U125JU#&03ZL.W'KW':K"2>ACZ@6-/GAH]-[N M=(B7PW'O'$QA_NJX=S0Z8Y?%<1R! MR1@W8G&#&0GS .-)=(P4\T$GVDM.^Z#NG?3Y0%^"K0P LZQC/$.N&Y6[S;(?YG6"N^2X@PW(3,EVV MDB%85DXX$K M5[Z)JJPSX-%@%[07FR&+;[YRJ<1472ISM?%CQUK#)1@@0L_T8M-$18O9)WP, MQ<,RM3RR@*#H'623R7?BNF$[8+VGZDZ^F$]3.6>'37P$ZLSK#E46'P80I!]UT@VR M74>*8)I8]?VTVF[CNSR7XCXBDQHA.W;0AU>'9/8W@S\'JZ-QD@DM3<$4#W$; M'*,3ODONX)/RJE:/NFQ,2(5.TO >83DX0(R*(IR (L=.)9\[KJ&74IN1"Y1Z M-#+W1#B1@?"&;F)MK+V/J[)NSZQI+%.D$'Y3*/4BIB^M QQQLVI1:VL-&,2^ M\&HT!9\,>8DH-E+YZ.")9]NVZT6ON,:LVL+0AJE F$;MBY.-)-JXZ$AP:/5] MDU]-IM&PA[1T9VWB@L_O>+;[YLZGA0-"W/O"AAUC5%L@MA2%A5)PTCMZ^Z9# MV>Y 1)KEDV8^/U-/%95"T[TD6&+MQF*7?FT<^U=*%+Z,VK5ID0J,1(I5C-QZJW, M#:VLB\F@33NSD#D=V]O^ N>5^#!<=SU'DB;1Z'+65>(5;<5H=,K_ME:NW<*Q M!5^=A*.)&OZ!,]N"XZM3!BFRLN:"\6ERQY]1%'S@ME*N: ,61.T""H3&O7ES M&@E32>JK2V1RD$JO9Y3],9P MI7(M21T@(FYNF7DZ+NXG\(7DXKS8F+!'KAPTE!) M.!H<]\1G*;XH [G/,?; O(66XNWP[?'(-7R2D!JI?\D";=R/J41YY&[BO4W% MW#]2][HHB%UKK&-GK/ZR,[>XR:5C6G)M5AP4#$.VAG$[8*QX8=,'.(<+7SAA MV+OG[[A(#F2 ^]BIO=M^*C9V7TAUR]UW9E]D#46-R-0,6P?]TY,]A[O#A2TK M_EYJ6EI;YOPS58!N-2W \UF)3NHOB$'[ =W'_P%02P,$% @ R$PT5/?V MD1.' @ 7P4 !D !X;"]W;W)K&ULK53;;MI M$'W/5XQ92_N[A+"WW=V35PJ-?2E M+][;G#-GQGNVO]7FT9:(#IZE4'80E-F9\73J_ M$0_[%5OC'-U#-36TBAN6@DM4EFL%!E>#*.U,(,A?!$)./GGC-J4GK@X?R%_6.HG6I9,HN9%E]YXQ9!OK%.RSV8%$BNZI$][_MP +AL MOP)(]H DZ*X3!977S+%AW^@M&!]-;'X22@UH$L>5_RES9^B4$\X-TRR[?[A; MS&$VSL8W7]+19'Q*\TFZ&%_#-)TMOO5C1WE\=)SO.4X%XMY_[>9QSKO[Q?CDH@7_YH8TS_5&.7LRPQSY$UL*A&*# ML#):P@P%4)P=Q;]]<)IV+#Q8$S\G2"&QM$,G= MCBZ\*^%S-H%%B895N'$\M_!NC@AWVB&HED':UL(':CO?[/; MO!YI;9K?X?73<\O,FBO2ABN"MEL79%93V[E>.%T%"RVU(T.&:4DO(!H?0.5.'OP!02P,$% @ R$PT5'O^?M7K" A1T !D !X;"]W M;W)K&UL[5E=<]NX%7WGK\"H.QU[1M67[<2;V)ZQ M'6?C-K'3V.E.I],'2(0D3$B" 4$IZJ_ON1<@15FBXMEFVH?N0V*1!"[NQSD' M%^39TM@OQ5PI)[ZE25:<=^;.Y:_Z_6(R5ZDL>B97&9Y,C4VEPZ6=]8O<*AGS MI#3ICP:#%_U4ZJQS<<;W/MJ+,U.Z1&?JHQ5%F:;2KJY48I;GG6&GNO%)S^:. M;O0OSG(Y4P_*?I/@JTK;VO4 M8NM(?#"9FQ?B)HM5O#F_#[]JYT:5CO0;?J$E/' V[8C08#??8.ZJ#/6)[ M1RWV;KZ6VJW$/R['A;/ PS_WV#RN;1ZSS>,?DL"]MHB KXI<3M1Y!PPKE%VH MSL7=_>--=-H3[0N)Q[F*@)3)E[E)8F6+ZK'R\1:! 68JW%R):Y/F,EN)"8H% MUA9\@:[X M20Q$;S 8#,5Q]W0PZ [\/UR=O#C&KU'W]&@D?M5N'B'$'*X)9X22DSE@[9PB MP1BG&K]B>B#%PCA%"S<#7(=BN[=$@_L>S&722+&2JC,:9=X MVQ-9N,C-I1-9R2%A%JU6B.5 M@Y"& ** M&*C.EU4#>[P?$X28N-)895MMWOB(\186:OBZ*'&D8=1$T0OPM\3 M_^>HB:^CG[NCGX^ZQX,7F_>/ZY\C_V?H_Q!IY-@L5$J8,%2T4%%9NKFQ^E^X MDY>V*.6Z^D_#GBCK]%1/I,>HSB;KH(#G%4$.Y2MA:FI-RCA@6_1W"1(@_U%N M-;(L\]P:8*U*#SL3,MHC;\65D39F#FK4SYF-"C.E?7'G43@A!NI0;T@/9H2D<6[,0_I*, C( ) 9-XQV)O3C)CJ M;[00QE?H97^P1J+AAXJ[(L7>J?.$%YZ2(F.43(!**S)#7"3[EC96 A7,\C*Q M*O0LXQSC=L[(4=E$X>)K*1-?#_\0BP.ZDW!E\O #_B^05FXLV#H;-X@5\@-- MTE0&"X%*)#4-U2 B"F79AQER[VG%,A(*3OX!R9!L'AA=7J[A'89# !Y4[KR2 M#D]HAQL>;Y1RJDFEI+B^^?1X^_;V^O+Q1MR_%6]N'FY_N;M\O+V_$P<$P]'@ M]?4F"-\TTL,CAJ\/&6ML_TXM9"SAVL0JTIH(,QX<304W.=^@?!C;2&TS3UP^ M;Y]3(C*U)-%8TV:=H;P.W&\B5>TH-ICZDD$NH0M1",5G3&QG+ 0B#E BI3,Y MI9VB'D(;12&>:>.0V11]GTW,HT94E?H$8:JJNZNX?Y9924(>2GOR>VGKLOR MRO[HPC;WBW=><:.*W2U+(NO;#46UJZ)_4-B*I<^IGB(UZ*JL%UZR.JY9R?XT*:&Q7L30[D []4+'BJ;"QD] M\I"V!=)-B[SWQ*W?J=6"6AYR9#V!-O(J$%+H7.J8A)M&>>G<:!30/:4R!FQ# MUP+@-1J^K;YDJW-IS;RLD@5]QG8;BY@@7F]DZRQ[(% 'X[>-$(EXVM*8K*U- M:JLO53:.M=^NHG6*FE6[K < B&% S5D)9J0&W9XX %8X>:%'HG.V[[V+>9=: M]Q)[-S/.ABRC34#)W.J0NE-8]]F,*GL,N;6MPPI9CEH[VIVJTM3)K%G M20B9KN*PTW-'UTH/W[\A#/%7;_DKC112$A]+E<,Z5"?0J9\C_HU M7W/ISRX;]ZC^Y6[KK+MMK373D1G-R6]MV0]P$N=7#0N5K*@# M#C!XOUZPJGXW&C-# [^:2+1U,#4 F40D@T2SZ5.6;!X]FF1L%>H-ID7[F+:/ M!"+HT*Z^_DG.N,YA#($A'"L) #9/2@)DI*3-D'IN\RIJU/!>ZU2-IAT^-\G7 MR+JX9&LU]7A%BJL696),F9&<-:C,.DJX($!M G_'VG.55+*30D2GW:C,Z9T3 MJO&^B;C6;*USC1-Y.<66K\.A$X#@@=LAP9R9^12SO#XS(!T:<<(4G1;V22Y[ M'+8$8 #Q9\I]+X(:TN0*T#F+=AQ*=ZWE#XTK\I!$#LU*X\3I#S,<. N$/Z/C MR2KH%<-^J0M%/H2MAME8PS=:'R$:K"NJOIV9AK5YHV1ZUUHKG/R"/$ G-5:? M2@TED$F)XSPT*%:.3E9T@L24F3$QC4!!FOO0(2O,&$YV(YCAC":;+V9X7&^C M?1QP^_A2?%(S+'^E30X0IK*+?7K2J[M$?EH#_#GM96=/8]DYC%I;2O%?;2FC MEI92= )Z/CR5K,[>-K)]VM[6T2=_7],83@1D8IM.6ZOMT-5*5&NZ?K^'W.&K MIK?^K.)<[WU)])UO_T1NK MFB"_Y5T53V9:?I 6VC%ZX5](MY%2_+^R\LYD_L6*TY3.4-"[ZZV*/H>CV]-^ M"TE'S^#G#@=_)V@[05O3]3]GZ*ZO.?W&I[%4V1E_ *07F$B,_TI6WZV_,5[Z M3VOKX?X#)=@_H\\EB9IBZJ#W\J3C&55=.)/SAS9L\LZD_'.NT%-8&H#G4V-< M=4$+U%]>+_X-4$L#!!0 ( ,A,-%1>P0 +L) 9 >&PO=V]R M:W-H965T00D%3MM\4>8'6VU[>[AJ2_OK-K0\CU$E6Z?K'W;9Z99]YVSW=2?=$;1 -/ M15[J"V]C3'76Z>AT@P77I[+"DG964A7B,SBN^QCF:AVJJ:-8Y MH&2BP%(+68+"U84W#L\N8WO>'7@4N--'8[!,EE)^L9.;[,(+K$&88VHL J?? M%J\PSRT0F?&UQ?0.*JW@\7B/_LEQ)RY+KO%*YG^(S&PNO($'&:YXG9N9W/V& M+9^>Q4MEKMT7=LW9;M^#M-9&%JTP65"(LOGSI]8/1P*#X V!J!6(G-V-(F?E M-3=\=*[D#I0]36AVX*@Z:3).E#8HRW?(0,/ M5D9[*R^C=P&O,3V%;NA#%$3A.WC= ^NNP^N^Q;K_E%HLE*HB&+;K9(%S)HN+E,U5@BI5UT <(_1[A3!5:KFSR1+U.4R8DL1\-!^RZ1K92LH!) M4>7R&+UAEV_VTO8E:1M900).!W' &'@*),.69=&LRE_;M;]J#_T@[BQZF6=>.T% MG%$';D=9[I0/AGXO&O[[7!1T_:";L(EE4RFAL75GY ^B/ODM8;>H]1E;2$-. MO<:E@8^T&?1#OQ\D<,*F4MG.R\C_+R#0@(R-46)9&V>KD3"GY,.-S#-4Y'YR MZ)!L/XKAE'+#G:&@!:=!V$]@L4'&ES;CR)VD!YO$-,+4Y+JC!/KYIT$4)K]H MT)*4J99_Q6T*B)=.H%\"0LE/1A\GI>L\,-;L>^MGKS*1TH]*] M ?TC/PSM/V"'TD-E'75'Q80K5(IP?I",-?>'NA =$(AC3X M&-(@AA/+"+[7Z3M'%VJ!:NV>#1IE]+09>^&&WI=H;(':'\EJ:[;B55P>*^-_@%02P,$ M% @ R$PT5%!R.V,-! +@D !D !X;"]W;W)K&ULI59M3R,W$/Z^OV*4GBJ0HNQ+$@A^%D.:LE5M;GH:A27,L MF.FH$B7MK)0NF*6I7H>FU,@R;U2(,(FBH[!@7+9&0[\VTZ.AJJS@$F<:3%44 M3&\N4*CZK!6WGA?N^#JW;B$<#4NVQCG:^W*F:1;N4#)>H#1<2="X.FN=QZ<7 M/7?>'WC@6)N],;A(EDH]NLDT.VM%CA *3*U#8/3SA&,4P@$1C6];S-;.I3/< M'S^C?_&Q4RQ+9G"LQ)\\L_E9:]""#%>L$O9.U;_A-IZ^PTN5,/X_U,W97M*" MM#)6%5MC8E!PV?RR[UL=]@P&T3L&R=8@\;P;1Y[E);-L--2J!NU.$YH;^%"] M-9'CTB5E;C7M>9UD7P(>(EI![IQ&Y(HB3_ Z^[B['J\[GMX MW*1"F4HC3.43&DN%96&.::6YY6C@?&FLIAKYP%=OYZOG??7^KZ8?P]S<+B9! M''7@33RX).9R'=@UWL",E@K6)JTH#66E3<5(+JN T45::T0O'_VA M)H]<6A4L-[29P1)MC2CAC_$5+'+4K,3*\M1LL0Z 09TK(3:@:DFVIEH:GG%J M"([ 'MM##_@D -S,-G^$2MJ/0!. ]. M!-0I9X+_S7RG(!XI:DL=S45,Z2,4$E)IZH;8;./CUET&21)^OMM#3F5^( M/Q\Z+SXEECID4V.$DE<%DUY@1U="RB0Y\(P8D(2%VUKQE77";9!I RNM"C@O M-1=PW&2R\[,9C[L^N=VH2?*[5G,L+19+FK^8#KQ)?-+WO^MOL%TV' M. 3[A'^X QJ?F*@H_/\6!+,>Q?404I-*@5+_7+"O(*1;#&X78YAQ^4C-6C^B M[;PGYFDPIXU.7H*$:C!L_\X^I!A?,< -?&-?!@PL5%LHR$=Q+*DFJ M<0K]2AE#"#=H]U>_NH*GDCQPVX>P6\]\ <&/!?1:Y^ 3'!T?MV-2]1,<]]IQ MW*?!492T3P9N=! GW?;@)#Y\J\>&>V\8W<>U?ZD-:5M)VSQGN]7=Q\!Y\P:^ M'&^^)*Z97G.Z;P)79!IUCOLMT,WKW$RL*OV+N%26WE<_S.F#!K4[0/LKI>SS MQ#G8?2*-_@%02P,$% @ R$PT5'A*2'UY @ S04 !D !X;"]W;W)K M&ULI91M;]HP$,??]U.<\CHBMO- 4@$2T$ZKID)5 MV/;:)(9$36QFF])^^]H.R:@VT*2]B9_N]_?=Q7>CHY OJF1,PUM3\EHX:"F#@A"2=#0BGN3D=M[DI.1..BZ MXNQ)@CHT#97O,U:+X]C#7K?Q7.U*;3>"R6A/=VS%]/?]DS2KH%3@#4G0!("> .+_;BYR7=U33R4B*(TAK M;=3LQ(7J:.-U/66EI3BO#Z M"E*+_ 76DG)%W6-05T2C7C1RHM%_9>ZZQF*YOK_!9 !_BL&2WRQS+39,PBD3 MH$L&<]'L*7^'2JD#*P C[ ]QZJ,XA8C$/D(( +\J:5NBO\W;1O=(Y:[B"FJV-2@:#&,/9-L\VH46>U>P&Z%- M^;MI:?HMD]; G&^%T-W"7M!W\,D'4$L#!!0 ( ,A,-%0K7\XXY ( D& M 9 >&PO=V]R:W-H965TD@!-FV'=UC9KVNYAV(-BT[$P67(E.6[_?I2<>!EZ>=F+K MY> Y- M"B'-.,BM+8_"T"0Y%LST5(F27C*E"V;IJ%>A*36RU#L5(HRC MZ&-8,"Z#RY=1?A9%2R%2[0 MWI9S3:>P14EY@=)P)4%C-@Y.^D?3H;/W!G<<:[.S!Z=DJ=1O=SA/QT'D"*' MQ#H$1I\UGJ(0#HAHW&\P@S:D<]S=;]$_>>VD9/8>7*&'\"G5C&Q\&D%3&JF+C3 P*+ILO>]CD8(.7-%9+@_<52@NS-:T&?IXLC=54$;]>@1^V\$,//_R?%+X. M<7EU,^OT!SUX@@57LO.%R8H:!OH#GY(8KG&%$J90XU%)VW1J>]O.N9.F MO?^:-T/R@FD2:D!@1JY1;W\O -T,GN9@5>F;?:DLC0Z_S6E6HW8&])XI9;<' M%Z"=_I,_4$L#!!0 ( ,A,-%3A:&\./PP $4? 9 >&PO=V]R:W-H M965T9:H(@622R;Q6$4)FJ,V0 M%&1F[_;J/@A;@&YLBY7L$/;7W],MV9B$,/LE 2RU^N7II[OE#RMC?[B%4H5X MS-+][KO++F_@%=^U6KG&9T&F3(WY05^&R<># M#FFD4A47)$+BWX/JJS0E2=#CSR#TH#Z3-C8_5]*OV7@8,Y5.]4WZNTZ*Q<># MBP.1J)DLTV)L5E]4,.B,Y,4F=?Q7K/S:-S@Q+EUALK 9WS.=^__R,3BBL>&B M\\*&D[#AA/7V![&65[*0GSY8LQ*65D,:?6!3>3>4TSE%95)8/-785WRZ'7_N MC89_].Z'MR/1&UV)R;>O7WOC?XO;:S$9?AX-KX?]WNA>]/K]VV^C^^'HL[B[ MO1GVAX.).+PSJ8ZUQ^'<2W_NR0OGGHJO)B\63@SR1"7;^X]A M0VW(267(Y@5^2=UHXY97FG+\CKQ;$I\T+GV0(^X7*IKI7.:Q MEJEPA2P4,JEP8B$?E)@JE0OD\%):E8C2D8W%0A&ZM1-FAE2I;9^K7%F9IFOZ M42T+;- YK_Z6:_HV(>&\JY@3ON&=K"CZZ "^(5,NI3G6APR*=QZ6%06VR7O1-MI3Y&@:[ M2":&%9=B0A9D4VAWVA%K''>D\J2])YAG=3#/]L;A;CP<]8=W-P..1/]V-$&2 M7'%6[0KJ7F%$Q._<4L;JXP&BY)1]4 >?+MO1GD,XXK')':":2#)V9_CAH[1, M%#LQ1(2C\UO_AB18N51EH6/7$L,\;K?@L9%ZD(D4\/_26.F)%.%9+0QAPJPH M7JZ<.IUHD#ID16,%S+3%1,]S/0,>\@+'%LH>Q2$DR*#<22;E)B!5JL%OI#M' M,*HB*'.9KO]"D$EIF/B@+)>$F9)%B;A#_3[_6NAIJL3($!Q1KL#-5C]((OTF MH,E)&H^\+25#M3?IBXONV5'W3/SS'QP ?V?E')'+O;S:56_5EJ MRXH%7#[7SD-SJF>EC3DL),Q1YN&;3RI2C.(%C9$"$HX 0!-">\, 2"Y08E42 MA>P+WB%UNV_>NW"T=T&BIH7/@EVBD(^QM%;C5Y.'O$\!%25\&P!;9E);\2#3 M4L%@A*#,4?!3_1>VQ N9SQ5IL5G4(L43A1AG.O=9JF2\$)F2#CX@Z(DE%#!) MBTYO9CPA*UN:G)8@D*0-,&J0WC5JV64,6.<, $W.(@/6B$CQ,I7QCZ-)#.AC_1)<1T\RDZC4(Y87B)T+ M( 9B"[-Q$XO7IQM'GTWJ2R\^1Y+2YM^Z M[QOE-0AI41NJJ/9%.(_R1!6.T^9IC6PD*;6R-0,D>@8!BG)GJHH5T3%CH:XA M:!:,9?[D;,0IM-]7]IW'1=YFE4L*(>^PW"@P6:YTFN(DPJ_"R7%1-154DS>H MWE;-FZ "*BB9J)&P[DD^>WHA:J',9IJ/)&&:J0&[S&P&C6N?B8;/]&S;+RMN MZMG*!ZE32?FH&(PQ6$\SQV3&JJ-4_P"='\&X_ @)ZZUT%#OVF\E;PEA2HU71 MW*[CV2VT?4H]CV?<0.3>2U"KN2\$(- :^[#V\[/4#XB$&JEQKG*XYV6O;^@. M A=2Y)A_J9]X4I*7RU0'OEA:\Z =UW+J 3V C[J=H[,-C!N]-$8I #@&N:&< M(0V&N6B"/&"\%0# PDFC.)66NPD.IU6I#! (*@ =KED@5KI8-*L^I619' M6AJG?0O2F=+N[)U0"-2AT8EH&:WT(B;!S$'+:,]:Z@)Z66: M0*K#D$K6H4[XFLB1#?Y[VDML2.HID_EVP)54<39B_"%3%6%(QK%PVPN"O1X, M%/C-!H^P\A#KU?^SE!92J+FDG_,2XH(QG)HM,@/]4]$2Y3*DZ4ZY[!1ZZN5Z M&3" ES4'@5 %FW5U(1/DX4N(:?D6F)*5^C*-688L5IYOU#;8H@W00LK-2NH, MMS/*CUE^2-EBAA@?-/&)->5\(7(05S 1J.9$YEZ(SEQ)"_N^F!6Q8JO)?V+# M?["]V^G4A9J;6T!8IEPCC+<4&M# F_/0NYT>E%,V85&<8[W^I)EGP&>>2*9? M<#6RUCFD[18!>=[:$A5Y4>".>[/4\89!CKIO]TUG;^J:_^:GHW9?#'KC$8;C MB3B\N9U,7HF[P5A,OO3&@UUMP'Z!0S]V[Y')T;VN>:3!@)/:19<&_\3A=6]R M^:IJ\'8N[)ND)C]Q"#^]$B?G&WH=8&S&!B?N@.?) I[?IM'(H612&*H9*D-C M)WU5X@$S+S:37:)=#%R5/';S@.-'1P*UJ@XZ).2]HIQ"KTV1YJ=0FU'$T5R6 MTU3'2..%2HF'L@S$[0H3__!#% QH3E!J6Q/#A1A0>/E(KVQ:4M*\N.K998 ( MEP'1[MI%6OE:2RWNS)J,8 NRP**VN"25(LI!SKR&+IGO_&BV8N_Z=BZAQK5J M_6A;2('0Q?ON@I(#"2M1P/.2*0FZ>']YZ5 .?3B!@2;0/>EP4:?#Q?Y+HZOO M@_']8WU][;," M/8E?1&>/N6]K<]_NU7AT>X].?3SH#X;?>Y 9U(K# 0 M45](IG*[P -P#->T1$IMB0;XM*4L:E&#"2!2%8J>C&([:I![,I#YJXUQ?>36 M9.;'Q(T^T1^2YH3H^;4.W'K6.GU[+G[A?Q$*1O*D8A-"_?X=UT*H]-(ZX30U M+OYNAT8^&-WM_,IIB31(4!/K^IR@5\+/H8<)9^Q#SN;[N[ W->/!],/HV MH,C>P73,8_Y,/]+88NL1CS#PGO4]U ^OH&Q*+T*JQHZG ^D,+5M3XUQ6-Z?( M3A+@"WBQ1CGFVU],FAS/P)MJ*=>L+C>(#\9?=?#EUD(OLW"=4SEFN]>IAU"/ M[W"%PW,EW0#.N0\V:[0DZ^JJ>#.5Z8+ONO@6GEI#.; M"6)0B8A6T,!&3T=%#I-[=B"%K;J/+L/ 77DFX+AQM+\255M7<_5-HPNS7%W9 M@N\BY-R4B]"4@M46OR^(]+PFU<1>&RX)/S$5R'EH_[U)PA%(&SX[HO0D-U;> M;VUI]=SFJ':RG^S6OF)IUSSQA8X>B:^IZV<@TU08,Q=N*[==A/W% /\0TIDYS>&YF_DK;+;<3P))/5!R6\.D.E5AM0[CI24L M^=$$C%DIC)6-FW"&7;1]U[>7+AMO^[H_N?VZ'XP'D_N?E,.?2/E*MV#/!&V& MBD951#3_;E'<9>!QX\UFIM!&T/M;8@!0AG_)6?]:OR/N^3>CF^7^!?-7="$: MT4G5#%L[[3=G!\+Z=[;^2V&6_)YT:HK"9/QQH23"10OP?&908L,7.J!^<_[I M_U!+ P04 " #(3#14M8-8Q[H" (!@ &0 'AL+W=O52B !I@21=*5P$)%53]<'L M#F#%:V]M \G?U_:2#:T"Z0OKRYQSY@R>Z>R%?%(;1 W/*>.JZVVTSJY\7\4; M3(DJBPRYN5D)F1)MMG+MJTPB21PH97Y0J33]E%#N]3KN;"I[';'5C'*<2E#; M-"7RI8],[+M>U7L]F-'U1ML#O]?)R!KGJ.^SJ30[OV!):(I<4<%!XJKKA=6K M?L/&NX 'BGMUM ;K9"G$D]U$2=>KV(208:PM S&?'0Z0,4MDTOA]X/0*20L\ M7K^RWSCOQLN2*!P(]ITF>M/U6AXDN");IF=B_PT/?ER"L6#*_<(^CVVV/8BW M2HOT #89I)3G7_)\J,,1H%4Y 0@.@,#EG0NY+(=$DUY'BCU(&VW8[,)9=6B3 M'.7V3YEK:6ZIP>G>9'8;CJ/'0N&D37<[A8D"5#]:7C:Y.)Y?/C@VH_5PU.J-9@)+C>*+CF M"29_XWWCH+ 1O-KH!V<)AQB7H5:]A* 25,_PU8JRU!Q?[01?&,=BRS7E:Y@* M1F.*"GZ&2Z6E>4:_S@C4"X&Z$ZB?$)B;[DJV#$&L8(B2[HA]G7!'R9(RJE_> MJ^E91MN]5RHC,78]TYX*Y0Z]#V5*,ZJ>2C<2$2*NT> TS(A&J);K;?A:+@3-$:1=$: M_UTT+K3Y3R3&:$R99_A>P:QNK2U,T\O4_0 MN*RUF^^:](^Z,T6Y=C-(@7M@>:,6I\68"_/N?@O/9^2(R#7E"ABN#+12_FH< MRGSNY!LM,M?K2Z'-Y'#+C1G5*&V N5\)X^FPL0+%\._] 5!+ P04 " #( M3#14\I0XKFT" #)!0 &0 'AL+W=O9 #('@HAS=C/$,MA$)@D@X*;"U6"I)N-T@5' M,O4V,*4&GCI0(8(H#-\&!<^E/QDYWTI/1JI"D4M8:6:JHN#Z, .A]F._ZS\Z M;O-MAM813$8EW$:\$NYTF0%+4N:%R!-KB33L!G[T^YP-K#Q+N!K#GMS=&:V MDUBI>VM\2,=^: L" 0E:!DZO'GQ_9W[G>J9>8&Y@K M\2U/,1O[5SY+8<,K@;=J_QZ:?ER!B1+&/=F^CNV'/DLJ@ZIHP%1!D7*L.3<7ETGZ4-6JZS0F'DT^? M[Y9KMII^G\ZNE^SU'8\%F#>C (G;1@1)PS.K>:(3/#UVHR1FABUE"NF?^(!J M:@N+'@N;16<)%Y!O9[H.C\2I ;]T2,2Q1E<1ZTEIONZ>F]7@^A==+[H;K;2X-$[ A:'AQ M29WK>G'4!JK2#6NLD$;?'3/:M:!M -UO%'WPQK )VNT]^0U02P,$% @ MR$PT5%VRLRCO P S @ !D !X;"]W;W)K&UL MI591;^(X$'[WK["B?6BEJ'%"0J ")-JR=Y7:"@';T]V;209B;1)G;0?:_?4W M=BCE[K;HI+X0>SSSS7SC&0^CO53?=0%@Z$M5UGKL%<8TUT&@LP(JKJ]D S6> M;*2JN,&MV@:Z40"GW M8R_TW@0+L2V,%0234<.WL 3SK9DKW 5'E%Q44&LA:ZI@,_:FX?5-8O6=PK. MO3Y94\MD+>5WN[G/QQZS 4$)F;$('#\[N(6RM$ 8QH\#IG=T:0U/UV_H7QUW MY++F&FYE^8?(33'V!A[-8*JN-:';AJ#IK#$[4]E*6 M1N&I0#LSN7]ZGBU7C[.G%5W.;K\M[E?WLZ5/%[.'Z6IV1^?3Q9_T8L77)>C+ M46#0H[4+L@/Z38<>?8#>HX^R-H6FLSJ'_)_V 49Z##=Z"_GW'%[O(_KU#K3!(C-T"5FKA!&@Z0)*;B"G>9EZT[O:X,=@"W1\I+.%3:W,J_T"PW]A#$R5]!PD9/9"S:]QDRDL1\-!^2N M!;)1LJ*SJBGE*P#JLS0D3]( 64 &8F=+A/9C/T:8:9:I%G)BG6&,AIZH1,R/ MTIB$YZ<)#X9]OQ>DI);BX"'KAWZ?I?22S*6R3Q#!_+^#T YD:HP2Z]:X6(VDRX(K*&29 M@\+T8T*'&/O)'R*A?V4GBG1Y%BBR?\N4:P:K*S"/KP[.%.GGT,D M<E),ES&R;<: MQU$I?N)=_H9C2-,G,/\64JGHQ8/4^I(>Y3F67;VEI@#ZH\4B0*=@WRF\P@RJ M-6[QI;$/#?E"$S^-0TQYZ@^2 7XC/PSMEY$T2EQ]+4'9*GK$KH(-*(4XGR1C MP_TTER4TYD"&O9$)>WX8Q;;KD08;XN(BQ$5,+RVC7Y53<#)A*E!;-TE?OYOPC5UM[225LT)1=I5A'JIN=W<;(QLVKM30X_=RRP+\; MH*P"GF\D]O=A8QT<_\!,_@902P,$% @ R$PT5(HA7(Z3 @ 6P4 !D M !X;"]W;W)K&ULI51+;^) #+[S*ZRHAU9"Y $M MM *DTK*[2-LN:FCW/"2&C#H/.C,I[?[Z]220LE+I92\9V^/OLQW;,]QJ\VP+ M1 =O4B@["@KG-E=A:+,");,=O4%%-RMM)'.DFG5H-P997H&D"),HN@@EXRH8 M#RO;W(R'NG2"*YP;L*64S+Q/4.CM*(B#O>&!KPOG#>%XN&%K3-$];N:&M+!A MR;E$9;E68' U"J[CJTG/^U<.3QRW]D &7\E2ZV>OS/)1$/F$4&#F/ .CXQ5O M4 A/1&F\[#B#)J0''LI[]F]5[53+DEF\T>(WSUTQ"@8!Y+ABI7 />OL#=_6< M>[Y,"UM]85O[]I( LM(Z+7=@RD!R59_L;?S^:9HN[J;W"TBG-X\/L\5LFL+I M@BT%VK-AZ"B&]PRS'=^DYDN.\'7A3BM76)BJ'/-_\2'EUB28[!.<)%\2WF+6 M@6[XR/VTQH6QJ$F7I%ZVC"'*28E88[CA:NE]89&I8O M8O6:6+TJ5N](K)16*"\%@EX!_PAFFV"?_=__I&S%@W8WBEHW6DJ:^K1@AHHB M[U^*9D6OWV%.)LG:5'[6:4V8Y1:^,6Y:3TR4" OMF&@]*MIPP?]@#C^UM<1P MC^[0^IWV';2!4W]]!HT]IS34&ER!\%(RX] ^DD ZB/*):G42]_*U@E<]/OM M.(K@!/J]=AR?DW 1)>W+@9=.XZ3;'ES&9Y_U(3P8>(EF7:VUA4R7RM6SWUB; ME^.Z7I@/]_K9N6-FS94%@2N"1IW^>0"F7N5:<7I3K<]2.UK&2BSH]4/C'>A^ MI;7;*SY \YZ._P)02P,$% @ R$PT5#O$''&S @ S < !D !X;"]W M;W)K&ULM55I;]I $/TK(TN56BG"!W<$2.9*+85# M0%*U43\L>(!5O+O.[A+@WW=M@T.EX$:J\L7>Z[UY\^R=:>V%?%9;1 T'%G'5 MMK9:Q[>VK59;9$251(S<[*R%9$2;J=S8*I9(PA3$(MMSG)K-".56IY6N366G M)78ZHARG$M2.,2*/78S$OFVYUGEA1C=;G2S8G59,-CA'_1!/I9G9.4M(&7)% M!0>)Z[;EN[==-P6D)QXI[M7%&))4ED(\)Y,@;%M.H@@C7.F$@IC7*_8PBA(F MH^/E1&KE,1/@Y?C,/DR3-\DLB<*>B'[04&_;5L."$-=D%^F9V'_'4T+5A&\E M(I4^89^=K3L6K'9*"W8"&P6,\NQ-#BY0K .P&\5'<6*%79)YIT6E+L M02:G#5LR2%--T48/@U_^(IB,P1_W8?XP&OFSGS 9 MPCRX&P?#H.>/%^#W>I.'\2(8W\%TUF M8;TK8-NDD.?AG?/H>H6$?5R5H.S>@.=X;@%?.?>EG/*5 MK_!-I?GQI3[>P#0B7 /A(0Q>=C0V?Z2&IWMS' *-3/TN"%;)@U728)4KP694 M/<-0HJ'D&B4J#3.B\3U;BXG<4J7YI4!0-1=4+>09'&)S:S"$1Q$132.JC^^) M*29I>)52LUHDIY;+J14RCS/CF.HG5C@27.-5@=G7-])\A"G48!-W@ M=6'&-Q6YA3")MVR#E_PE>/!G,3@ MG*R4^N62K!P$'2<(!1;D&)A][7&$0C@B*^/WD3-H6SK@:?S*?N^]6R\K9G"D MQ#=>4C4(/@90XIKM!,W4X0L>_5P[OD()XY]P:&IOHP"*G2%5'\%60M7=6[-JNE#!$:2."J6 2 MQMP40IF=1OCQ:+=V9W*?7/<^W<3A_E11>#(R[O0],;WATH# M85UKFZO M ]#-1#<)J:V?HI4B.Y,^K.PE@-H5V/VU4O2:N,%LKY7D+U!+ P04 " #( M3#14=88M;7<" "U!0 &0 'AL+W=OK8S#;0_?O93LA8 M!=%>XJ][SCW'SKV# QO*K( 2RP[? M,G:RY*K/12 M;%RY%8!S"RJIZWO>C5MBPIQP8/=F(ASPG:*$P4P@N2M++'Z/@/+#T.DZQXTY MV13*;+CA8(LWL "UW,Z$7KD-2TY*8))PA@2LAT[4O8W[)MX&/!,XR),Y,DY6 MG+^819(/'<\( @J9,@Q8#WN(@5)#I&7\JCF=)J4!GLZ/[/?6N_:RPA)B3K^2 M7!5#Y[.#@[*=5+RLP5I!25@UXM?Z'DX MFN<\P*\!_EM [P(@J &!-5HIL[;&6.%P(/@!"1.MV$F5=<**%/ MB<:I<#I_B-+D>_243%,4I6.T6$XFT?P;FMZC1?*0)O=)'*5/*(KCZ3)]2M(' M-)L^)G%RMT!78U"84(E2+ 0VSW&-/J+E8HRNWET/7*7EF21N5DL955+\"U(" M-.%,%1+=L1SR?_&NMM5X\X_>1GXKX1BR#@JZ'Y#O^=TS>N+_@7L6[K7("9JK M#BQ?<($ORC*^8XJP#9IQ2C("$OV(5E()_2__;$G0:Q+T;(+>A03/F.YP51Q4 M5R=F&9Q[A7:2KN=U/.]]BYQ^(Z??RA3E>Q"*2&,87G7;D2#/Z:E8;BR+:3K[ M4-_V_O2=VB(J:>Y)!90@-K8Q2&0OO/IAFMVF]T2VY-[LCW1/JEK(7YJJH4VP MV! F$86UIO0ZG[0J436):J'XUM;9BBM=M79:Z+X*P@3H\S7GZK@P"9I.'?X! M4$L#!!0 ( ,A,-%3+_13C-P( (D$ 9 >&PO=V]R:W-H965T"T8RT*2<\I83!UCC1:%,K M^#'=*2V-NGY>8#3J&8TB!;X;>&%K43VTYH(UVW+Y-M;L.-C79OOW MV$X656BMD!!?$I]][W/O.7:21IM[6P(@>5"RLK.H1*PO*+5Y"8K;@:ZAU4OC(MI3"J&@LD)7Q,!F%LU'%XO8YX>$KP(:>S F MOI.UUO<^N"YFT= ; @DY>@)WKSU<@I0>Y&S\ZIA17](+#\=/]'>A=]?+FENX MU/*;*+"<16\B4L"&[R3>ZN8]=/U,/2_7TH8G:=I<]C8B^K%5G.O\\7-U?D+ /D0MJ7"44']RDT[T"+%L2.@#+(!V0\>D78D(WN5ADY M>_$'A3IKO3_6^V,!.SZ"797:X&L$HT@&:R0_;EP"N490]N<)_+C'CP-^G \_4W_R,U65)9(V#C5<'#N6C3M[6D#U'4XL6N-[OR' M8>E^.&!\@EO?:&>K"_PEZ']AZ6]02P,$% @ R$PT5%Y?Q$H5 @ \00 M !D !X;"]W;W)K&ULM53O:]LP$/U7A-F'#K8H M=A)O%,>07V.%M O-NC'*/LC.)1:5+$^ZQ,U_/TEV31A-&(PY8.ND>^_>NTA* M:J6?3 & Y%F*THR# K&ZIM3D!4AF>JJ"TJYLE98,;:AWU%0:V,:#I*!1OQ]3 MR7@9I(F?6^DT47L4O(25)F8O)=/'*0A5CX,P>)FXY[L"W01-DXKM8 WX4*VT MC6C'LN$22L-5231LQ\$DO)[&+M\G?.-0FY,Q<4XRI9Y<<+,9!WTG" 3DZ!B8 M_1Q@!D(X(BOC5\L9="4=\'3\PO[)>[=>,F9@IL1WOL%B''P,R :V;"_P7M6? MH?4S%O,HY M0Y8F6M5$NVS+Y@;>JD=;<;QT?\H:M5WE%H?IW9>OBS5937Y,ILL%N9H#,BX, M"=\F%"V]2Z)Y2S5MJ*(S5'/(>V00OB-1/PH?UG-R]>8/%FK%=0JC3F'D:0=G M:->%TO@>04LRAPS)X](FD!L$:7Y>H!]T] -//SS7 (5@R(H=62;@-=,-//9P MM\4/:3CJNR>AAU?J#KNZPXMU9^H )>HC69366Z6YL3*6]C4W=:;0 M'A$_+.R=!-HEV/6MLM+:P)V3[I9+?P-02P,$% @ R$PT5+UGXH&ULK59;;]HP%/XK5K1) MK;21&^%2 1*73JNVMJBTF_9HD@-83>S,-M#NU\]V0DI+XO5A/!#;\?=]Y^+X MG,&>\4>Q 9#H*4NI&#H;*?,+UQ7Q!C(L6BP'JMZL&,^P5%.^=D7. 2<&E*5N MX'D=-\.$.J.!69OST8!M94HHS#D2VRS#_'D"*=L/'=\Y+-R1]4;J!7!O3@:(^W*DK%'/;E*AHZG M+8(48JDIL'KL8 IIJIF4';]+4J?2U,#C\8']BW%>.;/$ J8L_4D2N1DZ/0\3U;L6F!R:8!JW<)U3G?2&Y M>DL43HYN;N\O%V@^_C6>?+]$9S.0F*0"W6#.L<[(.?J,'A8S=/;A?.!*):AA M;ER23PKRH('<1]>,RHU ES2!I 8_M>-#"]Y5CE;>!@=O)X&5< %Y"_G=3RCP M K_.'CM\!G$+A7XC?/9^N&?Q)JQR%QJ^=B/?4B)"A>1;]27JH00.0B*5.JC+ MEITN:GG>1XM9[Z?MAOCGBO4NY9E:\.9ZXYU[T3Y4X0 M'>D67U[OY$0$O7XW?+UK9C5&U\@+D>,8AHXJ@@+X#IP1LASI?N5EWQY?X(0E M)$:Y#C25HL[/_HD'H?_*T5?2OO=R0WM6\0>J8LLE^0.)[4A/2YKC0+=[4;_; MH']4(7S[-8-W)$'?&!.62/K!"UU@I;MA$G0<\3*M.ZC3$O[J) 1-3KQU+^YS8MU6M6'Q=VLO"]TNMA>M%[-E.N& MLW6:;JE7^=.+,SC;?_$INUM6S1>S MB_/[]$Y?Z^KS_<>B/IH=K"RRM=Z46;YQ"GW[XNPE/+^$*&JNV)[R>Z:?2O39 M:>[E)L__: [>+%ZJ7G56,CK7\\ZE=ZM6I,U8[\V5H].S3:7(@_[ZW_ MNKW[^FYNTE*_RE?_S!;5\L59?.8L]&WZL*H^Y4]_U^T=!8V]>;XJM_\[3[MS M _?,F3^45;YN+ZX]6&>;W<_T2QL)=(&"@0M4>X':^KUK:.OE55JE%^=%_N04 MS=FUM>;#]E:W5]?.99NF6ZZKHOYM5E]77;SZ\/[WUY]^>W/Y]K7S_L-OKZ^= MCR__];(Y^O%*5VFV*IWW:5&D3>Q^.I]5=9/-A;-Y:_YR9UX-F/><=_FF6I;. MZ\U"+[Z]?E:[>O!7[?V]5*3!*SU_YGCPLZ-'!H/" ;?Y5O'G7=^,U*.^_S M2O_BO$N+^=*)FR!"2-Q>>&@AG")ZT<%\)+Z!37T#3E:6#W4DT\W"J4E35O6' M;'/7%]"=X0 %%-SF7W]$XX-#,>U06B[W3M1D=.;?.=CG2=SI6LJ3Y.!)8A6: MGYUL4_>#+BNG?F=[':$-QL]<]Z]$GX%KP.*2EB[U1M]F\RQ=M?'9DOQ6I]5# MT>M8:^^;IU^%0Q$"1#@8Y>5KS>"'9:AM9=I69-L?S.-9__%8I9MY_ZTKJ^<4 M#-; LWSW7]X7V/ !D1<#? @')T KC3>I"CPNBGD M4-N&AQ[-0R$*6BO2A]50T)-GC#L4>'8H,,SSXDE08*CFV0V ;5#0S?6(Z/H& M?SZ=[QV# K\[]J5\,:3T[4@I0 %CD46!;YCIT\RT1H%O!4S? -.G\2:>GNOF MD4-MHYE!FH="%+16I ^KH:!_W.0@>%L*1%1'&]SYD\P/^@9H_F0SA'XWTZ," M:\CGCS]'Z'<'OY0O!I+^Z+.$C$66 H'!94#C4OKR!5U$#@0F,'@,:)@)7[[ M*FD,# #)FG<]4M]XX_IZD$[U3*M'/UEKO6BK ^T8*0X/) M?R$Z[JZKD,X85,:CKT0S M%EDZQ0:=,0TZ*9WB;E(Y%!A#QI@FHY!.<4_1(M4QJ&I1--8^C4YQEYVD=X:= M, Q!*3\8J*0T>$Q$>26BT[6^K[G1+(HI/H%*# 83F )1B6%@(L\! M+1&56,TF)H::"4/-(PC5FA0.[!)#R\0NOY04S=(664 EAI[).,O223>Y' J, M@6,RRK)T8C4OF1@^)J(!]VE\2JS6WZA; M&)@>@ZW6IE2.!%CQPDA>CN$68Y+G%E;$,)(8N1RHFWX.A@=A$T:I]]F;D3\Q M")TR/B.H@A$Y.;C,*MU3/$A'E'^(J(Y@1 M8TOUH;-.N6#(!X1.1FG3Q=8/RI!+ "ZDI8%6!3,VN)!D!AC-S"G@ZA'2D!V- M<,I):8X"5[=(B'('R6W LTM,)>!B3/+@0FH=8.0Z8G!YW:QT,#R(FXPT1PHN MKZ=:B.H@+,(6#>5/!)=G!U8DR0%&DR,&E]>7E!+@0FH<8.0X77!=Z7D[^>[R MV$+:&_ FJ48'I*\!"X&-+;8\NSTK (EQP!N_)GUO4SQ41-H=L!3OB,!U8F$Z M("$/,$H>,;AZY#M#X4':'6"D-E)P^=TI4;*'D$('&(G...3R+;>W0,H=8*0[ M8G3U:'?(H:*/][^P*U3_Q?E5WQ0/:?'54;M-=F+R@420]">I5@31#I'V(JHPH2 M(ZM'^>.'B1],XQAZYN1FB M*:<,.FI[LVY%$NT/WFUM]()WSB0/+J04 D;88[_-6=A-3>E@(8J.) W:VY%L M>(C$03"..@AZY$% ! #I@^#_(1""'H40Z1^B**,1&DJZ=N+!A'HFD0X(HDD* MX0$)@2":K!1^;UJ<6"/Y$'#ZH6/HU:,<2HC95:0< D8Z)'X?(_%.0X"T0L!( M>Z3O8]0_>!]R &]/.5(=4H\BR'/][W.&&=KL>JV+N^V6WJ6S#>MNW^O#MX=] MPU_N-LLVI^\V'7^7%G?9IG16^K:^U'W6=$"QV\9[=U#E]]NMLV_RJLK7VX]+ MG2YTT9Q0__XVKQ^G]J!IX+";^L7_ %!+ P04 " #(3#14HZY6T(8" !/ M!P &0 'AL+W=OM4LBHNA %Y'IF+61&47?EQE6%!)I8HXR[ M@>=UW8RRW(E".S:542BVR%D.4TG4-LNH?+P&+O8#QW>>!F9LDZ(9<*.PH!N8 M ]X54ZE[;DU)6 :Y8B(G$M8#9^A?7?O6P*[XRF"O&FUB0ED*<6\ZXV3@>$81 M<%BA05#]V<$(.#-7!75JG\:PV7ZB?[#!ZV"65,%(\&\LP73@]!V2P)IN M.<[$_B-4 74,;R6XLF^R+]>V>PY9;16*K#+6"C*6EU_Z4"6B81#X1PR"RB"P MNDM'5F5,D4:A%'LBS6I-,PT;JK76XEAN=F6.4L\R;8?1[.9VN+B)R70X6WPG MB]EP,A^.%N,ODSDYBP$IXXI,J)34).]MZ*+V:2S=5<6_+OG!$7X,JPO2\L]) MX 7^W3PF9V_^HKA:<2T[J&4'%MLZ@IVG0N([!)F1&)9(?MSJ!62,D*F?)_"M M&M^R^/81_$0@*#*ECW3)X5S_?9PB)*2@$A\/Y:"D=2W-G(-=% 2]T-T=D-"N M);1/2AB)? <2F19 C)SW9 Z%CF\)DK0\DT^_?R+23NVF\QJ)[-;X[HNB:"1U MM)42L)_[Q___G'W_=I]_Z3[F.Y80CX) MH4[D];*&7;[&MOG>G[+@_=<34.$ZSSD"?J,X^<]0490J#KKUGW'RW$9Y-%?- M9RHW+%>$PUI;>1<]K5J6U;OLH"ALQ5P*U/77-E-]XX$T"_3\6FA=5<<4X?H. MC7X#4$L#!!0 ( ,A,-%0-T),L\P, %H3 9 >&PO=V]R:W-H965T MO%;8=A MV ?&HFTADNB1=-SUUY>4%%&*K@GJ!(A%Z9S#YS"O7AJT:,C3]38L%ME?<,IC/=<"FZ.0+"F2%4$2I?DG^5(L1"4!=27@(@&/37"* M!"=K-"?+VKHDDBQFG)T U]&JFK[(UB;+5MU$J?XWKB573R.5)Q?KCQ^6?[S] M\.[RS<$[W:OX!?P8_ !F)/.!4S M6RH 7<;>%).]SB?#'9-=TLT%<- +@"%&+>G+_O0U/:ATV)9NJ[;+WG'9.\[J M.1WUEC$1 K M6$NVN0/_O%//P96DB?BWI[I35G>RZFY7=98D2J=9[1=@13A@ M7(V(I"'X3.(C!2NJ;NBE;%O)O/@D*Z[?Q?L%O( 0JK[OJRLV&%9C=TMV=PR[ MR-G)4>X9C[[2L TTK^15"-P %C^/8$>%UH"]$M@;#0PB(8[MK%X3P/-="''@ MX$>L+:&.!SW/]9#;SNJ7K/YX5N6L0I(TC-)=&[ _'K@E= !X4@)/>H%7REDI MYTJWA2 .2LSW6L)MR)-QPAT,JZ$&)6KP--3 ^,$ !]%0 &0 'AL+W=OV%@4.)FL2L8THKS<.O M$](XK1.3[?#(YXRA)KSH[*?>7CI.N=Q"S](+O M(5&_;+F(F52GXL%)]P+8)@^*(X>X;N#$+$PZPT%^;2:& WZ049C 3*#T$,=, MO'R%B!^O.KCS>F$>/NQD=L$9#O;L 18@[_8SHJXF2*(8"VS%$Q]/<$(HBC+I'3\4R3M ME#6SP.KQ:_9O>?.JF15+8<2CW\.-W%UU>AVT@2T[1'+.C[]!T9"?Y5OS*,T_ MT?%TK]_MH/4AE3PN@I6".$Q.W^RY&(A* /8: D@10-H&T"* YHV>E.5MC9ED MPX'@1R2RNU6V[" ?FSQ:=1,FV6-<2*%^#56<'$YO[R>+YBI$ M&@J-87V!*/Z"B$MP3?C('KZ O0IWZ\(=U7+9-RG[)GD^KR'?3,">A1LT>58+ M(H6TKJ%3AB#/D"V'IZ&'2:\W<)ZJNFONZF'/*^]Z(X^6\JA5WO5Z+0ZP0=-$ M@H!4HCFL(7QBJPCJE)Z2^14--/#?Z33O(=2M5^F5*KUS*ODAD2F:L9OU/Z*\;B%<@_D8_T)\LV8! RQT( MMH>##->I948%9;7 6NT;"P6Z9]$!$-_F#R[*6'5@$9H)A5TA7^K&)S#&!_MN MPW/IEE*Z_WMR=XVZ78\TC7BO+-RS%AZKYK>"QV@2[R/^ K4SHF=V['9Q?>%^ M6;AO+7S+)9Q9(WVC;.!Y32.-7NU"+;FV7HDFX#+G %X]@J8YH\J>)J M?Y5H >N#"&58_]R+/%4!?I]2O]N@0 ,5VXDZXDJ"D*%J'+5X'$6VM]/ ;7P> M&ISX+#G/,@F;+,0DZ+M>PRS$&HC83L2L<7MIDX>^:^E;LP[;8?GV?]!ND:!!B.PG?2ZFM;7*/N-2E3=-0HP_;V3?)UN%> MA"F<8%Q;W(0?Z9' =YNJ:_YA.P"_0YI>HB67BOIC6,G:ZB8 B1O@H+&ZAB"V M4W#&1>Z-U?[S?A@0DU*$JX/,)B:2'"UV3,".1VHGK'] ?6-+[@9>OVFB$@U, M8@=F99]4FR)*,QVU[NN4IEL1X%ZX.&@8):)12>RH7(!0;$0W'[<$I.(R[5#\ MH"D@IJEL=@5$LY'8V=C*])ILM!@#HLE([&1L90V(2<=F;T T&XF=C2VV(V*R MT&(/B&8A:T!,--KL =%D)'8R_D=[0.I<8N,V M230BB1V1;>P!,:VBU1Y0S3YJ9]]9>T!->VBS!U1#C]JA]P%[0$VG:+$'5#.1 MVIG8QAY0TQW:[ &M_*^V(["-/: U?Y5M]H!J"%([!-O8 VHRT&H/J,8@M6/P M9]J#HE1;>T U,&GKO]%6>U"D.6L/G,J[L>S%Y T3#V&2H@BV*M"]Z*I&Q.E= MW^E$\GW^NFS%I>1Q?K@#IL8ANT']ON5J$1&UL MM99=;]HP%(;_RE&TBU9JFSA\5X#$5S>D4B$"G;9I%R8I^-U%C^]: M!C'V Q.V6JMHP&PW-W2%#JK99BQTS\Q<%LS'0#(>@,!ER^B0^QXI18)XQC/# MG>!,1X.G*3B#WFPRG X'S@U,!H^=Z: /X\[D M&USU45'F22#7< LSIP]7GZZ;IM++1R:FFR[539:R3RQ5@A$/U%K"(%C@XE!O M:NR,W=ZS=^VSAGUT[Z!$;L"V;%+ TSLO=W"CY5:1_ "GE*6R%/N53Z4RV*)4 M>HLK<- -!5,,Y0T\4";@F7HA%J4LL:S&EM$GMVW7RH14FN8V'\CQ+-*HZP\U MFW8 7,Z RV>!>]SW]9?D*.Z^P(\1^G,4/^$O?*?Z!0F8KE'0#8:*N?),>BK9 M:I5+TM.EDLFBS"1NE5S,%9V:XHBK&4/UXU]1]0BD5J_4BT%J&4CM$I I5]2# M6: /9(_]P05\U@=Q$5/MB,DFY 13/6.J7\(4Z+OD'1%P 5>/7,IKV(\70=:/ M(*UBPD9&V#A+Z*#02#"Z?+,2Z^U3EUQT]%Z^=Y5K/$W.^CK69L/O= MG*TQ0'V7SR1%=E,EXBEFBHL,)*YZUHU[/>R8_#+AGN-6[8S!*%D*\6""<=2S M'$,($PRUJ<#HM<$!)HDI1#1^US6M9DL#W!T_5_]4:B43MG6N8T%8*"W2&DP,4IY5;_98^[ #.\%M&M ^[T OP;XI3.5E-*'(=.LWY5B"])D4S4S*,TLT22?9^:S!UK2*B>< M[H^G]Z-@,1E-%Q",!G?S\6(\"LY@/OIZLQ@-878S_PXG0]2,)PJF3$IFOM,I M?(0?+(M0PB)&R7(L- \5S=X%0SCY<-JU-9$S6]AA3>2V(N(=(/*ER%K@NF?@ M.>[5'OC@.'PJ-BWPK@["A\?A0PQ;T"YW]]R7<)L<;6SU&EN]LIY_B$Z1+LD< ML0(5,XD*N%(%1D#W%'))EU;J)XCXAD>81?O,JLIWRO+FZF[Z_H73N;SLVIM= M56^FO6#?;MBWC[(/4'+B/(&?$S0Z?AUQQ&]J^O_D",] T9E2*U8U DJ@_I4S M'E%7R330*:/F$,HJ5R-!];[CX?_EQ(77<1SGE6%OIKT0UVG$=8X;]M^2SF## MD@+W*:NV/M^A[+9=SW_%V-[I :9A3YA<\TQ!@BO".:T+*B.K)E@%6N1E6U@* M34VF',;TWT!I$FA])81^#DRG:?Y$_3]02P,$% @ R$PT5&('8I/8 @ MK@< !D !X;"]W;W)K&ULK57;;AHQ$/T5:]6' M1 K9"]>- "EN=:EH1DP"3A# E8=)Q[_ZX?&OOO2 _7>_:'/'8=RQQ+Z'/ZE20J[3@M!R6P MP&NJGOCV$^SBJ1N^F%.9_Z)M85L+'12OI>+9#JP59(057_RZR\,!0/.4 X(= M('@/J)T!5'> :AYHH2P/:X 5[K8%WR)AK#6;6>2YR=$Z&L+,*T9*Z%NB<:H[ M>GP>1M/Q\'&*HF%_]C2:CH81NAJ PH3*:U1!LVB KCYP5U M<(:ZBL:OJ7X1&L--PK M@Q_)J=K457.^VAF^^XU.$9Y3J.ABJDA, 440KP51!&19N@JZ1DYGJFO3;=9\ MO]YV-X=!G%KY84O7I#4[$ENS8FL7Q?9YENFJB12/7]"W,61S$-_1+_2%Z7\0 M7[ZA28IU5=BK"_FI6Y?UBRY'; -2Z8I7!WFY03TL26EZ"K;Z0>"-9M/WO/+ M&U9%X_^^4N-$QO$K':EH6A7-O\G%E"M,T8SI_DO)3TC01]UWRT0U3W/C!6'K MC*J65=6ZJ"H"H66@\3_^(4+K+KSH;OAC3=3;40(>GBN/HYOW&4!7G[F4I2TG M/*F.BA]46Z'_+A/N04O,0"SS22%1S-=,%=W1GMIA=)_W8/>/>3')QE@L"9.( MPD)#O=NF?@913(=BH_@J;[!SKG2[SI>I'J@@C(&^7W"N]AOCP([H[F]02P,$ M% @ R$PT5$A!K76- @ ZP4 !D !X;"]W;W)K&UL?53;;MLP#/T5PMA#"VRU8R>](3'07(9E6(*@;KN'H@^*3<=&98(GD.#Z60PRT7SS)#5/!64"9'3J94>>VZ,LZP(/*,E\AT M).6B($H?Q<:5I4"26%!!7=_SSMV"Y,P)A]:W$N&05XKF#%<"9%441+R/D?+M MR.DY.\=MOLF4<;CAL"0;C%#=ERNA3V[+DN0%,IES!@+3D7/3NYX,3+Y->,AQ M*SLVF$[6G#^;PSP9.9X1A!1C91B(_KSB!"DU1%K&2\/IM"4-L&OOV'_:WG4O M:R)QPNG?/%'9R+ET(,&45%3=\NTO;/JQ F-.I?V%;9U[<>5 7$G%BP:L%10Y MJ[_DK;F'#D#S[ ?X#<#_#.@? 0-(+"-ULIL6U.B2#@4? O"9&LV8]B[L6C= M3<[,*T9*Z&BN<2J<+Q]FT=UBMKR#:#:YOYW?S6<1G$Q1D9Q*6!(AB+GH4_@! M]TP@)0H36!&AWN%Q@<4:Q9,)15,X^78Z=)769)C=N*D_KNO[!^H'L.!,91)F M+,'D(][5O;0-^;N&QOY1P@C+,PB\[^![?F^/GLEQ^.^*'8)_D!.T]QM8ON MWQ13[4E@C$Q;"E:4,)CF,J9<5@+A\8\.PUQA(9^.E.NWY?JV7/] N65E7@1X M"C(C B5(3I-]KU+3#"R-F?37L'?I>=[0?>W>U9ZLH)OU0>.@U3@XJG$E>(R8 M2$@%+V N9458C, %1(2BT3Y[J7+UOD]VS7S>%70U^*K[:YJ1_46XVYF; L7& MKA,),:^8JO]QK;?=6#=V4#_YQWJ3U8OG/TV]!A=$;'(F@6*J*;VS"RU-U*NE M/BA>VNE<V9A P H0L !D !X;"]W;W)K&ULO5;;;N,V M$/T50NC#+M"-1$K496$;\"5!@W:3(,YN'XH^T-(X)B*)+DG;V[\O*2FJ;4F& M@:+[8I/B.6OO9=56Z@8*I&[&%TJRLA2R8 M-E/YZJJM!)95I")WB>>%;L%XZ4Q&U;,G.1F)G7_PS%\WVCYP)Z,M>X4EZ*_;)VEF;JN2\0)*Q46))*S'SA1_OL,5H4)\XW!0 M1V-D4UD)\68G]]G8\>R.((=46PEF_O8PASRW2F8??S6B3AO3$H_'[^IW5?(F MF153,!?Y[SS3F[$3.RB#-=OE^ED]W# )"G&E=I A7B)ECIQ:L_K%(]8H M/3IX/(-20U:"4GVGI8Y$JTCVE;J?Q"$)0^R/W/WQL>CBL(=I%1 MY%-*/>\4>-<%$AH%,0ZB%GAB#VWMH1?M^<;R'5@;5*]/6;]/F2E4GT%UK/!H MER:3\UP6751 : =VVX4E- F#,V.Z*!R)F?)=E&8!DF"SY+MPOPP":.S9+LH&@SF&K6Y1I<[!"0WE9^B)_/1 M!2E-VE=S&B/^/)D]:^>1'-?DLZ39OW_%<='$T#A,:)_W5P-Z_7TSOQ[7D MK D6GKPYNMGTP.AP&^&CSS_^KXTT:R1.>L0+"3W?8A=&?-,E9UMTCRXK]O+Z MA)O1*U MM_+)/U!+ P04 " #(3#14O!_G" P# "/$ #0 'AL+W-T>6QE3 M'.>ENM+UP];.H;%TC^ZY1W?GR'32Z@VGUTM*=;"NN6CS<*EU\S&*VL62UJ0] MEPT5!BFEJHDV4U5%;:,H*5IPJGDT' S2J"9,A-.)6-67M6Z#A5P)G8=);PK< M[4N1AW'Z/@P#V[.+8_NI!<["R$LZ>@+I M^%Y.".0B&A>12!=H4R.SAV,ZA?QU,S(96-[2*X[WFW_ C8SD @X[P7. R= M83IIB-94B4LSL8NM\0$4=..;36,45HILXN$HW#G8FPDREZJ@J@\3AUO3=,)I M"7(4JY9PU[*) -1:UF90,%))0:R&K4/\H![7>[5=0!5%?W0 M".J&CL9-@'^?S7'OT6;/H@T:=B?UYY79C;!S:!9ZI6C)UG:^+OOX&'N,LY.F MX9M/G%6BIF[O3PXXG9"M7["4BMV;:- I"V.@*@SNJ-)LL6_YI4AS0]=ZVTWK M$M<\?(6:_VZ>*RJH(GQ?M&G]EYSE9RM./OPKR?9'Y5BP5V-W8+UTD:/7(#)] MD2*C[@=][]0X.#-Z:P!G,:R:ZV9(5!14/C@Y#K\GTP, ,3M;O X1BYM)KCO'S(S'ZP.'Z?S%S^G699DJ0IEM'9S*M@AN4M3>'/SX9I P\L#D3ZLUSC MU<8[Y/$^P&KZ6(=@.\4[$=LIGFM _'D#CRSS5QN+ QY8%;#>@?C^.-!3?I\D M@:IBVK G&$>R#$.@%_T]FJ9(=E+X^.N#/25)DF5^!#"_@B3!$'@:<013 !HP M)$GL.7AT'D7;*NQS $P( L M !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,. M\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_' VZZIF M$B4T14LAPR12]C*1X"Q6 4?&;;=^_6RR+&9-K_;BY25@0\SA&OOXPM43%_=+ MSN_1CZJLFZ&SD7)[V>LUJPVM\N8]W]):'5ES4>52%<7W7K,5-"^:#:6R*GM> MOS_H53FKG4]7^[:FHF<6N*0KR7BM*G7%G-&GYG!<%]$C:]B2E4S^'#KM?DD= M5+&:5>R9%D.G[Z!FPY]NN6#/O)9Y25:"E^70<7<'YE1(MGI1331DEB^;MD;F MRS17($-GT%<-KIEH9'M&VWZN&!^I.GE7>I#\AI62BE$NZ5CPARVKO^MFU%WT MC-MHX[#?[H)X*?XEC'R]9BLZXJN'BM9R%T=!2PU8-QNV;1Q4YQ4=.@%_I$+? MC[I 5.SN32HH(U+BDJD#(BI:/(LH23P*8Q*.D-HCR20:^9DJ7/L3/PY"9$!Z M *1W0LAOG@&) 4AL'?* =B FF:JX"V,#\@R /+,,JH&(AM!_0'R- MR"87U( \!R#/_V,D]_'+4'*# I_A.5'WH9FZ;WU8S,,TBQ02>A405(EE MEZ3AI!VR4S_-%BA+_9CX@1X?Q"2$/.):%LGO@4"0'AC17 ?O'3I@FYB025S+ M*B%9$GR^32:C,"7?4/AE%F4+DPT2B&O9()%Z"$G63L@D#&9IE$4A.031Q(04 MXEIVR%%,$PY2AVO9'6W_OCI (%^XEH5!9M=$/6\Z;.%<_7; ($>XEB4!ZK:S M!'0A;[B6Q0%C8G,Y#:G$LZR2CC[0&Y4BE;1Y:])!'O$L>P2<8CI][8%)B669 M',4\&DS()9YEE\!/Y)F)"6G%LZP5&//2 Z/O34SP;9AE[\ 2-U="&/(. M/F4ZT]$CAKR#3Y'._,$T]8@A[V#+WGEE271D8L>0=[!E[\"89@Z+(?]@R_YY MF29VYG@3$[(0;BW4VW_6*.B:U;2(U24:5;_*R]54(+W9O9XY.]<9U/JA+ -5 ME]03GA?[KR3[+SR??@%02P,$% @ R$PT5$"[PRV' 0 O!< !H !X M;"]?0"%: :MN MV%:\0 3F(G)3[*KP]HU@ 0=UT0WR646VE7+(IZ:.AQ/;1A?56$8=/ZNC_9-UU5Q'[9'5Q;;,_%P3O-\XGKGF=DJ\7SS,'F MVOK_3&SV^]/6?S;;[\K7\8_![J?ISN'H?\BPGYP- MUKMEUJUWDKG400I!FC[((,C2!XT@:)0^: Q!X_1!$PB:I ^:0M T?= ,@F;I M@^80-$\?)#G*F!,DO6!-H+4@UT+@M2#80B"V(-E"8+8@VD*@MB#;0N"V(-Q" M(+<@W4)@MR#>0J"WHMY*H+>BWDJ@M[[\;!/HK:BW$NBMJ+<2Z*VHMQ+HK:BW M$NBMJ+<2Z*VHMQ+HK:BW$NAMJ+<1Z&VHMQ'H;:BW$>AM+YAOJ M;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM[]0[Q&OIPZ/GOL;;R'=2'?MW_>/SM^5] M$W$>W7!V<%F_^@502P,$% @ R$PT5/]Y:I*? 0 '1@ !, !;0V]N M=&5N=%]4>7!E&ULS9G-;H,P$(1?!7&-@F.[37^4Y-+VVN;0%W!A"2B M+=M)D[>O(3]2JQ0E2J7.!0N\.S-XI>\ D_>M(1=MZJIQT[CPWCPRYM*":N42 M;:@).[FVM?+AUBZ84>E2+8B)T6C,4MUX:OS0MQKQ;/),N5I5/GK9A,>NU,TT MME2Y.'K:%;9>TU@94Y6I\F&?K9OLA\MP[Y"$SJ[&%:5Q@U 0LY,.[<[O!ON^ MMS596V84S97UKZH.56Q3,>>W%;FD7^)$1IWG94J93E=U:$F M),<#2 X^0@F"0E2.@E2.PE2. E6.0E6.@E6.PE6. E:.0E:!0E:!0E:!0E:! M0E:!0E:!0E:!0E:!0E:!0E:!0E:)0E:)0E:)0E:)0E:)0E:)0E:)0E:)0E:) M0E;YGV3]T'KYUQ^LVS6I5=D<_%GW5V#V!5!+ 0(4 Q0 ( ,A,-%0'04UB M@0 +$ 0 " 0 !D;V-0&UL4$L! M A0#% @ R$PT5!"&UL4$L! A0#% @ R$PT5)E&PO=V]R:W-H M965T&UL4$L! A0#% @ R$PT5#LZ/_B[!P DB( !@ M ("!,PT 'AL+W=O&PO=V]R:W-H965T&UL M4$L! A0#% @ R$PT5#OF&I!L#0 N%H !@ ("!&Q\ M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ R$PT M5#XDEFJB#P /2T !@ ("!,4$ 'AL+W=OR[\RX$ '"0 &0 @($"5 >&PO=V]R:W-H M965T( 9 M " @6=8 !X;"]W;W)K&UL4$L! M A0#% @ R$PT5-[_S3#<#0 3"< !D ("![V8 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ R$PT M5%R6WYY[! NPD !D ("!XH 'AL+W=O&PO=V]R:W-H965T0( ,T% 9 " @=B) !X;"]W;W)K M&UL4$L! A0#% @ R$PT5"M?SCCD @ "08 M !D ("!B(P 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ R$PT5/*4.*YM @ R04 !D M ("!"I\ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ R$PT5#O$''&S @ S < !D ("!GJ@ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ R$PT5,O] M%.,W @ B00 !D ("!J; 'AL+W=O&PO=V]R:W-H965T7\1*%0( /$$ 9 " @4^U !X;"]W;W)K&UL4$L! A0#% @ R$PT5+UGXH&PO M=V]R:W-H965T&UL4$L! A0#% @ R$PT5 W0DRSS P 6A, !D ("! M2,D 'AL+W=O ^,$ !]%0 &0 @(%RS0 >&PO=V]R:W-H965T&UL4$L! A0#% M @ R$PT5 XE(>V7 @ E08 !D ("!V=4 'AL+W=OV9A M P H0L !D ("!>MX 'AL+W=O&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #(3#14 M_WEJDI\! =& $P @ '$ZP 6T-O;G1E;G1?5'EP97-= :+GAM;%!+!08 +P O , , "4[0 ! end XML 52 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 130 342 1 false 43 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://regenbiopharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statement of Shareholder's Deficit (Unaudited) Sheet http://regenbiopharma.com/role/StatementOfShareholdersDeficit Consolidated Statement of Shareholder's Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) Sheet http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 00000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://regenbiopharma.com/role/RecentAccountingPronouncements RECENT ACCOUNTING PRONOUNCEMENTS Notes 8 false false R9.htm 00000009 - Disclosure - GOING CONCERN Sheet http://regenbiopharma.com/role/GoingConcern GOING CONCERN Notes 9 false false R10.htm 00000010 - Disclosure - NOTES PAYABLE Notes http://regenbiopharma.com/role/NotesPayable NOTES PAYABLE Notes 10 false false R11.htm 00000011 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://regenbiopharma.com/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE Notes 11 false false R12.htm 00000012 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://regenbiopharma.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 12 false false R13.htm 00000013 - Disclosure - ACCOUNTS RECEIVABLE, RELATED PARTY Sheet http://regenbiopharma.com/role/AccountsReceivableRelatedParty ACCOUNTS RECEIVABLE, RELATED PARTY Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://regenbiopharma.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - INVESTMENT SECURITIES, RELATED PARY Sheet http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPary INVESTMENT SECURITIES, RELATED PARY Notes 15 false false R16.htm 00000016 - Disclosure - INVESTMENT SECURITIES Sheet http://regenbiopharma.com/role/InvestmentSecurities INVESTMENT SECURITIES Notes 16 false false R17.htm 00000017 - Disclosure - STOCK TRANSACTIONS Sheet http://regenbiopharma.com/role/StockTransactions STOCK TRANSACTIONS Notes 17 false false R18.htm 00000018 - Disclosure - SUBSEQUENT EVENTS Sheet http://regenbiopharma.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 18 false false R19.htm 00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - NOTES PAYABLE (Tables) Notes http://regenbiopharma.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://regenbiopharma.com/role/NotesPayable 21 false false R22.htm 00000022 - Disclosure - INVESTMENT SECURITIES, RELATED PARY (Tables) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyTables INVESTMENT SECURITIES, RELATED PARY (Tables) Tables http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPary 22 false false R23.htm 00000023 - Disclosure - INVESTMENT SECURITIES (Tables) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesTables INVESTMENT SECURITIES (Tables) Tables http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPary 23 false false R24.htm 00000024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 00000025 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Details http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://regenbiopharma.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://regenbiopharma.com/role/GoingConcern 27 false false R28.htm 00000028 - Disclosure - NOTES PAYABLE (Details) Notes http://regenbiopharma.com/role/NotesPayableDetails NOTES PAYABLE (Details) Details http://regenbiopharma.com/role/NotesPayableTables 28 false false R29.htm 00000029 - Disclosure - NOTES PAYABLE (Details 1) Notes http://regenbiopharma.com/role/NotesPayableDetails1 NOTES PAYABLE (Details 1) Details http://regenbiopharma.com/role/NotesPayableTables 29 false false R30.htm 00000030 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://regenbiopharma.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://regenbiopharma.com/role/NotesPayableTables 30 false false R31.htm 00000031 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://regenbiopharma.com/role/ConvertibleNotesPayable 31 false false R32.htm 00000032 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://regenbiopharma.com/role/RelatedPartyTransactions 32 false false R33.htm 00000033 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://regenbiopharma.com/role/StockholdersEquity 33 false false R34.htm 00000034 - Disclosure - INVESTMENT SECURITIES, RELATED PARY (Details) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails INVESTMENT SECURITIES, RELATED PARY (Details) Details http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyTables 34 false false R35.htm 00000035 - Disclosure - INVESTMENT SECURITIES, RELATED PARY (Details 1) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1 INVESTMENT SECURITIES, RELATED PARY (Details 1) Details http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyTables 35 false false R36.htm 00000036 - Disclosure - INVESTMENT SECURITIES, RELATED PARY (Details Narrative) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetailsNarrative INVESTMENT SECURITIES, RELATED PARY (Details Narrative) Details http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyTables 36 false false R37.htm 00000037 - Disclosure - INVESTMENT SECURITIES (Details) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesDetails INVESTMENT SECURITIES (Details) Details http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyTables 37 false false R38.htm 00000038 - Disclosure - INVESTMENT SECURITIES (Details Narrative) Sheet http://regenbiopharma.com/role/InvestmentSecuritiesDetailsNarrative INVESTMENT SECURITIES (Details Narrative) Details http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyTables 38 false false R39.htm 00000039 - Disclosure - STOCK TRANSACTIONS (Details Narrative) Sheet http://regenbiopharma.com/role/StockTransactionsDetailsNarrative STOCK TRANSACTIONS (Details Narrative) Details http://regenbiopharma.com/role/StockTransactions 39 false false All Reports Book All Reports rgbp123121form10q.htm ex31_1.htm ex31_2.htm ex32_1.htm ex32_2.htm rgbp-20211231.xsd rgbp-20211231_cal.xml rgbp-20211231_def.xml rgbp-20211231_lab.xml rgbp-20211231_pre.xml http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 57 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rgbp123121form10q.htm": { "axisCustom": 0, "axisStandard": 7, "contextCount": 130, "dts": { "calculationLink": { "local": [ "rgbp-20211231_cal.xml" ] }, "definitionLink": { "local": [ "rgbp-20211231_def.xml" ] }, "inline": { "local": [ "rgbp123121form10q.htm" ] }, "labelLink": { "local": [ "rgbp-20211231_lab.xml" ] }, "presentationLink": { "local": [ "rgbp-20211231_pre.xml" ] }, "schema": { "local": [ "rgbp-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 385, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 20, "http://regenbiopharma.com/20211231": 9, "http://xbrl.sec.gov/dei/2021": 5, "total": 34 }, "keyCustom": 105, "keyStandard": 237, "memberCustom": 32, "memberStandard": 7, "nsprefix": "RGBP", "nsuri": "http://regenbiopharma.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://regenbiopharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - NOTES PAYABLE", "role": "http://regenbiopharma.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RGBP:ConvertibleNotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - CONVERTIBLE NOTES PAYABLE", "role": "http://regenbiopharma.com/role/ConvertibleNotesPayable", "shortName": "CONVERTIBLE NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RGBP:ConvertibleNotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://regenbiopharma.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - ACCOUNTS RECEIVABLE, RELATED PARTY", "role": "http://regenbiopharma.com/role/AccountsReceivableRelatedParty", "shortName": "ACCOUNTS RECEIVABLE, RELATED PARTY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "role": "http://regenbiopharma.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - INVESTMENT SECURITIES, RELATED PARY", "role": "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPary", "shortName": "INVESTMENT SECURITIES, RELATED PARY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RGBP:InvestmentSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - INVESTMENT SECURITIES", "role": "http://regenbiopharma.com/role/InvestmentSecurities", "shortName": "INVESTMENT SECURITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RGBP:InvestmentSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RGBP:StockTransactionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - STOCK TRANSACTIONS", "role": "http://regenbiopharma.com/role/StockTransactions", "shortName": "STOCK TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RGBP:StockTransactionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SUBSEQUENT EVENTS", "role": "http://regenbiopharma.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "role": "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - NOTES PAYABLE (Tables)", "role": "http://regenbiopharma.com/role/NotesPayableTables", "shortName": "NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - INVESTMENT SECURITIES, RELATED PARY (Tables)", "role": "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyTables", "shortName": "INVESTMENT SECURITIES, RELATED PARY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "RGBP:InvestmentSecuritiesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - INVESTMENT SECURITIES (Tables)", "role": "http://regenbiopharma.com/role/InvestmentSecuritiesTables", "shortName": "INVESTMENT SECURITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "RGBP:InvestmentSecuritiesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31_custom_ZanderTherapeuticsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermInvestmentsAndReceivablesNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)", "role": "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31_custom_ZanderTherapeuticsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermInvestmentsAndReceivablesNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2012-04-242021-12-31", "decimals": "0", "first": true, "lang": null, "name": "RGBP:NetIncomeLossSinceInception", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - GOING CONCERN (Details Narrative)", "role": "http://regenbiopharma.com/role/GoingConcernDetailsNarrative", "shortName": "GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2012-04-242021-12-31", "decimals": "0", "first": true, "lang": null, "name": "RGBP:NetIncomeLossSinceInception", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesClassifiedCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - NOTES PAYABLE (Details)", "role": "http://regenbiopharma.com/role/NotesPayableDetails", "shortName": "NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "RGBP:NonRelatedPartyTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - NOTES PAYABLE (Details 1)", "role": "http://regenbiopharma.com/role/NotesPayableDetails1", "shortName": "NOTES PAYABLE (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "RGBP:NonRelatedPartyTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "role": "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-09-012021-09-17", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - NOTES PAYABLE (Details Narrative)", "role": "http://regenbiopharma.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-09-012021-09-17", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)", "role": "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "shortName": "CONVERTIBLE NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "RGBP:ConvertibleNotesPayableTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31_custom_March82016Member", "decimals": "0", "lang": null, "name": "us-gaap:ConvertibleNotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesClassifiedCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31_custom_DavidKoosMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "role": "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31_custom_SeriesAAPreferredStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - INVESTMENT SECURITIES, RELATED PARY (Details)", "role": "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails", "shortName": "INVESTMENT SECURITIES, RELATED PARY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock", "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember", "decimals": "0", "lang": null, "name": "RGBP:FairValueOfIntellectualProperty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - INVESTMENT SECURITIES, RELATED PARY (Details 1)", "role": "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1", "shortName": "INVESTMENT SECURITIES, RELATED PARY (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember", "decimals": "0", "lang": null, "name": "RGBP:InvestmentSecuritiesBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2019-05-302019-06-11_custom_ZanderTherapeuticsMember", "decimals": "INF", "first": true, "lang": null, "name": "RGBP:NumberOfSharesIssuedForPropertyDividend", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - INVESTMENT SECURITIES, RELATED PARY (Details Narrative)", "role": "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetailsNarrative", "shortName": "INVESTMENT SECURITIES, RELATED PARY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "RGBP:InvestmentSecuritiesRelatedPartyTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2019-05-302019-06-11_custom_ZanderTherapeuticsMember", "decimals": "INF", "first": true, "lang": null, "name": "RGBP:NumberOfSharesIssuedForPropertyDividend", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - INVESTMENT SECURITIES (Details)", "role": "http://regenbiopharma.com/role/InvestmentSecuritiesDetails", "shortName": "INVESTMENT SECURITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "RGBP:InvestmentSecuritiesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember_custom_OncologyPharmaMember", "decimals": "0", "lang": null, "name": "RGBP:InvestmentSecuritiesBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "p", "RGBP:InvestmentSecuritiesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-07-012021-09-30_custom_UnrelatedPartyMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - INVESTMENT SECURITIES (Details Narrative)", "role": "http://regenbiopharma.com/role/InvestmentSecuritiesDetailsNarrative", "shortName": "INVESTMENT SECURITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "RGBP:InvestmentSecuritiesTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-07-012021-09-30_custom_UnrelatedPartyMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "p", "RGBP:StockTransactionsTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-11-012021-11-04_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - STOCK TRANSACTIONS (Details Narrative)", "role": "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative", "shortName": "STOCK TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "RGBP:StockTransactionsTextBlock", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-11-012021-11-04_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (Unaudited)", "role": "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations", "shortName": "CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2020-09-30_custom_PreferredStockSeriesAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statement of Shareholder's Deficit (Unaudited)", "role": "http://regenbiopharma.com/role/StatementOfShareholdersDeficit", "shortName": "Consolidated Statement of Shareholder's Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "AsOf2020-09-30_custom_PreferredStockSeriesAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)", "role": "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows", "shortName": "CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2020-10-012020-12-31", "decimals": "0", "lang": null, "name": "RGBP:CommonStockIssuedForExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS", "role": "http://regenbiopharma.com/role/RecentAccountingPronouncements", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - GOING CONCERN", "role": "http://regenbiopharma.com/role/GoingConcern", "shortName": "GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rgbp123121form10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 43, "tag": { "RGBP_AccruedExpensesRelated": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued Expenses, Related Party" } } }, "localname": "AccruedExpensesRelated", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "RGBP_AccruedRent": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued Rent" } } }, "localname": "AccruedRent", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "RGBP_AdditionsToContributedCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Additions to Contributed Capital Quarter ended 12/31/2020" } } }, "localname": "AdditionsToContributedCapital", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_April192017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; April 19, 2017" } } }, "localname": "April192017Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_April62016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; April 6, 2016" } } }, "localname": "April62016Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Investment Securities, Total Unrealized Gain" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1" ], "xbrltype": "monetaryItemType" }, "RGBP_CashIssuedForConvertibleNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cash issued for convertible note" } } }, "localname": "CashIssuedForConvertibleNote", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RGBP_CommonSharesIssuedForDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Common shares Issued for Debt" } } }, "localname": "CommonSharesIssuedForDebt", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_CommonSharesIssuedForInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Common shares Issued for Interest" } } }, "localname": "CommonSharesIssuedForInterest", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_CommonStockIssuedForExpenses": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "CommonStockIssuedForExpenses", "negatedLabel": "Common Stock issued for Expenses" } } }, "localname": "CommonStockIssuedForExpenses", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_ContributedCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contributed Capital [Member]" } } }, "localname": "ContributedCapitalMember", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "RGBP_ConvertibleNoteReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Convertible Note Receivable" } } }, "localname": "ConvertibleNoteReceivable", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "RGBP_ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible Notes Payable, Related Parties Less\u00a0\u00a0unamortized discount" } } }, "localname": "ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "RGBP_ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNoncurrent": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNoncurrent", "verboseLabel": "Convertible Notes Payable, Related Parties Less\u00a0\u00a0unamortized discount" } } }, "localname": "ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNoncurrent", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "RGBP_ConvertibleNotesPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE NOTES PAYABLE" } } }, "localname": "ConvertibleNotesPayableTextBlock", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "RGBP_CoventryEnterprisesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Coventry Enterprises L L C [Member]" } } }, "localname": "CoventryEnterprisesLLCMember", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetails1" ], "xbrltype": "domainItemType" }, "RGBP_DavidKoosMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "David Koos" } } }, "localname": "DavidKoosMember", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_Dec2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; December 20, 2017" } } }, "localname": "Dec2017Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_DisclosureConvertibleNotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable" } } }, "localname": "DisclosureConvertibleNotesPayableAbstract", "nsuri": "http://regenbiopharma.com/20211231", "xbrltype": "stringItemType" }, "RGBP_DisclosureInvestmentSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "verboseLabel": "Investment Securities" } } }, "localname": "DisclosureInvestmentSecuritiesAbstract", "nsuri": "http://regenbiopharma.com/20211231", "xbrltype": "stringItemType" }, "RGBP_DisclosureInvestmentSecuritiesRelatedParyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Securities Related Pary" } } }, "localname": "DisclosureInvestmentSecuritiesRelatedParyAbstract", "nsuri": "http://regenbiopharma.com/20211231", "xbrltype": "stringItemType" }, "RGBP_DisclosureStockTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Transactions" } } }, "localname": "DisclosureStockTransactionsAbstract", "nsuri": "http://regenbiopharma.com/20211231", "xbrltype": "stringItemType" }, "RGBP_DueToInvestor": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Due to Investor" } } }, "localname": "DueToInvestor", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "RGBP_EnterpriseValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Enterprise Value" } } }, "localname": "EnterpriseValue", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "RGBP_FairValueOfIntellectualProperty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fair Value of Intellectual Property" } } }, "localname": "FairValueOfIntellectualProperty", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "RGBP_FairValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value per share" } } }, "localname": "FairValuePerShare", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "perShareItemType" }, "RGBP_Feb2818Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; February 28, 2018" } } }, "localname": "Feb2818Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_GainLossOnDerecognitionOfAccountsPayable": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gain (Loss) on derecognition of Accounts Payable" } } }, "localname": "GainLossOnDerecognitionOfAccountsPayable", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "RGBP_GainLossOnForgivenessOfDebt": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "(Gain) Loss on Forgiveness of Debt" } } }, "localname": "GainLossOnForgivenessOfDebt", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_IncreaseDecreaseInBankOverdraft": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Bank Overdraft" } } }, "localname": "IncreaseDecreaseInBankOverdraft", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_IncreaseDecreaseInContributedCapital": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Increase(Decrease) in Contributed Capital" } } }, "localname": "IncreaseDecreaseInContributedCapital", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_IncreaseDecreaseInConvertibleNotesPayable": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Increase( Decrease) in Convertible Notes Payable" } } }, "localname": "IncreaseDecreaseInConvertibleNotesPayable", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_IncreaseDecreaseInLossOnSaleOfInvestmentSecurities": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInLossOnSaleOfInvestmentSecurities", "negatedLabel": "Increase (Decrease) in Loss on Sale of Investment Securities" } } }, "localname": "IncreaseDecreaseInLossOnSaleOfInvestmentSecurities", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_IncreasedecreaseInSaleOfInvestmentSecurities": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "IncreasedecreaseInSaleOfInvestmentSecurities", "negatedLabel": "Increase(Decrease) in Sale of Investment Securities" } } }, "localname": "IncreasedecreaseInSaleOfInvestmentSecurities", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_InterestExpenseAttributableToAmortizationOfDiscount": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Interest Expense attributable to Amortization of Discount" } } }, "localname": "InterestExpenseAttributableToAmortizationOfDiscount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "RGBP_InterestReceivablePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INTEREST RECEIVABLE" } } }, "localname": "InterestReceivablePolicyTextBlock", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "RGBP_InvestmentSecuritiesBasis": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Investment Securities, Basis" } } }, "localname": "InvestmentSecuritiesBasis", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1" ], "xbrltype": "monetaryItemType" }, "RGBP_InvestmentSecuritiesRelatedParty": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_OtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Investment Securities, Related Party" } } }, "localname": "InvestmentSecuritiesRelatedParty", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "RGBP_InvestmentSecuritiesRelatedPartyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTMENT SECURITIES, RELATED PARY" } } }, "localname": "InvestmentSecuritiesRelatedPartyTextBlock", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedPary" ], "xbrltype": "textBlockItemType" }, "RGBP_InvestmentSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTMENT SECURITIES" } } }, "localname": "InvestmentSecuritiesTextBlock", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecurities" ], "xbrltype": "textBlockItemType" }, "RGBP_July112018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; July 11, 2018" } } }, "localname": "July112018Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_July192019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; July 19, 2019" } } }, "localname": "July192019Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_June262017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; June 26, 2017" } } }, "localname": "June262017Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_March132017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; March 13, 2017" } } }, "localname": "March132017Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_March312017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note: March 31, 2017" } } }, "localname": "March312017Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_March82016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; March 8, 2016" } } }, "localname": "March82016Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_May52017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; May 5, 2017" } } }, "localname": "May52017Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_NetIncomeLossSinceInception": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net loss since inception" } } }, "localname": "NetIncomeLossSinceInception", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RGBP_NonRelatedPartyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of non related party" } } }, "localname": "NonRelatedPartyTextBlock", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "RGBP_Nov0117Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; November 01, 2017" } } }, "localname": "Nov0117Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_Nov0120172Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; #2 November 1, 2017" } } }, "localname": "Nov0120172Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_NumberOfSharesIssuedForPropertyDividend": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of shares issued for property dividend" } } }, "localname": "NumberOfSharesIssuedForPropertyDividend", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "RGBP_NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of shares issued in satisfaction of prepaid rent and accrued interest" } } }, "localname": "NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "RGBP_Oct0317Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; October 3, 2017" } } }, "localname": "Oct0317Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_Oct1617Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; October 16, 2017" } } }, "localname": "Oct1617Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_October3120162Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note #2; October 31, 2016" } } }, "localname": "October3120162Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_October3120163Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note #3; October 31, 2016" } } }, "localname": "October3120163Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_October312016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; October 31, 2016" } } }, "localname": "October312016Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_OncologyPharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Oncology Pharma [Member]" } } }, "localname": "OncologyPharmaMember", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetails" ], "xbrltype": "domainItemType" }, "RGBP_OriginalSsueDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Original ssue discount" } } }, "localname": "OriginalSsueDiscount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RGBP_OtherAccruedExpenses": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Other Accrued Expenses" } } }, "localname": "OtherAccruedExpenses", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "RGBP_PortionOfEnterpriseValueAttributableToShareholders": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Portion of Enterprise Value attributable to Shareholders" } } }, "localname": "PortionOfEnterpriseValueAttributableToShareholders", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "RGBP_PreferredSharesIssuedForDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Preferred Shares Issued for Debt" } } }, "localname": "PreferredSharesIssuedForDebt", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_PreferredSharesIssuedForInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Preferred Shares issued for Interest" } } }, "localname": "PreferredSharesIssuedForInterest", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_PreferredStockIssued2": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "PreferredStockIssued2", "negatedLabel": "Preferred Stock issued to Consultants" } } }, "localname": "PreferredStockIssued2", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_PreferredStockIssuedAsCompensation": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "PreferredStockIssuedAsCompensation", "negatedLabel": "Preferred Stock issued as compensation" } } }, "localname": "PreferredStockIssuedAsCompensation", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_PreferredStockSeriesAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Series A [Member]" } } }, "localname": "PreferredStockSeriesAMember", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "RGBP_ResearchAndDevelopmentRelatedParty": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Research and Development, Related Party" } } }, "localname": "ResearchAndDevelopmentRelatedParty", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "RGBP_RevenuesRelatedParty": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "RGBP_TotalRevenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Revenues, Related Party" } } }, "localname": "RevenuesRelatedParty", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "RGBP_SecuritiesAcceptedAsCompensation": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "SecuritiesAcceptedAsCompensation", "negatedLabel": "Securities accepted as compensation" } } }, "localname": "SecuritiesAcceptedAsCompensation", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_Sept252017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; September 25, 2017" } } }, "localname": "Sept252017Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_September302018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note; September 30, 2018" } } }, "localname": "September302018Member", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_SeriesAAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A A Preferred Stock [Member]" } } }, "localname": "SeriesAAPreferredStockMember", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/StatementOfShareholdersDeficit", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_SeriesMMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series M [Member]" } } }, "localname": "SeriesMMember", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/InvestmentSecuritiesDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetailsNarrative", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_SeriesMPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series M Preferred Stock [Member]" } } }, "localname": "SeriesMPreferredStockMember", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "RGBP_SeriesNCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series N C [Member]" } } }, "localname": "SeriesNCMember", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_SeriesNCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series N C Preferred Stock [Member]" } } }, "localname": "SeriesNCPreferredStockMember", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "RGBP_SharesIssuedForDebt10Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt10Amount", "verboseLabel": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebt10Amount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebt10Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt10Shares", "verboseLabel": "Shares Issued for Debt, Shares" } } }, "localname": "SharesIssuedForDebt10Shares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForDebt11Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt11Amount", "verboseLabel": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebt11Amount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebt11Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt11Shares", "verboseLabel": "Shares Issued for Debt, Shares" } } }, "localname": "SharesIssuedForDebt11Shares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForDebt12Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt12Amount", "verboseLabel": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebt12Amount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebt12Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt12Shares", "verboseLabel": "Shares Issued for Debt, Shares" } } }, "localname": "SharesIssuedForDebt12Shares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForDebt14Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt14Amount", "verboseLabel": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebt14Amount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebt14Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued for debt, Shares" } } }, "localname": "SharesIssuedForDebt14Shares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForDebt1Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt1Amount", "verboseLabel": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebt1Amount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebt1Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt1Shares", "verboseLabel": "Shares issued for Debt, Shares" } } }, "localname": "SharesIssuedForDebt1Shares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForDebt2Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt2Amount", "verboseLabel": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebt2Amount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebt2Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt2Shares", "verboseLabel": "Shares issued for Debt, Shares" } } }, "localname": "SharesIssuedForDebt2Shares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForDebt3Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt3Amount", "verboseLabel": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebt3Amount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebt3Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt3Shares", "verboseLabel": "Shares issued for Debt, Shares" } } }, "localname": "SharesIssuedForDebt3Shares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForDebt4Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt4Amount", "verboseLabel": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebt4Amount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebt4Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt4Shares", "verboseLabel": "Shares issued for Debt, Shares" } } }, "localname": "SharesIssuedForDebt4Shares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForDebt5Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt5Amount", "verboseLabel": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebt5Amount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebt5Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Issued for Debt, Shares" } } }, "localname": "SharesIssuedForDebt5Shares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForDebt6Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt6Amount", "verboseLabel": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebt6Amount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebt6Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt6Shares", "verboseLabel": "Shares Issued for Debt, Shares" } } }, "localname": "SharesIssuedForDebt6Shares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForDebt7Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt7Amount", "verboseLabel": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebt7Amount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebt7Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt7Shares", "verboseLabel": "Shares Issued for Debt, Shares" } } }, "localname": "SharesIssuedForDebt7Shares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForDebt8Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt8Amount", "verboseLabel": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebt8Amount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebt8Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt8Shares", "verboseLabel": "Shares Issued for Debt, Shares" } } }, "localname": "SharesIssuedForDebt8Shares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForDebt9Amount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt9Amount", "verboseLabel": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebt9Amount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebt9Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForDebt9Shares", "verboseLabel": "Shares Issued for Debt, Shares" } } }, "localname": "SharesIssuedForDebt9Shares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForDebtAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for Debt" } } }, "localname": "SharesIssuedForDebtAmount", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForDebtShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued for Debt, Shares" } } }, "localname": "SharesIssuedForDebtShares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForFeesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued for Fees, shares" } } }, "localname": "SharesIssuedForFeesShares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForFeesValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for Fees" } } }, "localname": "SharesIssuedForFeesValue", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Issued For Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestShares1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestShares1", "verboseLabel": "Shares Issued For Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares1", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestShares10": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestShares10", "verboseLabel": "Shares issued for Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares10", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestShares11": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestShares11", "verboseLabel": "Shares issued for Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares11", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestShares12": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestShares12", "verboseLabel": "Shares issued for Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares12", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestShares13": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestShares13", "verboseLabel": "Shares issued for Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares13", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestShares14": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestShares14", "verboseLabel": "Shares issued for Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares14", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestShares2": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestShares2", "verboseLabel": "Shares Issued For Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares2", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestShares3": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued for Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares3", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestShares4": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestShares4", "verboseLabel": "Shares issued for Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares4", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestShares5": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestShares5", "verboseLabel": "Shares issued for Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares5", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestShares6": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestShares6", "verboseLabel": "Shares issued for Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares6", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestShares7": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestShares7", "verboseLabel": "Shares issued for Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares7", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestShares8": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestShares8", "verboseLabel": "Shares issued for Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares8", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestShares9": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestShares9", "verboseLabel": "Shares issued for Interest, Shares" } } }, "localname": "SharesIssuedForInterestShares9", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "RGBP_SharesIssuedForInterestValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue1", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue1", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue10": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue10", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue10", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue11": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue11", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue11", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue12": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue12", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue12", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue13": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue13", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue13", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue14": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue14", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue14", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue2": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue2", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue2", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue3": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue3", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue3", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue4": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue4", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue4", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue5": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue5", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue5", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue6": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue6", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue6", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue7": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue7", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue7", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue8": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue8", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue8", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedForInterestValue9": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForInterestValue9", "verboseLabel": "Shares issued for Interest" } } }, "localname": "SharesIssuedForInterestValue9", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RGBP_SharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterestValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued in satisfaction of prepaid rent and accrued interest, value" } } }, "localname": "SharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterestValue", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RGBP_StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Value of shares issued in satisdaction of convertible debt" } } }, "localname": "StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RGBP_StockTransactionsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK TRANSACTIONS" } } }, "localname": "StockTransactionsTextBlock", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/StockTransactions" ], "xbrltype": "textBlockItemType" }, "RGBP_SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Disclosure of Noncash investing and financing activities:" } } }, "localname": "SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "RGBP_TotalRevenues": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "TotalRevenues", "totalLabel": "TOTAL REVENUES" } } }, "localname": "TotalRevenues", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "RGBP_TransactionCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Transaction cost" } } }, "localname": "TransactionCost", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RGBP_UnearnedIncome": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unearned Income" } } }, "localname": "UnearnedIncome", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "RGBP_UnrealizedLossgainOnInvestmentSecurities": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "UnrealizedLossgainOnInvestmentSecurities", "negatedLabel": "Unrealized Loss(Gain) on Investment Securities" } } }, "localname": "UnrealizedLossgainOnInvestmentSecurities", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RGBP_UnrelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unrelated Party [Member]" } } }, "localname": "UnrelatedPartyMember", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "RGBP_ZanderTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Zander Therapeutics" } } }, "localname": "ZanderTherapeuticsMember", "nsuri": "http://regenbiopharma.com/20211231", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetailsNarrative", "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r401", "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Series [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://regenbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MaximumMember": { "auth_ref": [ "r174", "r214", "r248", "r249", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r373", "r374", "r389", "r390" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r174", "r214", "r248", "r249", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r373", "r374", "r389", "r390" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r174", "r214", "r241", "r248", "r249", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r373", "r374", "r389", "r390" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r174", "r214", "r241", "r248", "r249", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r373", "r374", "r389", "r390" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndNontradeReceivableTextBlock": { "auth_ref": [ "r148", "r154" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable.", "label": "ACCOUNTS RECEIVABLE, RELATED PARTY" } } }, "localname": "AccountsAndNontradeReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/AccountsReceivableRelatedParty" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accrued Payroll" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r32", "r323" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable", "verboseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r23", "r140", "r141" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Related Party" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInvestmentIncomeReceivable": { "auth_ref": [ "r23", "r350", "r367" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.", "label": "Accrued Interest Receivable" } } }, "localname": "AccruedInvestmentIncomeReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Interest" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r11", "r36" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued payroll taxes" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r24", "r257", "r323" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r87", "r88", "r89", "r253", "r254", "r255", "r291" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net Income to net cash" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "ADVERTISING" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising expenses" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r72", "r194", "r204", "r205", "r308" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Increase (Decrease) in Interest expense attributable to amortization of Discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r83", "r126", "r129", "r135", "r150", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r278", "r283", "r294", "r321", "r323", "r351", "r362" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r10", "r47", "r83", "r150", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r278", "r283", "r294", "r321", "r323" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_OtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Investment Securities", "terseLabel": "Available-for-sale Securities", "verboseLabel": "Investment Securities, Fair Value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://regenbiopharma.com/role/InvestmentSecuritiesDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_BankOverdrafts": { "auth_ref": [ "r36", "r158" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.", "label": "Bank Overdraft" } } }, "localname": "BankOverdrafts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "BASIS OF ACCOUNTING" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r28", "r323", "r383", "r384" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r28", "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash at End of Period", "periodStartLabel": "Cash at Beginning of Period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r68", "r298" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net Increase (Decrease) in Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r80", "r83", "r108", "r109", "r110", "r113", "r115", "r119", "r120", "r121", "r150", "r159", "r163", "r164", "r165", "r168", "r169", "r212", "r213", "r217", "r221", "r294", "r407" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/InvestmentSecuritiesDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetailsNarrative", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r87", "r88", "r291" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1", "http://regenbiopharma.com/role/StatementOfShareholdersDeficit", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)", "verboseLabel": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common stock, authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Common stock issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r228" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "verboseLabel": "Common stock outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22", "r323" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock ($.0001 par value) 500,000,000 shares authorized; 4,800,000,000 authorized and\u00a0\u00a04,564,002,832 issued and outstanding as of December 31,2021 and 4,800,000,000 authorized and 4,350,554,514 shares issued and outstanding as of September 30 ,2021." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r76", "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "PRINCIPLES OF CONSOLIDATION" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r170", "r171", "r172", "r174", "r184", "r185", "r186", "r190", "r191", "r192", "r193", "r194", "r202", "r203", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r18", "r353", "r363", "r385" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable Less\u00a0\u00a0unamortized discount" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible note issued and outstanding", "verboseLabel": "Convertible Notes Payable, Current" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r61" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total Costs and Expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COST AND EXPENSES" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CreditLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Credit Loss [Abstract]" } } }, "localname": "CreditLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Less: Total Debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r79", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r188", "r195", "r196", "r197", "r208" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r17", "r18", "r82", "r85", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r184", "r185", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r202", "r203", "r204", "r205", "r309", "r352", "r353", "r360" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/NotesPayableDetails1", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r18", "r198", "r353", "r360" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Note payable", "verboseLabel": "Notes payable" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Beneficial conversion feature" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": { "auth_ref": [ "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.", "label": "Converted value that exceeds the principal amount" } } }, "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r171", "r202", "r203", "r307", "r309", "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r38", "r191", "r307" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt instrument interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r38", "r200", "r307", "r309" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Convertible note, interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r39", "r82", "r85", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r184", "r185", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r202", "r203", "r204", "r205", "r309" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/NotesPayableDetails1", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r39", "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Periodic payments" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r184", "r306", "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesUnrealizedGainLoss": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Unrealized Gain ( Loss) on sale of Investment Securities" } } }, "localname": "DebtSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetailsNarrative", "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r289" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative Income (Expense)" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r48", "r49", "r50", "r293" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "verboseLabel": "Derivative Liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromEmployees": { "auth_ref": [ "r315", "r317", "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from an Entity employee, not to include stockholders or officers.", "label": "Due from Employee" } } }, "localname": "DueFromEmployees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "BASIC EARNINGS (LOSS) PER SHARE" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r264", "r274" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r55", "r56", "r57", "r87", "r88", "r89", "r93", "r100", "r102", "r118", "r151", "r228", "r235", "r253", "r254", "r255", "r269", "r270", "r291", "r299", "r300", "r301", "r302", "r303", "r304", "r375", "r376", "r377", "r412" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r149", "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Investment Securities, net Unrealized Gain or (Loss) realized", "verboseLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss)" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r72", "r206", "r207" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on\u00a0\u00a0Extinguishment Convertible Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r54", "r262", "r263", "r265", "r266", "r267", "r268" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r71" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r71" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "(Increase) Decrease in Accounts Receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "auth_ref": [ "r71" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedLabel": "(Increase( Decrease in Accrued Interest Receivable" } } }, "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in accrued Expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).", "label": "Increase (Decrease)\u00a0\u00a0in Derivative Expense" } } }, "localname": "IncreaseDecreaseInDerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInNotesPayableCurrent": { "auth_ref": [ "r71" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes.", "label": "Increase ( Decrease)\u00a0\u00a0in Notes Payable" } } }, "localname": "IncreaseDecreaseInNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInNotesReceivables": { "auth_ref": [ "r71" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note.", "label": "Increase (Decrease) in Notes Receivables", "negatedLabel": "(Increase( Decrease in Notes Receivable" } } }, "localname": "IncreaseDecreaseInNotesReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r71" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "(Increase) Decrease in Prepaid Expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInUnearnedPremiums": { "auth_ref": [ "r71" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) unearned premiums written. Excludes portion of unearned premiums amortized into income.", "label": "Increase (Decrease) in Unearned Income" } } }, "localname": "IncreaseDecreaseInUnearnedPremiums", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r58", "r125", "r305", "r308", "r357" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r64", "r192", "r201", "r204", "r205" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "verboseLabel": "Accrued Interest" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r356" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OtherNoncashIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Cash Paid for Interest", "verboseLabel": "Interest amount" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r369" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "verboseLabel": "Investment Securities" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Rent" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r35", "r83", "r130", "r150", "r159", "r160", "r161", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r279", "r283", "r284", "r294", "r321", "r322" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r83", "r150", "r294", "r323", "r354", "r366" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r37", "r83", "r150", "r159", "r160", "r161", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r279", "r283", "r284", "r294", "r321", "r322", "r323" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r12", "r13", "r14", "r18", "r19", "r83", "r150", "r159", "r160", "r161", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r279", "r283", "r284", "r294", "r321", "r322" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total Long Term Liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermInvestmentsAndReceivablesNet": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle) and amount due to the Entity from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such investments and receivables to an amount that approximates their net realizable value.", "label": "Long-term Investments and Receivables, Net" } } }, "localname": "LongTermInvestmentsAndReceivablesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Schedule of investment securities" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by (Used in) Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Provided By Investment Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Investment Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r68", "r70", "r73" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by (Used in) Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r52", "r53", "r57", "r60", "r73", "r83", "r92", "r96", "r97", "r98", "r99", "r101", "r102", "r111", "r126", "r128", "r131", "r134", "r136", "r150", "r159", "r160", "r161", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r292", "r294", "r355", "r371" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (loss)", "totalLabel": "NET INCOME (LOSS)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations", "http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r96", "r97", "r98", "r99", "r106", "r107", "r112", "r115", "r126", "r128", "r131", "r134", "r136" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "NET INCOME (LOSS) attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r2", "r90", "r91", "r94", "r95", "r103", "r104", "r105", "r146", "r147", "r152", "r153", "r237", "r238", "r239", "r240", "r256", "r271", "r272", "r273", "r290", "r295", "r296", "r297", "r311", "r335", "r336", "r337", "r378", "r379", "r380", "r381", "r382", "r413" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "RECENT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/RecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesAndLoansPayable": { "auth_ref": [ "r18", "r353", "r364" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Notes Payable" } } }, "localname": "NotesAndLoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r18", "r353", "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable [Default Label]", "verboseLabel": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Outstanding balance", "verboseLabel": "Notes Payable, Current" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r31", "r84", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes Payable, related party", "verboseLabel": "Notes Payable" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesNoncurrent": { "auth_ref": [ "r40", "r84", "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).", "label": "Notes Payable, Related Parties, Noncurrent", "verboseLabel": "Notes Payable" } } }, "localname": "NotesPayableRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableRelatedPartiesCurrent": { "auth_ref": [ "r44", "r84", "r315" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).", "label": "Note Receivable, Related Party" } } }, "localname": "NotesReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r126", "r128", "r131", "r134", "r136" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "OPERATING INCOME (LOSS)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r86", "r105", "r122", "r288" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAdditionalCapital": { "auth_ref": [ "r46", "r65" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additional paid-in capital (APIC) classified as other.", "label": "Contributed Capital" } } }, "localname": "OtherAdditionalCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r15", "r350", "r361" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "totalLabel": "Total Other Assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER ASSETS" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INCOME & (EXPENSES)" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "totalLabel": "TOTAL OTHER INCOME (EXPENSE)" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForFees": { "auth_ref": [ "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for fees classified as other.", "label": "Paymemt for fee" } } }, "localname": "PaymentsForFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21", "r212" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21", "r212" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued and outstanding" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21", "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r7", "r9", "r155", "r156" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r387", "r388" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Consulting and Professional Fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r3", "r52", "r53", "r57", "r67", "r83", "r92", "r101", "r102", "r126", "r128", "r131", "r134", "r136", "r150", "r159", "r160", "r161", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r277", "r281", "r282", "r286", "r287", "r292", "r294", "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r23", "r27", "r323", "r368", "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Note Receivable" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r142", "r143", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "NOTES RECEIVABLE" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r242", "r314", "r315" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r242", "r314", "r315", "r318" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r242", "r314", "r318", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r312", "r313", "r315", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r261", "r333", "r391" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r235", "r257", "r323", "r365", "r378", "r382" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r87", "r88", "r89", "r93", "r100", "r102", "r151", "r253", "r254", "r255", "r269", "r270", "r291", "r375", "r377" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r77", "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "REVENUE RECOGNITION" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r59", "r83", "r123", "r124", "r127", "r132", "r133", "r137", "r138", "r139", "r150", "r159", "r160", "r161", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r294", "r358" ], "calculation": { "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "RGBP_TotalRevenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "REVENUES" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Number of shares sold" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of notes receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.", "label": "Schedule of comprehensive income" } } }, "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of notes payable related party" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r243", "r244", "r245", "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesDetailsNarrative", "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "Schedule of Derivative Liability" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the detailed components of other nonoperating income. May include methodology, assumptions and amounts for: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.", "label": "Schedule of dividend income" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeByComponentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r30", "r157" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/NotesPayableDetails1", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r41", "r80", "r119", "r120", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r217", "r221", "r226", "r229", "r230", "r231", "r232", "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r250", "r258" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, Shares", "periodStartLabel": "Beginning balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetails", "http://regenbiopharma.com/role/NotesPayableDetails1", "http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r20", "r21", "r22", "r80", "r83", "r108", "r109", "r110", "r113", "r115", "r119", "r120", "r121", "r150", "r159", "r163", "r164", "r165", "r168", "r169", "r212", "r213", "r217", "r221", "r228", "r294", "r407" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/InvestmentSecuritiesDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetailsNarrative", "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative", "http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r43", "r55", "r56", "r57", "r87", "r88", "r89", "r93", "r100", "r102", "r118", "r151", "r228", "r235", "r253", "r254", "r255", "r269", "r270", "r291", "r299", "r300", "r301", "r302", "r303", "r304", "r375", "r376", "r377", "r412" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/InvestmentSecuritiesDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative", "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r87", "r88", "r89", "r118", "r334" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://regenbiopharma.com/role/InvestmentSecuritiesDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetails1", "http://regenbiopharma.com/role/InvestmentSecuritiesRelatedParyDetailsNarrative", "http://regenbiopharma.com/role/NotesPayableDetailsNarrative", "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r42", "r189", "r228", "r229", "r235" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Shares issued in satisfaction of convertible identedness" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/StockTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r56", "r83", "r87", "r88", "r89", "r93", "r100", "r150", "r151", "r235", "r253", "r254", "r255", "r269", "r270", "r275", "r276", "r285", "r291", "r294", "r299", "r300", "r304", "r376", "r377", "r412" ], "calculation": { "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders' Equity (Deficit)" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/CondensedConsolidatedBalanceSheets", "http://regenbiopharma.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r81", "r213", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r227", "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r106", "r115" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenbiopharma.com/role/ConsolidatedCondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "310", "URI": "http://asc.fasb.org/topic&trid=2196771" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "326", "URI": "http://asc.fasb.org/topic&trid=82887179" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r325": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r392": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r393": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r394": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r395": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r396": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r397": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r398": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r399": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r401": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r402": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r403": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r404": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r405": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r406": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r407": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r408": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r409": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r411": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e526-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.T)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868742-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" } }, "version": "2.1" } ZIP 58 0001607062-22-000026-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001607062-22-000026-xbrl.zip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